col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


1031 Ergebisse       Seite 1

 [1] 
BMJ: Annals of the Rheumatic Diseases
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2024―Apr―04 Development and evaluation of a text analytics algorithm for automated application of national COVID-19 shielding criteria in rheumatology patients Meghna Jani, Ghada Alfattni, Maksim Belousov, Lynn Laidlaw, Yuanyuan Zhang, Michael Cheng, et al. (+5)
2 [GO] 2024―Feb―23 Acute rheumatic fever in the province of Manitoba, Canada, before and after the coronavirus (COVID-19) pandemic Kayla Edison, Dion Pepelassis, Reeni Soni, Daryl Schantz, Ilan Buffo
3 [GO] 2024―Jan―10 Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study Abigail E Schiff, Xiaosong Wang, Naomi J Patel, Yumeko Kawano, Jennifer L Hanberg, Emily N Kowalski, et al. (+10)
4 [GO] 2023―Nov―21 Improving the nosology of Long COVID: it is not so simple Leonard H Calabrese, Philip J Mease
5 [GO] 2023―Nov―03 Long COVID: a new word for naming fibromyalgia? Xavier Mariette
6 [GO] 2023―Jul―20 AB1291 COVID-19 AND CRYOGLOBULINEMIC VASCULITIS.LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT’S POPULATION L. Gragnani, M. Visentini, S. Lorini, S. Santini, G. Lauletta, C. Mazzaro, et al. (+25)
7 [GO] 2023―Jul―20 AB1287 FACTORS ASSOCIATED WITH ADHERENCE TO ANTI TNF-Α THERAPY DURING THE COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATOID ARTHRITIS W. G. Rojas Zuleta, M. Barbosa, O. J. Felipe Díaz, A. E. Pantoja Marquez, J. Canizales, C. Becerra-Arias, et al. (+2)
8 [GO] 2023―Jul―20 AB1290 IMPACT OF THE COVID-19 PANDEMIC ON SEPTIC ARTHRITIS MANAGEMENT S. Zemrani, B. Amine, I. EL Binoune, S. Rostom, R. Bahiri
9 [GO] 2023―Jul―20 AB1292 EFFECTS OF DMARD TREATMENT ON SARS-CoV-2 mRNA VACCINATION IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE: A MATCHED, PROSPECTIVE COHORT STUDY E. Simader, T. Deimel, F. Kartnig, S. Tobudic, H. Haslacher, T. M. Karonitsch, et al. (+11)
10 [GO] 2023―Jul―20 AB1286 HUMORAL AND CELLULAR IMMUNOGENICITY INDUCED BY THIRD BOOSTER OF SARS-CoV-2 VACCINES IN PATIENTS WITH RHEUMATIC MUSCULOSKELETAL DISEASES Y. Kondo, M. Takeshita, S. Saito, J. Kikuchi, H. Hanaoka, K. Suzuki, Y. Kaneko
11 [GO] 2023―Jul―06 Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study Annemarie Lyng Lyng Svensson, Hanne-Dorthe Emborg, Lars Erik Bartels, Torkell Ellingsen, Thomas Adelsten, René Cordtz, et al. (+2)
12 [GO] 2023―Jun―07 POS1219 INCIDENCE, FEATURES AND OUTCOME OF DISEASE RELAPSE AFTER COVID-19 VACCINATION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES T. G. Béldi, M. Nagy-Vincze, K. Szabó, A. Vincze, B. Miltényi-Szabó, Z. Varga, et al. (+2)
13 [GO] 2023―Jun―07 POS1215 FLARES AFTER COVID-19 INFECTION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM THE COVAD STUDY S. S. Ali, N. Ravichandran, P. Sen, J. Day, M. Joshi, S. Saha, et al. (+12)
14 [GO] 2023―Jun―07 POS0999-HPR THE IMPACT OF THE COVID-19 PANDEMIC ON REFERRALS TO MUSCULOSKELETAL SERVICES FROM PRIMARY CARE AND SUBSEQUENT INCIDENCE OF INFLAMMATORY RHEUMATIC MUSCULOSKELETAL DISEASE: AN OBSERVATIONAL STUDY R. Bajpai, C. Burton, K. Mason, J. Bailey, M. Frisher, K. Jordan, et al. (+2)
15 [GO] 2023―Jun―07 POS0781-PARE RETROSPECTIVE STUDY OF VITAMIN D DEFICIENCY IN RHEUMATOLOGIC PATIENTS DURING THE COVID-19 PANDEMIC IN POLAND B. Nieradko-Iwanicka
16 [GO] 2023―Jun―07 POS0570 IMPACT OF CLINICIAN-RELATED FACTORS ON PHONE CONSULTATIONS IN RHEUMATOLOGY - ANALYSIS OF MEDICAL VS NON-MEDICAL CLINICIANS’ OUTCOMES FROM A COVID-19 INITIATIVE M. Hannides, S. Wig, S. Vasireddy
17 [GO] 2023―Jun―07 POS0559 ACCELERATED WANING OF HUMORAL IMMUNE RESPONSE TO A THIRD COVID-19 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES D. Mrak, F. Kartnig, D. Sieghart, E. Simader, H. Radner, P. Mandl, et al. (+12)
18 [GO] 2023―Jun―07 POS0558 FLARES OF AUTOIMMUNE RHEUMATIC DISEASE FOLLOWING COVID-19 INFECTION: OBSERVATIONS FROM THE COVAD STUDY N. Ravichandran, N. Sandhu, A. Nune, J. Day, P. Sen, E. Nikiphorou, et al. (+15)
19 [GO] 2023―Jun―07 POS0557 COVID-19 OUTCOMES IN KOREAN PATIENTS WITH GOUT M. J. Kim, B. Ryu, S. Yi, J. W. Park, Y. Jang, K. Shin
20 [GO] 2023―Jun―07 POS0555 HIGH DOSE INTRAVENOUS ANAKINRA TREATMENT IS SAFE AND EFFECTIVE IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PROPENSITY SCORE MATCHED STUDY IN A SINGLE CENTER M. Bektaş, S. Yüce, M. Ay, M. Uyar, M. Önder, M. İ. Kiliç
21 [GO] 2023―Jun―07 POS0554 ANTIPHOSPHOLIPID ANTIBODIES AND VASCULAR THROMBOSIS IN PATIENTS WITH THE MOST SEVERE FORMS OF COVID-19 M. Zlatkovic-Svenda, M. Zdravković, M. Ovuka, M. Ogrič, S. Čučnik, P. Zigon
22 [GO] 2023―Jun―07 POS0552 NEUTROPHIL EXTRACELLULAR TRAPS AND B-CELL ACTIVATING FACTOR AS MARKERS TO PREDICT AND MONITOR ADVERSE EFFECTS AFTER COVID-19 VACCINES Y. M. Kuo, Z. Y. Lai, C. C. Hsu, C. J. Jung
23 [GO] 2023―Jun―07 POS0551 SARS-COV-2 BREAKTHROUGH INFECTION IN COVID-19-VACCINATED ADOLESCENTS AND YOUNG ADULTS WITH CHILDHOOD-ONSET RHEUMATIC DISEASES T. Arkachaisri, K. L. Teh, Y. X. Book, S. F. Hoh, X. Gao, L. Das, J. G. Yeo
24 [GO] 2023―Jun―07 POS0549 BREAKTHROUGH SARS-COV-2 INFECTION IN FULLY VACCINATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASE (COVAD) STUDY E. Kihlgren Olsson, N. Ravichandran, E. Nikiphorou, J. Lindblom, S. Saha, S. S. Shaharir, et al. (+18)
25 [GO] 2023―Jun―07 POS0546 REVACCINATION OF PATIENTS WITH SLE OR RA WITHOUT AN INITIAL COVID-19 VACCINE RESPONSE ELICITS SEROCONVERSION IN HALF OF THE PATIENTS C. Ammitzbøll, M. K. Thomsen, J. B. Andersen, J. M. B. Jensen, R. Bayarri-Olmos, P. Garred, et al. (+15)
26 [GO] 2023―Jun―07 POS0545 PRE-EXPOSURE PROPHYLAXIS OF COVID-19 WITH TIXAGEVIMAB AND CILGAVIMAB IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB: DATA FROM A SINGLE-CENTRE COHORT M. Manara, M. Sette, L. Giudice, M. Biggioggero, N. Del Papa, E. G. Favalli, et al. (+3)
27 [GO] 2023―Jun―07 POS0544 THE CONTRIBUTION OF THE 3RD AND 4TH BOOSTER BNT162B2 MRNA VACCINES TO PREVENT SEVERE COVID-19 AMONG AUTOIMMUNE INFLAMMATORY RHEUMATOID DISEASES (AIRD) PATIENTS DURING THE OMICRON OUTBREAKS Y. Braun-Moscovici, M. Kaplan, M. Braun, R. Dr, D. Markovits, S. Giryes, et al. (+7)
28 [GO] 2023―Jun―07 POS0542 LYMPHOCYTES POPULATIONS AND AUTOANTIBODIES, IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS: A LONG-TERM STUDY OF COVID-19 CASES AND NON-COVID-19 CONTROLS J. Arias-Aponte, A. Gómez-López, P. D. Nieto-Zambrano, M. C. Cortés-Osma, H. F. Restrepo-Guerrero, M. L. Monsalve-Córdoba, et al. (+5)
29 [GO] 2023―Jun―07 POS0541 INFLAMMATORY RHEUMATIC DISEASES (IRD) WITH ONSET AFTER SARS-COV-2 INFECTION OR COVID-19 VACCINATION: A COHORT STUDY FROM THE COVID-19 & ASD COLLABORATIVE STUDY GROUP F. Ursini, P. Ruscitti, O. Addimanda, R. Foti, V. Raimondo, G. Murdaca, et al. (+32)
30 [GO] 2023―Jun―07 POS0538 THE IMPACT OF IMMUNOMODULATING TREATMENT ON THE SEROLOGICAL IMMUNOGENICITY FOLLOWING THREE DOSES OF COVID-19 VACCINE AND PERSISTENCE OF IMMUNOGENICITY OF TWO VACCINE DOSES IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES - A SWEDISH STUDY (COVID19-REUMA) M. Frodlund, P. Nived, K. Chatzidionysiou, A. Södergren, E. Klingberg, M. Hansson, et al. (+3)
31 [GO] 2023―Jun―07 POS0371 DEVELOPMENT AND EVALUATION OF A TEXT-ANALYTICS ALGORITHM FOR AUTOMATED APPLICATION OF NATIONAL COVID-19 SHIELDING CRITERIA IN RHEUMATOLOGY PATIENTS M. Jani, G. Alfattni, M. Belousov, Y. Zhang, M. Cheng, K. Webb, et al. (+4)
32 [GO] 2023―Jun―07 POS0547 RISK OF SARS-COV-2 INFECTION FOLLOWING THREE DOSES OF BNT162B2 OR MRNA-1273 IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES C. E. Raptis, C. Polysopoulos, C. Berger, A. Ciurea, D. O. Andrey, P. Lescuyer, et al. (+10)
33 [GO] 2023―Jun―07 POS0537 SAFETY OF BIVALENT SARS-COV-2 VACCINES AS A SECOND BOOSTER DOSE IN ARTHRITIS PATIENTS ON IMMUNOSUPPRESSIVE THERAPIES H. Ørbo, I. Jyssum, A. T. Tveter, I. E. Christensen, J. Sexton, K. H. Bjørlykke, et al. (+11)
34 [GO] 2023―Jun―07 POS0539 CELLULAR AND HUMORAL IMMUNOGENICITY OF THE NEOANTIGEN S1 FROM SARS-COV-2 VACCINES IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES M. P. Álvarez Hernandez, I. Pérez - Sancristóbal, K. Mohamed Mohamed, M. Rodríguez Laguna, C. Martinez Prada, D. Freites, et al. (+8)
35 [GO] 2023―Jun―07 POS0540 PERFORMANCE OF COMMERCIAL SARS-COV-2 WILD-TYPE AND OMICRON BA.1 ANTIBODY ASSAYS COMPARED WITH PSEUDOVIRUS NEUTRALIZATION TESTS E. Habermann, L. M. Frommert, K. Ghannam, L. Nguyen My, L. Gieselmann, P. Tober-Lau, et al. (+10)
36 [GO] 2023―Jun―07 POS0550 IMMUNE RESPONSE AFTER VACCINATION AGAINST SARS-COV2 IN PATIENTS WITH IMMUNOMEDIATED DISEASES (RIM-COV PROJECT) A. Boteanu, V. Garcia Garcia, N. Villarrubia Migallón, A. Corral Bote, A. M. Ruiz Bejerano, J. Arroyo Palomo, et al. (+9)
37 [GO] 2023―Jun―07 POS0562 FREQUENCY OF IN-PERSON AND VIRTUAL VISITS FOR RHEUMATOID ARTHRITIS: ANALYSIS OF THREE YEARS OF VISIT DATA BEFORE AND AFTER THE COVID PANDEMIC D. Solomon, M. Jiang, L. Santacroce, R. Rudin
38 [GO] 2023―Jun―07 POS0584-HPR PROS AND DISEASE ACTIVITY IN YEAR PRIOR TO COVID PREDICT TRAJECTORIES OF DEPRESSION IN ADULTS WITH RA IN FIRST 2 YEARS OF PANDEMIC: DATA FROM THE CANADIAN EARLY ARTHRITIS COHORT S. J. Bartlett, O. Schieir, M. F. Valois, J. Pope, L. Bessette, G. Boire, et al. (+6)
39 [GO] 2023―Jun―07 AB1852 DERMATO-NEURO SYNDROME PRECIPITATED BY COVID-19 INFECTION IN THE SETTING OF SCLEROMYXEDEMA C. G. Hobayan, J. Lin
40 [GO] 2023―Jun―07 AB1830-HPR MUSCULOSKELETAL DISORDERS DURING COVID-19 INFECTION: A SURVEY OF HEALTHCARE WORKERS H. Ziedi, D. Brahim, I. Youssef, M. Mersni, Z. Athimni, N. Mechergui, et al. (+3)
41 [GO] 2023―Jun―07 AB1790-HPR COVID-19: AFTER TWO YEARS OF IATROGENIC AND BIOLOGIC IMMUNIZATION/ VACCINATION DO WE ACTUALLY NEED FURTHER BOOSTER IMMUNIZATION/ VACCINATION? C. Pohl
42 [GO] 2023―Jun―07 AB1752-PARE THE RATE OF COVID-19 VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS. SINGLE-CENTER CROSS-SECTIONAL PILOT STUDY H. Elhani, L. Taoubane, N. EL Ouardi, H. Taoufik, A. Majjad, A. Bezza
43 [GO] 2023―Jun―07 AB1751-PARE MUSCULOSKELETAL DISORDERS IN THE ERA OF THE COVID-19 PANDEMIC L. Ben Afia, D. Brahim, I. Youssef, Z. Athimni, M. Mersni, N. Mechergui, et al. (+3)
44 [GO] 2023―Jun―07 AB1744-PARE TREATMENT ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) DURING THE COVID-19 PANDEMIC L. L. Holguín Arias, V. V. Castro Coello, C. Soliz, G. Gómez, L. Sorrentino, A. Hamaui, D. Dubinsky
45 [GO] 2023―Jun―07 AB1739-PARE COVID-19 PANDEMIC: THE IMPACT ON PSORIATIC DISEASE PATIENTS’ LIFE U. Viora, G. Mascarino, D. Rava, D. Romagnolo, M. T. Mascarino
46 [GO] 2023―Jun―07 AB1736-PARE CHALLENGES FOR PATIENTS WITH RMD’S IN BULGARIA DURING THE COVID-19 PANDEMIC A. Marinkov, Z. Batalov, R. Karalilova, A. Batalov, B. Boteva
47 [GO] 2023―Jun―07 AB1699 COVID-19 IMPACT ON SECOND YEAR MEDICAL STUDENTS EXPERIENCE WITH INTERACTIVE PATIENT ENCOUNTERS AS A SUPPLEMENT TO TEACHING THE SKIN AND RHEUMATOLOGY COURSE E. Littman, S. Beg
48 [GO] 2023―Jun―07 AB1679 VASCULITIS DISEASE ACTIVITY SCORES BEFORE AND DURING THE COVID-19 PANDEMIC: A COMPARISON OF FACE-TO-FACE CLINICIAN SCORING AND PROMS COLLECTED USING REMOTE MONITORING IN A SINGLE-CENTRE COHORT D. Kurzeja, K. Song, M. Mirza, M. Ashraf, R. Luqmani
49 [GO] 2023―Jun―07 AB1364 VACCINATION AGAINST COVID-19 IN PARAGUAYAN PATIENTS WITH RHEUMATOID ARTHRITIS S. Cabrera-Villalba, G. Avila, A. Amarilla, M. Zarza, E. Leiva, P. Pusineri, et al. (+3)
50 [GO] 2023―Jun―07 AB1363 FIRST PRESENTATION OF AUTOIMMUNE RHEUMATIC DISEASES AFTER COVID-19 VACCINATION: A SYSTEMATIC REVIEW C. Soto, A. Peña, F. Gonzalez, P. Flores, A. C. Medina-Garcia, A. Bernal, et al. (+3)
51 [GO] 2023―Jun―07 AB1361 COVID-19 IN PATIENTS WITH INFLAMMATORY ARTHRITIS IN THE VINSCHGAU VALLEY IN SOUTH TYROL P. Matzneller, A. Mulrenin, M. Wierer, C. Duftner, C. Dejaco
52 [GO] 2023―Jun―07 AB1362 STUDY OF ADVERSE REACTIONS TO COVID-19 VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES Y. Akiyama, M. Matsuda
53 [GO] 2023―Jun―07 AB1358 BIOLOGIC TREATMENT SUSPENSION AND ASSOCIATED FACTORS IN PATIENTS WITH RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC: DATA FROM MEXICAN ADVERSE REGISTRY (BIOBADAMEX) V. Rivera Teran, D. X. Xibille Friedmann, D. Vega-Morales, S. Sicsik, A. Castillo Ortiz, F. Irazoque-Palazuelos, et al. (+13)
54 [GO] 2023―Jun―07 AB1360 AUTOANTIBODIES RELATED TO RHEUMATIC DISEASES AFTER COVID-19 INFECTION X. Zheng, X. Wu, Y. Jiang, Y. Liang, S. Zhong, J. Gu, Z. Liao
55 [GO] 2023―Jun―07 AB1359 CLINICAL FEATURES OF COVID-19 IN PATIENTS WITH CONNECTIVE TISSUE DISEASES DURING THE RECENT PANDEMIC IN GUANGZHOU, CHINA Y. Jiang, X. Zheng, X. Wu, S. Zhong, Y. Liang, Q. Wei, et al. (+2)
56 [GO] 2023―Jun―07 AB1357 RISK OF APS AND aPLs POSITIVE PATIENTS FOR THROMBOSIS WITH COVID-19 F. Berianu, R. Butendieck, B. Wang
57 [GO] 2023―Jun―07 AB1356 COVID-19 VACCINE PERCEPTION AND HESITANCY AMONG PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASE (AIRD) IN MALAYSIA S. S. Shaharir, L. Kamaruzaman, T. N. Mariamutu, M. S. Mohamed Said, A. Mohammed Nawi, W. S. Wan Ghazali, M. Mohd Noh
58 [GO] 2023―Jun―07 AB1355 EFFECT OF COVID-19 VACCINES ON ACTIVITY OF AUTOIMMUNE RHEUMATIC DISEASES M. A. Mahmoud Besar, A. Abd El Salam
59 [GO] 2023―Jun―07 AB1353 RHEUMATOLOGICAL PAIN CONDITIONS ARE NOT RISK FACTORS FOR THE DEVELOPMENT OF WIDESPREAD POST-COVID PAIN IN COVID-19 SURVIVORS L. Arendt-Nielsen, B. D. Ebbesen, R. Giordano, J. A. Valera-Calero, C. Fernández-de-Las-Peñas
60 [GO] 2023―Jun―07 AB1350 THE KINETICS OF HUMORAL AND CELLULAR RESPONSES AFTER THE BOOSTER DOSE OF COVID-19 VACCINE IN INFLAMMATORY ARTHRITIS PATIENTS J. Wroński, B. Jaszczyk, L. Roszkowski, A. Felis-Giemza, K. Bonek, A. Kornatka, et al. (+9)
61 [GO] 2023―Jun―07 AB1341 COVID-19 IN PATIENTS WITH RHEUMATIC IMMUNE-MEDIATED INFLAMMATORY DISEASES IN AMERICA: DIFFERENCES AND SIMILARITIES BETWEEN MEXICO AND ARGENTINA C. A. Isnardi, D. Alpizar-Rodriguez, M. U. Martínez-Martínez, R. Quintana, I. E. Petkovic, S. Ornella, et al. (+18)
62 [GO] 2023―Jun―07 AB1340 CRYOFIBRINOGENEMIA IN PRECOVID-19 AND COVID-19 ERA: A COMPARATIVE STUDY IN A SINGLE UNIVERSITY HOSPITAL C. Lasa, M. E. Peiró Callizo, J. Irure-Ventura, M. Lopez-Hoyos, M. Renuncio García, A. Martínez Gutiérrez, et al. (+3)
63 [GO] 2023―Jun―07 AB1348 PERICARDITIS AFTER COVID-19 VACCINATION: A CASE SERIES F. Casarin, C. Carollo, R. Mascolo, A. Pedroli, G. Faraci, E. Bizzi, et al. (+5)
64 [GO] 2023―Jun―07 AB1346 ASSOCIATION OF URIC ACID LEVELS WITH COVID-19 SEVERITY DURING 2020 AND 2021 YEARS A. Sydorova, O. Iaremenko
65 [GO] 2023―Jun―07 AB1345 COVID-19 AND ADVERSE MENTAL HEALTH OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS M. Ghali, M. Ardhaoui, J. Mahbouba, S. Zrour, I. Bejia, M. Touzi, N. Bergaoui
66 [GO] 2023―Jun―07 AB1337 COVID-19 AND JAKI: ANALYSIS AFTER THREE-YEAR PANDEMIC AT A SPANISH TERTIARY CARE HOSPITAL P. Muñoz Martinez, L. Mas Sanchez, E. Grau García, A. M. Torrat Noves, D. Ramos Castro, C. Riesco Barcena, et al. (+14)
67 [GO] 2023―Jun―07 AB1342 THE EMERGENCE OF FIBROMYALGIA FOLLOWING ACUTE COVID-19 INFECTION E. Savin, A. M Tsur, G. Rosenn, O. Gendelman, D. Buskila, G. Halpert, et al. (+2)
68 [GO] 2023―Jun―07 AB1333 THE IMPACT OF IMMUNOCOMPROMISE ON OUTCOMES OF COVID-19 IN CHILDREN AND YOUNG PEOPLE - A SYSTEMATIC REVIEW AND META-ANALYSIS C. Ciurtin, J. Greenan- Barett, S. Aston, C. Deakin
69 [GO] 2023―Jun―07 AB1332 CLINICAL OUTCOMES AND RISK FACTORS OF COVID-19 IN AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES: A LARGE REAL-WORLD SURVEY IN CHINA Y. Geng, Y. Fan, Z. Zhang
70 [GO] 2023―Jun―07 AB1330 FREQUENCY OF DISEASE FLARE AND ITS RISK FACTORS FOLLOWING TWO-DOSE OF COVID-19 VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS S. Kojima, Y. Kondo, Y. Sakai, S. Kasai, J. Kikuchi, Y. Kaneko
71 [GO] 2023―Jun―07 AB1327 COVID-19 CUTANEOUS AND SYSTEMIC MANIFESTATIONS AMONG DIFFERENT RACIAL GROUPS: A META-ANALYSIS A. El-Said, A. Ahmad, M. Valenti, N. Shah, S. Soto, S. Beg
72 [GO] 2023―Jun―07 AB1324 COVID-19 CHALLENGE IN THE ANTIPHOSPHOLIPID SYNDROME - AN OBSERVATIONAL STUDY OF A SERBIAN COHORT A. Djokovic, L. Stojanovich, N. Stanisavljevic, S. Djokic, D. Colic, D. Škrijelj, et al. (+2)
73 [GO] 2023―Jun―07 AB1323 ANALYSIS OF ADVERSE EFFECTS AFTER VACCINATION AGAINST COVID-19 IN PATIENTS WITH IMMUNO-MEDIATED RHEUMATIC DISEASES IN MANAUS - AMAZONAS M. M. Sousa Dias, N. Seixas de Melo, S. E. B. Dias, C. Pinheiro Martins, V. Miki Pang Takatani, R. Beatriz Nazareth Alagia, et al. (+6)
74 [GO] 2023―Jun―07 AB1322 COVID-19 PANDEMIC AND SYSTEMIC INFLAMMATORY RHEUMATIC DISEASES: OUR EXPERIENCE IN DAKAR, SENEGAL (SUB-SAHARAN AFRICA) B. S. Kane, M. Dieng, B. Fall, M. Sow, A. T. Lemrabott, M. A. Ndour, et al. (+3)
75 [GO] 2023―Jun―07 AB1320 COVID-19 OUTCOME IN AN ITALIAN RHEUMATOID ARTHRITIS COHORT E. Molteni, C. Castellani, G. Sciarra, L. Di Sanzo, G. Bevignani, M. Di Franco, et al. (+5)
76 [GO] 2023―Jun―07 AB1317 EFFICACY AND SAFETY OF COVID-19 VACCINES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH DIFFERENT ANTI-RHEUMATIC THERAPIES Q. Y. Su, J. Luo, Y. Zhang, B. R. Zhao, Y. Cao, Q. Yu, et al. (+3)
77 [GO] 2023―Jun―07 AB1315 EFFECTS OF COVID-19 IN RHEUMATOLOGICAL PAIN CONDITIONS SIX MONTHS AFTER INFECTION B. D. Ebbesen, C. Fernández-de-Las-Peñas, J. A. Valera-Calero, R. Giordano, L. Arendt-Nielsen
78 [GO] 2023―Jun―07 AB1313 EFFICACY AND SAFETY OF COVID-19-SPECIFIC TREATMENTS IN SLE: A MULTICENTRE CASE-CONTROL STUDY G. A. Ramirez, M. Gerosa, D. Arroyo-Sánchez, C. Asperti, L. M. Argolini, G. Gallina, et al. (+9)
79 [GO] 2023―Jun―07 AB1312 MYOSITIS PATIENTS WITHOUT AUTOIMMUNE MULTIMORBIDITY AT LOWER RISK OF DELAYED ONSET COVID-19 VACCINE ADVERSE EVENTS THAN OTHER AUTOIMMUNE DISEASES: RESULTS FROM THE COVAD STUDY S. S. Shaharir, B. Doskaliuk, N. Ravichandran, J. Day, P. Sen, S. Katsuyuki Shinjo, et al. (+15)
80 [GO] 2023―Jun―07 AB1306 HOW DOES COVID-19 VACCINATION AFFECT DISEASE ACTIVITY AND SAFETY IN SECUKINUMAB TREATED PATIENTS WITH AXIAL SPONDYLOARTHRITIS? REAL WORLD DATA FROM THE GERMAN AQUILA STUDY J. Brandt-Juergens, K. Gente, P. Kästner, D. Peterlik, U. Kiltz
81 [GO] 2023―Jun―07 AB1305 RHEUMATOID ARTHRITIS FLARE FOLLOWING COVID-19 VACCINATION IN MALAYSIAN POPULATION AND ITS ASSOCIATED RISK FACTORS N. A. Zakaria, L. Mohd Isa, L. Mohamednor, B. H. Ng, T. Chou Luan, F. N. Sulaiman, et al. (+3)
82 [GO] 2023―Jun―07 AB1304 CHRONIC CHILBLAIN-LIKE LESIONS ASSOCIATED WITH THE COVID-19 PANDEMIC J. Nathan, A. Rastogi, P. Kiely
83 [GO] 2023―Jun―07 AB1302 IMPACT OF THE COVID-19 PANDEMIC ON TREATMENT ADHERENCE AND THE ACTIVITY OF RHEUMATOID ARTHRITIS M. Ghali, M. Ardhaoui, J. Mahbouba, S. Zrour, I. Bejia, M. Touzi, N. Bergaoui
84 [GO] 2023―Jun―07 AB1296 EQUATED HOSPITALIZATION RATE OF PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES AS COMPARED TO GENERAL POPULATION - DATA FROM THE SECOND WAVE OF THE COVID-19 PANDEMIC G. Dallagiacoma, C. Weichenberger, B. Raffeiner, S. Zandonella Callegher, P. Matzneller, A. Maier, et al. (+5)
85 [GO] 2023―Jun―07 AB1294 SAFETY OF COVID-19 VACCINES AND HEALTH CARE UTILIZATION FOLLOWING VACCINATION AMONG ADULTS WITH RHEUMATOID ARTHRITIS - A POPULATION-BASED SELF-CONTROLLED CASE SERIES ANALYSIS J. Lee, S. Bernatsky, J. Kwong, Q. Li, T. Kwok, J. Widdifield
86 [GO] 2023―Jun―07 AB1289 IS THERE HIGHER RISK OF FATIGUE, DEPRESSION, ANXIETY AND STRESS AFTER COVID-19 IN PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASES? DATA FROM THE REUMACOV BRASIL COHORT C. Marques, M. Pinheiro, S. Ribeiro, R. Barros DE Souza, L. D. D. A. Valadares, A. Ranzolin, et al. (+14)
87 [GO] 2023―Jun―07 AB1285 MODELING OF ANTIBODY RESPONSE TO COVID-19 VACCINATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS Y. K. Kim, Y. Choi, J. I. Jung, J. Y. Kim, M. H. Kim, J. Curtis, E. B. Lee
88 [GO] 2023―Jun―07 AB1284 COMPARISON OF THE EFFECTS OF COVID-19 AND INFLUENZA VACCINATION ON RHEUMATIC DISEASES: ANALYSES OF PATIENT SURVEY DATA AFTER VACCINATION J. W. Kim, H. A. Kim, J. Y. Jung, C. H. Suh
89 [GO] 2023―Jun―07 AB1283 COVID-19 WAS NOT TRIGGER FOR RHEUMATIC DISEASE ACTIVITY AFTER 6 MONTHS FOLLOW-UP: RESULTS FROM REUMACOV BRASIL REGISTER C. Marques, R. Xavier, S. Ribeiro, J. Scrignoli, L. D. D. A. Valadares, R. Cavalheiro Do Espírito Santo, et al. (+26)
90 [GO] 2023―Jun―07 AB1086 COVID-19-RELATED ADVERSE EVENTS IN THE PHASE 3 POETYK TRIALS OF THE ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS D. Thaçi, K. B. Gordon, M. Gooderham, A. Alexis, V. Lalchandani, J. Scotto, et al. (+5)
91 [GO] 2023―Jun―07 AB0768 NEW INSIGHTS ON EPIDEMIOLOGICAL DATA AND IMPACT OF THE COVID-19 PANDEMIC ON IGA VASCULITIS IN CHILDREN AND ADULTS IN FRANCE: A NATIONWIDE COHORT V. Maisons, Y. Ramdani, C. Messaien, A. S. Jannot, B. Sautenet, J. M. Halimi, et al. (+3)
92 [GO] 2023―Jun―07 AB0697 COMPARISON OF COVID-19 VACCINATION WITH INFLUENZA VACCINATION IN KOREAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PERCEPTION, ADVERSE EVENTS, AND FLARES FROM THE CIVIL STUDY S. C. Shim, J. Lee, Y. H. Lee, S. K. Kwok, Y. G. Kim, Y. Park, et al. (+10)
93 [GO] 2023―Jun―07 AB0614 EFFECT OF COVID-19 INFECTION ON DISEASE FLARES AND HERPES ZOSTER REACTIVATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE-CONTROL STUDY C. L. Cheung, C. H. To, L. Y. Ho, K. L. Chan, S. M. Tse, C. C. Mok
94 [GO] 2023―Jun―07 AB0591 COVID-19 VACCINE SAFETY DURING PREGNANCY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS N. Giannopoulou, L. Gupta, L. Andreoli, D. Lini, E. Nikiphorou, R. Aggarwal, et al. (+2)
95 [GO] 2023―Jun―07 AB1349 D-DIMER AND FIBRINOGEN TRENDS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES INFECTED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2: A RETROSPECTIVE COMPARATIVE STUDY O. Alsaed, S. Al Emadi, K. Becetti, R. Saleh, H. Ashour, E. Elsayed, et al. (+6)
96 [GO] 2023―Jun―07 AB1319 DYNAMIC IMMUNE FEATURES REVEALED BY SINGLE-CELL RNA AND SINGLE-CELL TCR/BCR SEQUENCING IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING SARS-CoV-2 BOOSTER VACCINATION Y. Fan, Y. Geng, J. Zhao, H. Huang, J. Zhang, Y. Wang, Z. Zhang
97 [GO] 2023―Jun―07 AB1352 IMPACT OF SYSTEMIC THERAPIES ON THE SEROPREVALENCE OF SARS-CoV-2 IN PATIENTS WITH IMMUNE-MEDIATED DISEASES M. L. C. Romero Bogado, M. Steiner, T. Cobo-Ibáñez, A. Gómez, B. Paredes Romero, I. Thuissard Vasallo, et al. (+15)
98 [GO] 2023―Jun―07 AB1316 SAFETY AND IMMUNOGENICITY OF TWO HETEROLOGOUS VACCINE SCHEDULES AGAINST SARS-CoV-2 IN PATIENTS WITH RHEUMATOID ARTHRITIS: BRAZILIAN MULTICENTER STUDY V. Cruz, K. Lysie Libardi Lira Machado, V. Gonçalves Da Silva, K. Rosemarie Lallemand Tapia, L. Baptista Ferreira, A. P. Neves Burian, et al. (+55)
99 [GO] 2023―Jun―07 AB1321 CLINICAL CHARACTERISTICS AND DISEASE COURSE BEFORE AND AFTER SARS-CoV-2 INFECTION IN A LARGE COHORT OF SYSTEMIC SCLEROSIS PATIENTS A. Avanoglu Guler, B. Ozcimen, M. Aydogdu, A. Sari, N. Aliyeva, N. Tuzun, et al. (+13)
100 [GO] 2023―Jun―07 AB0767 OUTCOMES OF SARS-COV-2 INFECTION IN PATIENTS WITH ASSOCIATED ANCA VASCULITIS. DATA FROM THE NATIONAL SAR-COVID REGISTRY J. A. Brigante, C. A. Isnardi, D. Emili, V. Saurit, Y. Tissera, M. E. D’Angelo, et al. (+28)
101 [GO] 2023―Jun―07 AB1343 PERSISTENCE OF SYMPTOMS AFTER SARS-CoV-2 INFECTION IN PATIENTS WITH INFLAMMATORY ARTHRITIS: A RETROSPECTIVE STUDY C. Castellani, E. Molteni, G. Sciarra, L. Di Sanzo, G. Bevignani, M. Di Franco, et al. (+6)
102 [GO] 2023―Jun―07 AB1329 CLINICAL CHARACTERISTICS OF SARS-CoV-2 INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN ARGENTINA: DATA FROM THE SAR-COVID NATIONAL REGISTRY C. A. Isnardi, K. Roberts, Y. Tissera, I. Petkovic, G. Berbotto, C. Gobbi, et al. (+29)
103 [GO] 2023―Jun―07 AB1309 CLINICAL CHARACTERISTICS OF NEW-ONSET IDIOPATHIC INFLAMMATORY MYOPATHIES FOLLOWING SARS-CoV-2 INFECTION OR VACCINATION - ANALYSIS OF A CASE SERIES A. Marian, M. M. Tamas, L. Muntean, O. M. Resteu, D. A. Vaida-Voevod, I. Felea, et al. (+6)
104 [GO] 2023―Jun―07 AB1297 EFFECT OF ABO AND RH BLOOD TYPE ON SARS-CoV-2 INFECTION SEVERITY IN PATIENTS WITH RHEUMATIC DISEASES: DATA FROM THE NATIONAL SAR-COVID REGISTRY F. Valdez Donelli, V. Carrizo Abarza, C. A. Isnardi, E. E. Schneeberger, G. Citera, M. E. D’Angelo, et al. (+33)
105 [GO] 2023―Jun―07 AB1318 CLINICAL CHARACTERISTICS & OUTCOMES AMONG PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: 2-YEAR DATA FROM A TERTIARY RHEUMATOLOGY CENTRE IN GREECE N. Gerolymatou, N. Koletsos, T. Zoi, T. E. Memi, A. Drosos, P. Voulgari
106 [GO] 2023―Jun―07 AB1335 INTAKE OF ACETAMINOPHEN SUPPRESSES ANTIVIRAL HUMORAL IMMUNE RESPONSES IN PATIENTS WITH RA FOLLOWING VACCINATION WITH ANTI SARS-CoV-2 mRNA BASED VACCINES K. Schmiedeberg, J. Beyer, I. Abela, N. Vuilleumier, M. Schwarzmueller, S. Pagano, et al. (+2)
107 [GO] 2023―Jun―07 AB1298 PATIENTS WITH AXIAL SPONDYLOARTHRITIS HAVE BETTER SARS-CoV-2 OUTCOMES COMPARED WITH PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL SAR-COVID REGISTRY A. Bravo, T. Barbich, C. Isnardi, G. Citera, E. E. Schneeberger, R. Quintana, et al. (+32)
108 [GO] 2023―Jun―07 AB1326 DIFFERENCES IN ADVERSE EVENTS EXPERIENCED BY INDIVIDUALS WITH INFLAMMATORY RHEUMATIC DISEASES AND HEALTHY INDIVIDUALS AFTER SARS-CoV-2 VACCINATION L. Huppke, C. Gebhardt, L. Grümme, J. Lichtnekert, D. Singh, F. Ullrich, et al. (+3)
109 [GO] 2023―Jun―07 AB1365 COMPARISON OF HOMOLOGOUS AND HETEROLOGOUS BOOSTER SARS-CoV-2 VACCINATION IN AUTOIMMUNE RHEUMATIC AND MUSCULOSKELETAL PATIENTS D. Honfi, G. Szebeni, A. Balog
110 [GO] 2023―Jun―07 AB1336 EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF THE SARS-CoV-2 VACCINE IN PATIENTS WITH CHRONIC INFLAMMATORY DISEASES TREATED WITH BIOLOGICAL THERAPY J. Calvo Gutierrez, M. C. Ábalos-Aguilera, D. Ruíz-Vilchez, E. Iglesias, R. Ortega Castro, A. Escudero Contreras, C. López-Medina
111 [GO] 2023―Jun―07 AB1339 EFFICACY AND SAFETY OF THE SARS-CoV-2 VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS E. F. Vicente-Rabaneda, M. Torres, M. Uriarte, P. Quiroga Colino, F. Gutiérrez-Rodríguez, A. Triguero-Martinez, et al. (+5)
112 [GO] 2023―Jun―07 AB1374 ADVERSE EVENTS AFTER VACCINATION FOR SARS-CoV2 IN A CASE SERIES OF FIBROMYALGIA PATIENTS VERSUS HEALTHY CONTROLS M. L. Aprile, L. Cutore, D. Sambataro, G. Sambataro, M. Colaci
113 [GO] 2023―Jun―07 AB1344 DO PATIENTS ON SUPPRESSIVE THERAPY HAVE A DECREASED HUMORAL RESPONSE TO SARS-CoV2 VACCINATION? R. Bourguiba, K. Dridi, M. Ayari, M. Boudokhane, I. Abdelaali, T. Jomni, et al. (+2)
114 [GO] 2023―Jun―07 AB1301 CYCLOPHOSPHAMIDE THERAPY DURING THE COVID19 PANDEMIC B. Bitik, C. S. Oygur, A. Yalçintaş Kanbur, A. E. Yucel
115 [GO] 2023―Jun―07 AB0669 CUTANEOUS LUPUS ERYTHEMATOSUS OVER THE COVID MAJOR PANDEMIC PERIOD, INCIDENCE AND CLINICAL CHARACTERISTICS M. Ferraioli, P. Conigliaro, C. Bonini, S. Ferrigno, M. Teoli, C. Paganini, et al. (+5)
116 [GO] 2023―Jun―07 POS1259 SYSTEMIC SCLEROSIS AND COVID-19 VACCINE-ASSOCIATED DELAYED ADVERSE EVENTS: INSIGHTS FROM THE COVAD-2 STUDY B. Doskaliuk, P. Sen, M. Joshi, N. Ravichandran, A. L. Tan, S. Katsuyuki Shinjo, et al. (+10)
117 [GO] 2023―Jun―07 AB0127 ANTIGENIC ASSESSMENT FOR THE Β2GPIOX-PF4 COMPLEX IN A MONOCENTRIC COHORT OF PATIENTS WITH APS, THROMBOSIS DURING SARS-COV-2 INFECTION AND VITT F. M. Ucci, F. Villani, A. Capozzi, M. De Michele, S. Truglia, S. Mancuso, et al. (+8)
118 [GO] 2023―Jun―07 POS1477 DISEASE FLARES AFTER SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS ARE ASSOCIATED WITH DISEASE ACTIVITY BEFORE VACCINATION J. Kikuchi, Y. Kondo, S. Kojima, S. Kasai, Y. Sakai, M. Takeshita, et al. (+5)
119 [GO] 2023―Jun―07 AB0113 CHRONIC STIMULATION WITH SARS-COV-2 SPIKE PROTEIN DOES NOT TRIGGER AUTOIMMUNITY M. Scherlinger, J. Sibilia, G. Tsokos, J. E. Gottenberg
120 [GO] 2023―Jun―07 POS0556 LONG COVID IN RHEUMATOID ARTHRITIS AND IN PSORIATIC ARTHRITIS: CLINICAL PATTERN AND GENDER-BASED DIFFERENCES FROM A SINGLE-CENTRE CASE-CONTROL STUDY M. Ferraioli, L. De Marco, L. Fiannacca, M. Iacovantuono, B. Monosi, P. Triggianese, et al. (+3)
121 [GO] 2023―Jun―06 POS0284 COVID-19 SYMPTOMS AND DISEASE COURSE IN GERMAN PEDIATRIC RHEUMATOLOGY PATIENTS REPORTED TO BIKER A. Klein, T. Hospach, F. Dressler, D. Windschall, M. Hufnagel, W. Emminger, et al. (+6)
122 [GO] 2023―Jun―06 POS0273 POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVAD STUDY P. Sen, N. Ravichandran, M. Joshi, S. Saha, K. Jagtap, V. Agarwal, et al. (+46)
123 [GO] 2023―Jun―06 POS0272 IMPACT OF THE COVID-19 PANDEMIC ON ADHERENCE TO DISEASE MODIFYING DRUGS AMONG PATIENTS WITH RHEUMATIC DISEASES: A POPULATION-BASED, INTERRUPTED TIME SERIES ANALYSIS N. Rebić, E. C. Sayre, M. Law, M. De Vera
124 [GO] 2023―Jun―06 POS0271 HETEROLOGOUS COVID-19 BOOSTER VACCINATION PRODUCED GREATER ANTIBODY TITERS IN AUTOIMMUNE DISEASE PATIENTS: DATA FROM MULTICENTRIC PROSPECTIVE PHASE IV SAFER STUDY K. Lysie Libardi Lira Machado, S. T. Miyamoto, A. P. Neves Burian, L. H. Dias, F. Z. Pretti, D. Cristina Filgueira Alves Batista, et al. (+61)
125 [GO] 2023―Jun―06 POS0270 BURDEN OF COVID-19 IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: INSIGHTS FROM A SWISS APP-BASED SURVEY C. Blapp, S. Yaghmaei, A. Ciurea, A. Scherer, M. Kuster, K. Lauper
126 [GO] 2023―Jun―06 POS0275 COVID-19 INFECTION IN PATIENTS WITH RHEUMATIC DISEASE DURING OMICRON OUTBREAK IN SOUTH KOREA: A SINGLE-CENTER PROSPECTIVE STUDY Y. K. Kim, J. I. Jung, J. K. Park, E. Y. Lee, E. B. Lee, J. W. Park
127 [GO] 2023―Jun―06 POS0268 PRE-EXPOSURE PROPHYLAXIS WITH TIXAGEVIMAB/CILGAVIMAB IS EFFECTIVE IN LIMITING THE RISK AND THE SEVERITY OF COVID-19 IN PATIENTS WITH AUTOIMMUNE OR INFLAMMATORY DISEASES AT INCREASED RISK OF SEVERE COVID-19 WHO ARE POOR RESPONDERS TO VACCINATION M. Thomas, M. Masson, S. Bitoun, R. Seror, H. Dupuy, E. Lazaro, et al. (+3)
128 [GO] 2023―Jun―06 POS0269 COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN SJÖGREN’S SYNDROME: RESULTS FROM THE COVAD STUDY A. Alunno, F. Carubbi, J. Day, J. Knitza, S. Katsuyuki Shinjo, S. Saha, et al. (+7)
129 [GO] 2023―Jun―06 POS0267 MORTALITY OUTCOME OF ACUTE MYOCARDIAL INFRACTION AND ACUTE HEART FAILURE HOSPITALIZATION IN RHEUMATIC DISEASES PATIENTS PRE-COVID-19 VS. COVID-19 PANDEMIC FROM 2016-2020 NATIONAL INPATIENT SAMPLE (NIS) DATABASE Z. Y. LI, S. Huang, S. Gokcebel, A. M. Reginato
130 [GO] 2023―Jun―06 POS0266 CELLULAR IMMUNE RESPONSE PERSISTENCE AFTER COVID-19 MRNA VACCINES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS UNDER RITUXIMAB J. Marin, P. Bourgoin, N. Saverna, C. Cartagena García, P. Lafforgue, J. Roudier, et al. (+2)
131 [GO] 2023―Jun―06 POS0131 RELATION BETWEEN COVID-19 AND ANCA VASCULITIS. STUDY IN A SINGLE UNIVERSITY HOSPITAL F. Benavides-Villanueva, V. Calvo-Río, J. Loricera, J. Irure-Ventura, M. Lopez-Hoyos, R. Blanco
132 [GO] 2023―Jun―06 LB0006 COVID-19 severity, breakthrough infections and anti-SARS-CoV-2 vaccine safety in young people with rheumatic and non-rheumatic autoimmune diseases: results from the COVAD1 and COVAD2 projects A. Alunno, F. Carubbi, A. L. Tan, P. Sen, L. Cavagna, M. Joshi, et al. (+10)
133 [GO] 2023―Jun―06 OP0085 LONGITUDINAL T CELL RESPONSES TO A SERIES OF FOUR SARS-COV-2 VACCINE DOSES OR COVID-19 IN PATIENTS ON TNF INHIBITORS H. Ørbo, A. S. F. M. Wolf, K. H. Bjørlykke, S. Josefsson, G. Solum, I. Fadum Kjønstad, et al. (+17)
134 [GO] 2023―Jun―06 OP0081 PREVALENCE, CHARACTERISTICS, AND PREDICTORS OF BREAKTHROUGH COVID-19 INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASE (COVAD) STUDY N. Ravichandran, I. Parodis, L. Gupta, S. Katsuyuki Shinjo, N. Ziade, M. Milchert, et al. (+13)
135 [GO] 2023―Jun―06 OP0082 COVID-19 VACCINE SAFETY DURING PREGNANCY AND BREASTFEEDING IN WOMEN WITH AUTOIMMUNE DISEASES: RESULTS FROM THE COVAD STUDY L. Andreoli, D. Lini, K. Schreiber, P. Sen, N. Ravichandran, I. Parodis, et al. (+20)
136 [GO] 2023―Jun―06 OP0080 INCIDENCE AND CLINICAL OUTCOME OF COVID-19 RELATED TO POST-VACCINATION ANTIBODY LEVELS IN PATIENTS ON IMMUNOSUPPRESSIVE THERAPY: A PROSPECTIVE STUDY IN THE OMICRON ERA H. Ørbo, K. H. Bjørlykke, J. Sexton, A. T. Tveter, I. Jyssum, I. E. Christensen, et al. (+11)
137 [GO] 2023―Jun―06 OP0079 OMICRON VARIANT INFECTION IN INFLAMMATORY RHEUMATOLOGICAL CONDITIONS - OUTCOMES FROM A COVID-19 NAIVE POPULATION IN AOTEAROA NEW ZEALAND J. Brooks, A. Montgomery, N. Dalbeth, M. Sapsford, A. Cooper, R. Ngan Kee, et al. (+12)
138 [GO] 2023―Jun―06 OP0084 POSSIBLE ROLE OF PEPTIDE EPITOPES OF COVID-19 BNT-162B2 MRNA VACCINE IN FOMENTING AUTOIMMUNITY: AN IN SILICO ANALYSIS R. Talotta
139 [GO] 2023―Jun―06 OP0042 VACCINATION RATE, ADVERSE REACTIONS, AND REASONS FOR NONVACCINATION OF COVID-19 VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A JAPANESE REAL-WORLD CLINICAL PRACTICE Y. Hirano, Y. Saito
140 [GO] 2023―Jun―06 POS0274 PROSPECTIVE EVALUATION OF THE EFFECT OF THE VACCINE AGAINST SARS-COV-2 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM SAFER STUDY N. Sartori, F. M. Matos Melo Campos Peixoto, P. Dias Cardoso Ribeiro, K. Lysie Libardi Lira Machado, J. Geraldo Mill, F. Z. Pretti, et al. (+58)
141 [GO] 2023―Jun―06 POS0276 SARS-COV-2 INFECTION OUTCOMES IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES -A DANISH NATIONWIDE COHORT STUDY A. Svensson, H. D. Emborg, L. E. Bartels, C. Ammitzbøll, T. Ellingsen, T. Adelsten, et al. (+3)
142 [GO] 2023―Jun―06 OP0083 ANAKINRA PLUS STANDARD OF CARE FOR THE REDUCTION OF HYPERINFLAMMATION AND RESPIRATORY DISTRESS IN PATIENTS WITH SARS-COV-2 INFECTION: A MULTICENTRE, RANDOMISED, OPEN-LABEL PHASE 2/3 TRIAL (ANA-COVID-GEAS STUDY) P. Fanlo, B. Gracia Tello, E. Fonseca, J. Álvarez Troncoso, A. González, S. Prieto-González, et al. (+7)
143 [GO] 2023―Jun―06 OP0265 WORK PARTICIPATION AND THE COVID19 PANDEMIC: A DUTCH PROSPECTIVE COHORT STUDY IN PEOPLE WITH INFLAMMATORY RHEUMATIC DISEASES AND HEALTHY CONTROLS M. Butink, L. Boekel, A. Boonen, A. De Rijk, G. Wolbink, C. Webers
144 [GO] 2023―Mai―25 Rheumatology and Long COVID: lessons from the study of fibromyalgia Daniel J Clauw, Leonard Calabrese
145 [GO] 2023―Mrz―08 COVID-19 infection after autologous stem cell transplantation for systemic sclerosis Joerg Christoph Henes, Ioana Martac, Wichard Vogel, Claudia Lengerke, Reinhild Klein, Luca Hensen, Ann-Christin Pecher
146 [GO] 2023―Feb―14 Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries Pedro M Machado, Martin Schäfer, Satveer K Mahil, Jean Liew, Laure Gossec, Nick Dand, et al. (+48)
147 [GO] 2022―Okt―19 Database of synovial T cell repertoire of rheumatoid arthritis patients identifies cross-reactive potential against pathogens including unencountered SARS-CoV-2 Zihan Zheng, Ling Chang, Jie Mu, Qingshan Ni, Zhong Bing, Qing-Hua Zou, et al. (+4)
148 [GO] 2022―Sep―15 Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls Felix Kartnig, Daniel Mrak, Elisabeth Simader, Selma Tobudic, Helga Radner, Peter Mandl, et al. (+22)
149 [GO] 2022―Sep―05 Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases Eileen W Stalman, Luuk Wieske, Koos P J van Dam, Laura Y Kummer, Zoé L E van Kempen, Joep Killestein, et al. (+53)
150 [GO] 2022―Aug―17 Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study Daniel Mrak, Elisabeth Simader, Daniela Sieghart, Peter Mandl, Helga Radner, Thomas Perkmann, et al. (+18)
151 [GO] 2022―Aug―16 Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α Alexis Mathian, Paul Breillat, Karim Dorgham, Paul Bastard, Caroline Charre, Raphael Lhote, et al. (+25)
152 [GO] 2022―Aug―11 POS0195 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS HAVE AN INCREASED RISK OF MORTALITY, MECHANICAL VENTILATION, AND HOSPITALIZATION FROM COVID-19 S. Bruera, X. Lei, H. Zhao, J. Yazdany, M. Chavez-Macgregor, S. Giordano, M. Suarez-Almazor
153 [GO] 2022―Aug―11 POS0197 SARS-CoV-2 INFECTION CAUSED THROMBOSIS IN THE LUPUS MODEL WITH ANTIPHOSPHOLIPID ANTIBODY, WHEREAS COVID-19 ASSOCIATED THROMBOSIS WAS IRRELEVANT IN PATIENTS WITH POSITIVE ANTIPHOSPHOLIPID ANTIBODY S. Oba, T. Hosoya, D. Kawata, W. Lee, M. Kamiya, Y. Komiya, et al. (+4)
154 [GO] 2022―Aug―11 POS0204 RETROSPECTIVE STUDY OF THE COVID-19 COURSE IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE CENTER EXPERIENCE Z. Kolkhidova, I. Nikishina, V. Matkava, A. Shapovalenko, S. Arsenyeva, M. Kaleda, et al. (+3)
155 [GO] 2022―Aug―11 POS0202 CONTROL OF RHEUMATIC DISEASE AND COVID-19: RESULTS FROM THE INTERNATIONAL COVID-19 EUROPEAN PATIENT REGISTRY S. Shoop-Worrall, S. Verstappen, W. Costello, S. Angevare, Y. Uziel, C. Wouters, et al. (+2)
156 [GO] 2022―Aug―11 POS0194 MORBIDITY AND MORTALITY OF BREAKTHROUGH COVID-19 IN PATIENTS WITH IMMUNE MEDIATED CONDITIONS ON B CELL DEPLETING THERAPIES AND THE EFFECTS OF MONOCLONAL ANTIBODY TREATMENT C. Calabrese, E. Kirchner, M. E. Husni, B. Moss, A. Fernandez, Y. Jin, L. Calabrese
157 [GO] 2022―Aug―11 POS0203 PREDICTIVE SEVERITY FACTORS OF COVID-19 IN PATIENTS WITH RHEUMATIC IMMUNE MEDIATED DISEASES D. Martínez-López, I. Ferraz-Amaro, D. Prieto-Peña, F. Benavides-Villanueva, C. Corrales-Selaya, L. Sanchez-Bilbao, et al. (+5)
158 [GO] 2022―Aug―11 POS0170 EXPERIENCES WITH COVID-19 INFECTIONS IN GERMAN PEDIATRIC RHEUMATOLOGY CENTERS G. Horneff, F. Dressler, D. Windschall, S. Mrusek, T. Hospach, A. Kühn, et al. (+6)
159 [GO] 2022―Aug―11 POS0263 RE-VACCINATION COMPARED TO BOOSTER COVID-19 mRNA VACCINATION SIGNIFICANTLY INCREASES THE SEROLOGICAL RESPONSE IN RITUXIMAB-TREATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES WITHOUT A PRIMARY DETECTABLE SEROLOGICAL COVID-19 VACCINE RESPONSE C. Ammitzbøll, M. K. Thomsen, M. L. F. Hermansen, S. R. Vils, J. B. Andersen, A. D. Johannesen, et al. (+6)
160 [GO] 2022―Aug―11 POS0261 TIME SINCE LAST RITUXIMAB TREATMENT IS ESSENTIAL FOR DEVELOPING A HUMORAL RESPONSE TO THE COVID-19 MRNA VACCINE IN PATIENTS WITH RHEUMATIC DISEASES. A. Troldborg, M. K. Thomsen, L. E. Bartels, J. B. Andersen, S. R. Vils, C. M. Jørgensen, et al. (+6)
161 [GO] 2022―Aug―11 POS0198 COVID-19 OUTCOMES IN PATIENTS WITH DERMATOMYOSITIS: A REGISTRY-BASED COHORT ANALYSIS L. Gupta, H. Pakhchanian, H. Khan, R. Raiker, M. Abbasi, C. Deyoung, et al. (+5)
162 [GO] 2022―Aug―11 POS0088-PARE CHANGES IN PATIENT-REPORTED OUTCOME SCORES DURING COVID-19 PANDEMIC: DATA FROM THE ArthritisPower REGISTRY K. Gavigan, E. Rivera, J. R. Curtis, S. Venkatachalam, L. Stradford, D. Curtis, W. B. Nowell
163 [GO] 2022―Aug―11 OP0308-HPR MORE THAN HALF OF RA PATIENTS WITH A LIFETIME HISTORY OF MOOD DISORDERS WERE ANXIOUS AND DEPRESSED DURING THE COVID-19 PANDEMIC: RESULTS FROM THE CANADIAN EARLY COHORT (CATCH) STUDY S. J. Bartlett, O. Schieir, M. F. Valois, G. Boire, G. Hazlewood, C. Thorne, et al. (+6)
164 [GO] 2022―Aug―11 POS0201 COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY. L. Gupta, L. S. Hoff, N. R, P. Sen, S. Katsuyuki Shinjo, J. Day, et al. (+25)
165 [GO] 2022―Aug―11 POS0258 SAFETY AND IMMUNOGENICITY OF BNT162b2 mRNA COVID-19 VACCINE AMONG ADOLESCENTS WITH RHEUMATIC DISEASES TREATED WITH IMMUNOMODULATORY MEDICATIONS M. Heshin-Bekenstein, A. Ziv, N. Toplak, D. Hagin, D. Kadishevich, Y. Butbul, et al. (+6)
166 [GO] 2022―Aug―11 POS0255 PREDICTORS OF ANTIBODY RESPONSE TO COVID-19 VACCINE IN RITUXIMAB TREATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. A SWEDISH NATIONWIDE STUDY (COVID19-REUMA) M. Frodlund, K. Chatzidionysiou, A. Södergren, E. Klingberg, M. Hansson, E. Pin, et al. (+4)
167 [GO] 2022―Aug―11 OP0303-PARE HEALTH DEMOCRACY IN THE TIME OF COVID-19: A COLLABORATIVE INITIATIVE BETWEEN PATIENT ORGANIZATIONS AND HEALTHCARE PROFESSIONALS TO SUPPORT PEOPLE LIVING WITH RHEUMATOID ARTHRITIS S. Tropé, R. M. Flipo
168 [GO] 2022―Aug―11 POS0200 POST-mRNA VACCINE FLARES IN AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES: INTERIM RESULTS FROM THE CORONAVIRUS NATIONAL VACCINE REGISTRY FOR IMMUNE DISEASES SINGAPORE (CONVIN-SING) M. Ma, A. Santosa, K. O. Kong, C. Xu, J. T. G. Xiang, G. G. Teng, et al. (+21)
169 [GO] 2022―Aug―11 POS0254 IMMUNE RESPONSE TO SARS-CoV-2 INFECTION IN PATIENTS WITH RHEUMATIC MUSCULOSKELETAL DISEASES: THE MAINSTREAM STUDY E. G. Favalli, A. Favalli, G. Andrea, G. Maioli, E. Zagato, M. Bombaci, et al. (+21)
170 [GO] 2022―Aug―11 POS0275 SEROLOGICAL RESPONSE FOLLOWING THREE DOSES OF SARS-CoV-2 mRNA VACCINE IN PATIENTS WITH GIANT CELL ARTERITIS: EXPERIENCE OF A SINGLE-CENTRE COHORT A. Bartoletti, G. Franchi, C. Fornara, P. Delvino, F. Baldanti, D. Lilleri, et al. (+2)
171 [GO] 2022―Aug―11 POS0264 CHARACTERIZATION OF THE IMMUNE RESPONSE IN PATIENTS WITH INFLAMMATORY IMMUNE-MEDIATED DISEASES ON IMMUNOSUPPRESSIVE TREATMENT AFTER ONE MONTH OF SARS-CoV-2 VACCINATION A. Martínez-Feito, P. Nozal, M. Novella-Navarro, E. Fernández-Fernández, L. Del Pino Molina, M. Casas Temprano, et al. (+4)
172 [GO] 2022―Aug―11 POS0050 B CELL CHARACTERISTICS AT BASELINE PREDICT HUMORAL RESPONSE UPON SARS-CoV-2 VACCINATION AMONG PATIENTS TREATED WITH RITUXIMAB A. L. Stefanski, H. Rincon-Arevalo, E. Schrezenmeier, K. Karberg, F. Szelinski, J. Ritter, et al. (+7)
173 [GO] 2022―Aug―11 POS0256 CLINICAL PREDICTORS OF ATTENUATED ANTIBODY RESPONSE TO PRIMARY SARS-CoV-2 VACCINATION IN A LARGE PROSPECTIVE STUDY OF PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES C. Connolly, T. P. Y. Chiang, M. Teles, S. Frey, J. Alejo, A. Massie, et al. (+4)
174 [GO] 2022―Aug―11 POS0260 LONG-TERM HUMORAL RESPONSE TO SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASE K. Tascilar, D. Simon, A. Kleyer, F. Fagni, G. Krönke, C. Meder, et al. (+24)
175 [GO] 2022―Aug―11 POS0259 A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE C. Scognamiglio Renner Araujo, A. C. Medeiros Ribeiro, C. Saad, K. Bonfiglioli, D. S. Domiciano, A. Yukie Shimabuco, et al. (+10)
176 [GO] 2022―Aug―11 POS0257 COMPARISON OF SARS-CoV-2 VACCINE RESPONSE IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE; mRNA-1273 VACCINE INDUCES HIGHER HUMORAL IMMUNOGENICITY THAN BNT162b2 Y. Kondo, M. Takeshita, Y. Uwamino, H. Namkoong, S. Saito, J. Kikuchi, et al. (+5)
177 [GO] 2022―Aug―11 POS0262 HUMORAL AND CELLULAR SARS-CoV-2 VACCINE RESPONSES IN PATIENTS WITH GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA Y. Van Sleen, K. Van der Geest, R. Reitsema, I. Esen, J. H. Terpstra, E. Raveling-Eelsing, et al. (+6)
178 [GO] 2022―Aug―11 POS0196 NINE PERCENT OF PATIENTS PRESENT WITH MUSCULOSKELETAL SYMPTOMS AFTER A SEVERE SARS-CoV2 INFECTION: A DESCRIPTIVE ANALYSIS OF THE ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS CLINICAL DATA WAREHOUSE. A. Moltó, P. Pinson, N. Beeker, C. Roux
179 [GO] 2022―Aug―11 OP0304-PARE “THE CORONA PANDEMIC - AND HOW WE REACTED TO PATIENTS’ NEEDS” C. Elling-Audersch
180 [GO] 2022―Aug―11 LB0003 WITHDRAWING METHOTREXATE AFTER BOTH VERSUS ONLY SECOND DOSE OF THE ChAdOx1 nCoV-19 VACCINE IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY ARTHRITIS: TWO INDEPENDENT RANDOMIZED CONTROLLED TRIALS (MIVAC I AND II) A. Sreekanth, T. Skaria, S. Joseph, R. Umesh, M. Mohanan, A. Paul, et al. (+11)
181 [GO] 2022―Aug―09 Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave Yumeko Kawano, Naomi J Patel, Xiaosong Wang, Claire E Cook, Kathleen MM Vanni, Emily N Kowalski, et al. (+8)
182 [GO] 2022―Aug―03 Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination Giuseppe A Ramirez, Lorenza Maria Argolini, Tommaso Schioppo, Savino Sciascia, Luca Moroni, Gabriella Moroni, et al. (+13)
183 [GO] 2022―Jul―25 SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study Woo-Joong Kim, Seong-Ho Choi, Ji Young Park, Jung Soo Song, Jin-Won Chung, Sang Tae Choi
184 [GO] 2022―Jul―11 Correspondence on “Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry” by Machado et al Rim Bourguiba, Marion Delplanque, Léa Savey, Veronique Hentgen, Gilles Grateau, Sophie Georgin-lavialle
185 [GO] 2022―Jun―30 Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink Abhishek Abhishek, Edoardo Cipolletta, Georgina Nakafero, Anthony J Avery, Mamas Mamas, Laila J Tata
186 [GO] 2022―Jun―28 AB1128 MAINTENANCE THERAPY FOR PATIENTS WITH RHEUMATIC DISEASES DURING THE COVID-19 D. Ben Nessib, M. Yasmine, H. Ferjani, W. Triki, K. Maatallah, D. Kaffel, W. Hamdi
187 [GO] 2022―Jun―28 AB1143 MUSCULOSKELETAL PAIN AS A PART OF THE RHEUMATIC SPECTRUM IN COVID-19 S. Bogdanova-Petrova, T. Georgiev, S. Dimitrov, S. Hristova, T. Shivacheva
188 [GO] 2022―Jun―28 AB1182 SPECIALIZED PRO-RESOLVING MEDIATORS (SPMS) AND INFLAMMATORY NETWORKS IN PATIENTS AFFECTED BY ADULT ONSET STILL’S DISEASE (AOSD) AND COVID-19 L. Navarini, M. Vomero, O. Berardiucrti, D. Currado, A. Marino, A. Biaggi, et al. (+8)
189 [GO] 2022―Jun―28 AB1098 DEVELOPMENT OF INFLAMMATORY MYOPATHY AFTER COVID-19 I. Menshikova, A. Shilina, N. Nikolaeva
190 [GO] 2022―Jun―28 AB1097 FEATURES OF THE COURSE AND CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO UNDERWENT COVID-19 E. Aronova, G. Gridneva, B. Belov
191 [GO] 2022―Jun―28 AB1083 MUSCULOSKELETAL MANIFESTATIONS AND POSTCOVID SYNDROME IN HOSPITALIZED PATIENTS INFECTED WITH COVID-19 Ö. Küçülmez, G. Gençtoy
192 [GO] 2022―Jun―28 AB0981 DYNAMICS OF PAIN ACCORDING TO THE VAS SCALE, FUNCTIONAL ACTIVITY ACCORDING TO THE WOMAC INDEX AND QUALITY OF LIFE ACCORDING TO THE EQ-5D QUESTIONNAIRE IN ELDERLY AND SENILE PATIENTS WITH KNEE JOINT OSTEOARTHRITIS AFTER COVID-19 M. Letaeva, M. Koroleva, O. Malyshenko, J. Averkieva, T. Raskina
193 [GO] 2022―Jun―28 AB0812 EFFECT OF PRO-INFLAMMATORY CYTOKINE- INTERLEUKIN 6 ON THE COURSE OF ANKYLOSING SPONDYLITIS IN PATIENTS AFTER COVID-19 N. Abdurakhmanova, K. Akhmedov
194 [GO] 2022―Jun―28 POS1261 CLINICAL RESPONSE PREDICTORS OF TOCILIZUMAB THERAPY IN PATIENTS WITH SEVERE COVID-19 W. Schmidt, K. Pawlak-Bus, P. Leszczynski
195 [GO] 2022―Jun―28 POS1203 INCREASED PROTEASE-ACTIVATED RECEPTOR 1 AUTOANTIBODIES ARE ASSOCIATED WITH SEVERE COVID-19 F. Tran, A. Scharmacher, H. Grasshoff, S. Schinke, N. Kaeding, J. Bernades, et al. (+14)
196 [GO] 2022―Jun―28 POS1195 CAN PRE-TREATMENT INFLAMMATORY BIOMARKER LEVELS GUIDE TO DETERMINE APPROPRIATE TIME OF TOCILIZUMAB THERAPY IN COVID-19 D. Tecer, M. Çinar, M. N. Kaya, F. Bicakci, S. Colak, E. Tekgoz, S. Yilmaz
197 [GO] 2022―Jun―28 POS1234 DMARD DISRUPTION, INCREASED DISEASE ACTIVITY, AND PROLONGED SYMPTOM DURATION AFTER ACUTE COVID-19 AMONG PATIENTS WITH RHEUMATIC DISEASE: A PROSPECTIVE STUDY M. DI Iorio, C. Cook, K. Vanni, N. Patel, K. D’silva, X. Fu, et al. (+9)
198 [GO] 2022―Jun―28 AB1173 INCIDENT CASES OF COVID-19 AND VACCINATION ADHERENCE IN A MULTICENTRIC COHORT OF INFLAMMATORY ARTHRITIS IN BRAZIL S. M M de Souza, A. C. Medeiros-Ribeiro, M. Bredemeier, A. Duarte, M. Pinheiro, B. Stadler, et al. (+30)
199 [GO] 2022―Jun―28 POS1202 B-CELL RECONSTITUTION IS STRONGLY ASSOCIATED WITH A POSITIVE SEROLOGIC RESPONSE TO THE COVID-19 BOOSTER VACCINE IN PREVIOUSLY SEROLOGICALLY UNRESPONSIVE RITUXIMAB TREATED RHEUMATIC DISEASE PATIENTS K. Schultz, D. Jannat-Khah, R. Spiera
200 [GO] 2022―Jun―28 AB1466 CORRELATION BETWEEN SALES OF CERTAIN BEVERAGES AND GOUT ATTACKS DURING THE COVID-19 CURFEW IN CAMEROON: A HOSPITAL-BASED STUDY F. Kemta Lekpa, K. Frank Forex, H. Mbatchou, A. Jerome, H. Namme Luma, S. P. Choukem
201 [GO] 2022―Jun―28 POS1222 FOLIC ACID AND METHOTREXATE USE AND THEIR ASSOCIATION WITH COVID-19 DIAGNOSIS AND MORTALITY: AN ANALYSIS FROM THE UK BIOBANK R. Topless, R. Green, S. Morgan, P. Robinson, T. Merriman, A. Gaffo
202 [GO] 2022―Jun―28 AB1175 EFFECTS OF THE COVID-19 DISEASE ON AXIAL SPONDYLOARTHRITIS DISEASE FLARE B. Armagan, E. Atalar, B. Özdemir, Ö. Karakaş, E. Kayacan Erdogan, S. C. Güven, et al. (+3)
203 [GO] 2022―Jun―28 POS1567-PARE ASSESSMENT OF ADHERENCE AMONG GREEK PATIENTS WITH RHEUMATIC DISEASES DURING THE COVID-19 ERA K. Koutsogianni, E. Repa, K. Spanidou, I. Papadakis, I. Chatzikrystallis, P. Pratsidou-Gertsi, F. Asimakopoulou
204 [GO] 2022―Jun―28 AB1492 COMPARISON OF TELEREHABILITATION METHODS FOR SYSTEMIC SCLEROSIS PATIENTS IN THE COVID-19 ERA: A RANDOMIZED CONTROLLED STUDY T. Civi Karaaslan, E. Tarakci, O. Keles, Y. Aslan Keles, S. Ugurlu
205 [GO] 2022―Jun―28 AB1392 COVID-19 HAD AN ADVERSE IMPACT ON DENOSUMAB TREATMENT PROVISION - COMPARISON WITH PRE-PANDEMIC WAITING TIMES AT A UK-BASED RHEUMATOLOGY DEPARTMENT S. Ling, L. Bromilow, S. Vasireddy
206 [GO] 2022―Jun―28 AB1180 COVID-19 HAD DISPROPORTIONATE IMPACTS ON RA SYMPTOMS AND FUNCTION BY SEX AND AGE: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH) S. J. Bartlett, O. Schieir, M. F. Valois, D. Tin, E. Keystone, L. Bessette, et al. (+6)
207 [GO] 2022―Jun―28 POS1213 SAFETY AND EFFICACY ASSESSMENT OF COVID-19 IMMUNIZATIONS / VACCINATIONS IN PATIENTS OF A GERMAN GENERAL RHEUMATOLOGICAL PRACTICE C. Pohl
208 [GO] 2022―Jun―28 POS1253 THE COURSE OF COVID-19 IN A COHORT OF SPONDYLOARTHRITIS PATIENTS: A CASE-CONTROL PROSPECTIVE STUDY C. Castellani, R. Terribili, L. DI Sanzo, E. Molteni, G. Sciarra, G. Bevignani, et al. (+5)
209 [GO] 2022―Jun―28 AB0858 Clinical characteristics of patients with spondyloarthritis with COVID-19 in anamnesis in the Republic of Tatarstan V. Mukhamadieva, S. Lapshina, N. Shamsutdinova, A. Sagitova, A. Zakirova, L. Krasnova, et al. (+2)
210 [GO] 2022―Jun―28 AB1132 FEATURES OF THE COURSE OF COVID-19 IN ELDERLY PATIENTS WITH IMMUNO-INFLAMMATORY RHEUMATIC DISEASES (PRELIMINARY DATA). N. Muravyeva, B. Belov, A. Kulikov
211 [GO] 2022―Jun―28 AB1176 DOES VACCINATION AND VARIANTS AFFECT THE COURSE OF THE COVID-19 IN INFLAMMATORY RHEUMATIC DISEASE? S. Çelik, M. E. Kutu, B. Karadeniz, M. Soy
212 [GO] 2022―Jun―28 AB1161 COVID-19 IN MY RA CLINIC: DATA FROM QUESTIONNAIRE, VACCINATION, INFECTION AND FLARES FROM THE RA LOUVAIN BRUSSELS COHORT V. Pirson, T. Sokolova, X. Theunssens, L. Bricman, E. Sapart, S. DE Montjoye, et al. (+3)
213 [GO] 2022―Jun―28 AB1087 COVID-19 IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS A. Hočevar, B. Burja, M. Tomsic, Z. Rotar
214 [GO] 2022―Jun―28 POS1265 DISTURBED CELLULAR IMMUNITY FOLLOWING mRNA VACCINATION AGAINST COVID-19 IN PATIENTS WITH B-CELL DEPLETING THERAPY C. Sallegger, I. Hodl, B. Dreo, V. L. Ihm, J. Thiel, M. Stradner, et al. (+2)
215 [GO] 2022―Jun―28 POS1279 FAVOURABLE COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER USING BIOLOGIC AGENTS N. Aliyeva, S. Sari, S. Amikishiyev, B. Ç. Yalçin Dulundu, V. Suleymanova, P. Telli, et al. (+4)
216 [GO] 2022―Jun―28 POS1193 COVID-19 IN PATIENTS WITH GIANT CELL ARTERITIS J. Kramarič, R. Jese, M. Tomsic, Z. Rotar, A. Hočevar
217 [GO] 2022―Jun―28 POS1283 THE COURSE OF NOVEL CORONAVIRUS DISEASE 2019 (COVID-19) IN PATIENTS WITH IgG4-RELATED DISEASE TREATED WITH RITUXIMAB E. Sokol, A. Torgashina
218 [GO] 2022―Jun―28 POS1194 COVID-19 IN PATIENTS WITH INFLAMMATORY MYOPATHY A. Hočevar, B. Radič, M. Krosel, M. Tomsic, Z. Rotar
219 [GO] 2022―Jun―28 POS1205 COVID-19 IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES - DATA FROM THE ROMANIAN REGISTRY OF RHEUMATIC DISEASES D. Minca, A. Minca, C. E. Ionescu, O. G. Dinache, C. Popescu, M. Agache, et al. (+3)
220 [GO] 2022―Jun―28 AB1139 SARS-CoV2- INFECTION AFTER VACCINATION AGAINST COVID-19 IN PATIENTS WITH RHEUMATIC DISORDERS IN A REAL LIFE SETTING OF A RHEUMATOLOGICAL OUTPATIENT CENTER S. G. Werner, L. Moll, A. Uhlenberg-Moll, S. Mettler, H. E. Langer
221 [GO] 2022―Jun―28 POS1286 SEVERITY OF COVID-19 IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BIOLOGICAL DMARDs R. Samigullina, A. Dadalova, E. Vasilenko, V. Mazurov
222 [GO] 2022―Jun―28 AB1129 SAFETY OF VACCINES AGAINST COVID-19 IN PATIENTS WITH SPONDYLOARTHRITIS (PRELIMINARY DATA). A. Kulikov, N. Muravyeva, B. Belov
223 [GO] 2022―Jun―28 AB1126 CHARACTERISTICS AND OUTCOMES OF COVID-19 IN PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES: EXPERIENCE FROM A TERTIARY RHEUMATOLOGY CENTER IN MALAYSIA S. Selvananda, S. L. Kan
224 [GO] 2022―Jun―28 POS1271 THE COURSE AND OUTCOMES OF COVID-19 IN PATIENTS WITH TAKAYASU ARTERITIS: CASE SERIES OF 15 PATIENTS FROM A TERTIARY SINGLE CENTER G. Sevik, S. Kutluğ Ağaçkiran, K. Abacar, A. Aliyeva, H. Direskeneli, F. Alibaz-Oner
225 [GO] 2022―Jun―28 AB1082 FREQUENCY AND SEVERITY OF COVID-19 IN PATIENTS WITH VARIOUS RHEUMATIC DISEASES TREATED REGULARLY WITH COLCHICINE OR HYDROXYCHLOROQUINE M. Oztas, M. Bektaş, I. Karacan, N. Aliyeva, A. Dag, S. Aghamuradov, et al. (+9)
226 [GO] 2022―Jun―28 POS1192 INCIDENCE AND RISK FACTORS OF COVID-19 IN PATIENTS WITH VASCULITIS: A DANISH NATIONWIDE COHORT STUDY S. Kristensen, R. L. Cordtz, K. Duch, J. Lindhardsen, C. Torp-Pedersen, L. Dreyer
227 [GO] 2022―Jun―28 AB1171 PERSISTENT POST-DISCHARGE SYMPTOMS AFTER COVID-19 IN RHEUMATIC AND MUSCULOSKELETAL DISEASES I. Perez-Sancristobal, L. León, M. P. Álvarez Hernandez, A. Madrid García, L. Lopez Pedraza, J. I. Colomer, et al. (+6)
228 [GO] 2022―Jun―28 POS1246 COVID-19 IN RITUXIMAB TREATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES R. Hasseli, B. F. Hoyer, H. M. Lorenz, A. Pfeil, A. Regierer, J. Richter, et al. (+7)
229 [GO] 2022―Jun―28 AB1136 PREVALENCE OF COVID-19 IN SYSTEMIC LUPUS ERYTHEMATOSUS: A META-ANALYSIS J. Wang, S. X. Zhang, X. Y. Yin, B. R. Zhao, Y. R. Shi, J. Y. Meng, et al. (+3)
230 [GO] 2022―Jun―28 AB1179 CLINICAL CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO UNDERWENT COVID-19 IN THE REPUBLIC OF TATARSTAN N. Shamsutdinova, S. Lapshina, V. Mukhamadieva, A. Sagitova, A. Zakirova, L. Krasnova, et al. (+3)
231 [GO] 2022―Jun―28 AB1157 CLINICAL CHARACTERISTICS OF PATIENTS WITH RHEUMATIC DISEASES AFTER COVID-19 IN THE REPUBLIC OF TATARSTAN S. Lapshina, N. Shamsutdinova, V. Mukhamadieva, R. Abdrakipov, E. Sukhorukova, A. Sagitova, et al. (+3)
232 [GO] 2022―Jun―28 AB1133 MUSCULOSKELETAL MANIFESTATIONS AMONG PATIENTS WITH COVID-19 INFECTION S. Tharwat, N. M. Shabana, M. K. Nassar
233 [GO] 2022―Jun―28 POS1467 SEPTAL PANNICULITIS AS A MANIFESTATION OF COVID-19 INFECTION O. Egorova, G. Tarasova, A. Datsina
234 [GO] 2022―Jun―28 POS1264 LONGITUDINAL FOLLOW-UP OF HUMORAL RESPONSE AGAINST SARS-CoV-2 AND VIRAL PERSISTENCE IN 96 DMARDs-TREATED PATIENTS WITH PREVIOUS COVID-19 INFECTION O. Fogel, M. Beretta, C. Planchais, T. Bruneau, P. Goncalves, J. Avouac, et al. (+12)
235 [GO] 2022―Jun―28 POS1230 INCREASED ANTIBODY RESPONSE AFTER SARS-CoV-2 mRNA-BASED VACCINATION IN RITUXIMAB-TREATED PATIENTS WITH PREVIOUS COVID-19 INFECTION J. Avouac, R. Ghossan, O. Al Tabaa, A. Combier, A. Steelandt, M. Thomas, et al. (+7)
236 [GO] 2022―Jun―28 POS1254 RISK FACTORS FOR SEVERE COVID-19 INFECTION AMONG PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES (AIRD) AND THE IMPACT OF VACCINATIONS - AN ISRAELI, MULTI-CENTER EXPERIENCE F. Kharouf, T. Eviatar, M. Braun, E. Pokroy-Shapira, M. Brodavka, N. Agmon-Levin, et al. (+23)
237 [GO] 2022―Jun―28 POS0757 COVID-19 INFECTION AND RECOVERY AMONGST PATIENTS WITH MODERATE-TO-SEVERE LUPUS DURING THE PANDEMIC: RESULTS FROM THE BILAG-BIOLOGICS REGISTER (BILAG-BR) S. Dyball, M. Rodziewicz, E. Sutton, B. Parker, I. N. Bruce
238 [GO] 2022―Jun―28 AB1518 CASE REPORT OF A HARD TO TREAT DERMATOMYOSITIS AFTER A COVID-19 INFECTION AND SUBSEQUENT VACCINATION P. Peteva, L. Marinchev
239 [GO] 2022―Jun―28 AB1131 IDENTIFICATION OF FACTORS ASSOCIATED WITH THE OCCURRENCE OF SEVERE FORMS OF COVID-19 INFECTION IN PATIENTS WITH AUTOIMMUNE/INFLAMMATORY RHEUMATIC DISEASES K. Chevalier, M. Genin, T. Petit Jean, J. Avouac, R. M. Flipo, S. Georgin-Lavialle, et al. (+18)
240 [GO] 2022―Jun―28 AB1193 THE COURSE OF COVID-19 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING VARIOUS BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS R. Samigullina, A. Dadalova, E. Vasilenko, V. Mazurov
241 [GO] 2022―Jun―28 POS1269 CLINICAL COURSE AND OUTCOMES OF COVID-19 INFECTION IN PATIENTS WITH SJOGREN’S SYNDROME TREATED WITH RITUXIMAB. A. Torgashina, E. Sokol, B. Chalcev, J. Khvan, O. Golovina, S. Glukhova
242 [GO] 2022―Jun―28 AB1107 COVID-19 INFECTION MAY BE TRIGGER FOR DEVELOPMENT OF IMMUNE-MEDIATED DISEASES (IMDs) N. Manukyan, V. Vardanyan, K. Ginosyan, A. Sargsyan, S. Mardoyan
243 [GO] 2022―Jun―28 AB1122 HAVE TREATMENTS FOR AUTOIMMUNE DISEASES WORSENED THE PROGNOSIS OF COVID-19 INFECTION? A. I. Rebollo Giménez, M. González Peñas, J. Seoane Romero, L. Martín de la Sierra López, L. Jiménez Rodríguez, D. Castro-Corredor, et al. (+3)
244 [GO] 2022―Jun―28 POS1495-HPR COVID-19, INFLUENZA AND PNEUMOCOCCUS VACCINATION UPTAKE IN PATIENTS WITH RHEUMATIC DISEASE: A PROSPECTIVE AUDIT R. Mazumder, R. Yamin, M. Roberts, K. Afridi, E. Ntatsaki
245 [GO] 2022―Jun―28 AB1420 CLINICIAN-RELATED FACTORS MAY INFLUENCE REMOTE CONSULTATIONS IN RHEUMATOLOGY - ANALYSIS OF SENIOR VS TRAINEE CLINICIANS’ OUTCOMES FROM A COVID-19 INITIATIVE M. Hannides, S. Wig, S. Vasireddy
246 [GO] 2022―Jun―28 POS1491-HPR THE USEFULNESS OF THE PATIENT ACTIVITY SCORE-PASS-II TO ASSESS DISEASE ACTIVITY DURING THE COVID-19 LOCKDOWN IN PATIENTS WITH RHEUMATOID ARTHRITIS F. Rodriguez, D. Buitrago-Garcia, G. Sánchez, P. Santos-Moreno
247 [GO] 2022―Jun―28 AB0900 A temporary antirheumatic drugs withdrawal does not cause an excess of disease flares in patients with psoriatic arthritis undergoing Covid-19 mRNA vaccination R. Bixio, A. Milanesi, O. Viapiana, C. Montecucco, S. Bugatti, M. Rossini
248 [GO] 2022―Jun―28 AB1152 COVID-19 mRNA VACCINE BOOSTER IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES C. Cardelli, T. Caruso, C. Tani, F. Pratesi, R. Talarico, F. DI Cianni, et al. (+9)
249 [GO] 2022―Jun―28 AB1251 LATE ONSET PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN AN INDIAN ADOLESCENT BOY DURING A PEAK OF POST COVID-19 MULTISYSTEM INFLAMMATORY SYNDROME D. B. Pandya
250 [GO] 2022―Jun―28 AB1140 IMPACT OF COVID-19 NEWS SOURCES ON RHEUMATOID ARTHRITIS PATIENTS’ LIFESTYLE AND THEIR DISEASE ACTIVITY FROM NINJA 2020 COHORT STUDY A. Ihata, T. Matsui, S. Tohma
251 [GO] 2022―Jun―28 POS1221 EFFECT OF COVID-19 ON CHILDREN WITH RHEUMATIC DISEASE T. Limon, G. Kaya Aksoy, S. Akman, M. Koyun, G. Öngüt, D. Mutlu, et al. (+3)
252 [GO] 2022―Jun―28 AB1118 INVESTIGATION OF THE EFFECT OF THE HISTORY OF COVID-19 ON COGNITIVE LEVEL, PAIN CATASTROPHIZATION, AND PHYSICAL ACTIVITY LEVEL IN INDIVIDUALS WITH CHRONIC LOW BACK AND NECK PAIN A. Asliyüce, O. Ulger
253 [GO] 2022―Jun―28 POS1229 THE IMPACT OF COVID-19 ON MEDICATION NON-ADHERENCE IN A RHEUMATOID AND PSORIATIC ARTHRITIS UK COHORT P. Curry, H. Chinoy, M. Jani, D. Plant, K. Hyrich, A. Morgan, et al. (+5)
254 [GO] 2022―Jun―28 AB1124 IMPACT OF COVID-19 ON PATIENTS WITH RHEUMATIC DISEASES IN A SECOND LEVEL HOSPITAL S. García-Díaz, D. Roig-Vilaseca, M. Vacas-Moreira, D. Cerda, P. Estrada Alarcón, V. A. Navarro Angeles, et al. (+3)
255 [GO] 2022―Jun―28 POS1267 LONG-TERM SURVEY STUDY OF THE IMPACT OF COVID-19 ON SYSTEMIC AUTOIMMUNE DISEASES. LOW DEATH RATE DESPITE THE INCREASED PREVALENCE OF SYMPTOMATIC INFECTION. ROLE OF PRE-EXISTING INTERSTITIAL LUNG DISEASE AND ONGOING TREATMENTS. C. Ferri, V. Raimondo, L. Gragnani, D. Giuggioli, L. Dagna, A. Tavoni, et al. (+78)
256 [GO] 2022―Jun―28 POS1175 IMPACT OF COVID-19 ON THE CLINICAL COURSE OF GOUT AND THE OVERALL USAGE OF MEDICATION IN PATIENTS WITH GOUT S. Smiyan, O. Makhovska
257 [GO] 2022―Jun―28 POS1228 IMPACT OF COVID-19 ON THE PRESCRIPTION OF BIOLOGIC DMARDs: A POPULATION-LEVEL STUDY IN ENGLAND M. Russell, S. Balachandran, S. Norton, E. Alveyn, D. Nagra, M. Adas, J. Galloway
258 [GO] 2022―Jun―28 AB1125 SAFETY OF BIOLOGIC-DMARDs DURING COVID-19 OUTBREAK: FOLLOW-UP STUDY IN 1051 RHEUMATIC PATIENTS OVER THE FIRST TWO WAVES. A. Sonaglia, R. Comoretto, E. Pasut, G. Del Frate, D. Colatutto, A. Zabotti, et al. (+2)
259 [GO] 2022―Jun―28 POS0372 USE OF TELEMEDICINE FOR FOLLOW-UP OF LUPUS NEPHRITIS IN THE COVID-19 OUTBREAK: ONE-YEAR, PRAGMATIC RANDOMISED CONTROLLED TRIAL H. So, E. Chow, I. T. Cheng, S. L. Lau, T. K. LI, C. C. Szeto, L. S. Tam
260 [GO] 2022―Jun―28 AB1167 THE USE OF ORAL AMINO-BISPHOSPHONATES AND CORONAVIRUS DISEASE 2019 (COVID-19) OUTCOMES F. Pistillo, M. Rossini, A. Fassio, C. Benini, D. Gatti, G. Adami
261 [GO] 2022―Jun―28 AB1142 EFFECTS OF SULFASALAZINE USED IN AXIAL SPONDYLOARTHRITIS ON COVID-19 OUTCOMES: REAL-LIFE DATA FROM A SINGLE CENTER B. Armagan, E. Atalar, S. C. Güven, B. Özdemir, H. E. Konak, P. Akyüz Dağli, et al. (+7)
262 [GO] 2022―Jun―28 AB1187 AUTOIMMUNITY PROFILE AND LUNG INVOLVEMENT IN ITALIAN PATIENTS WITH DERMATOMYOSITIS DURING COVID-19 PANDEMIA P. Triggianese, A. D’antonio, E. Cela, B. Kroegler, S. Modica, M. Ferraioli, et al. (+4)
263 [GO] 2022―Jun―28 AB1533-HPR ASSOCIATED FACTORS OF FALL OR FRACTURE REPORTED BY RHEUMATOID ARTHRITIS PATIENTS IN ELECTRONIC MDHAQ DURING COVID-19 PANDEMIC I. Lineburger, C. V. Brenol, V. Naomi Hirakata
264 [GO] 2022―Jun―28 AB1498 THE BIOPSYCHOSOCIAL-BASED EXERCISE MODEL VIA TELEREHABILITATION IN PATIENTS WITH INFLAMMATORY AND NON-INFLAMMATORY RHEUMATIC DISEASES: A PROSPECTIVE COHORT STUDY DURING THE COVID-19 PANDEMIC N. E. Nacar, N. B. Karaca, L. Kiliç, S. Kiraz, E. Ünal
265 [GO] 2022―Jun―28 AB1412 IMPORTANCE OF TELEMEDICINE IN THE SYSTEMIC SCLEROSIS DURING COVID-19 PANDEMIC G. Cuomo, C. Di Vico, F. Masini, C. Iandoli, D. Perretta, R. Irace
266 [GO] 2022―Jun―28 AB1398 CORRELATES OF CANCELLED HEALTHCARE APPOINTMENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS DURING THE COVID-19 PANDEMIC N. Dorr, P. Fennell, L. Shapiro
267 [GO] 2022―Jun―28 AB1177 SEXUALITY, FAMILY PLANNING AND MENTAL HEALTH AMONG REPRODUCTIVE-AGE WOMEN WITH RHEUMATIC DISEASE DURING THE COVID-19 PANDEMIC A. Puchner, N. Rosenberg, N. Valenta, V. Ritschl, T. Stamm, P. Mandl, et al. (+2)
268 [GO] 2022―Jun―28 AB1159 HYDROXYCHLOROQUINE SHORTAGE AND ITS RELATION TO ANXIETY LEVEL AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS DURING COVID-19 PANDEMIC M. H. Abu-Zaid, H. Eitta, A. Moshrif, D. Abdeldaim, N. EL Ghobashy
269 [GO] 2022―Jun―28 AB0698 IMPACT OF ILOPROST WITHDRAWAL IN SCLERODERMA PATIENTS DUE TO COVID-19 PANDEMIC L. Verardi, E. de Lorenzis, G. Natalello, L. Gigante, P. G. Cerasuolo, M. A. D’Agostino, S. L. Bosello
270 [GO] 2022―Jun―28 POS1493-HPR FACTORS ASSOCIATED WITH THE OCCURRENCE OF MENTAL DISORDERS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC. R. V. Gamboa Cárdenas, J. Huarcaya-Victoria, M. F. Ugarte-Gil, C. Reategui Sokolova, V. Pimentel-Quiroz, F. Zevallos Miranda, et al. (+5)
271 [GO] 2022―Jun―28 POS1547-HPR CREATION OF A MULTI-DISCIPLINARY TEAM (MDT) RHEUMATOLOGY CLINIC AT UNIVERSITY COLLEGE LONDON HOSPITAL (UCLH) TO TACKLE THE BACKLOG OF PATIENTS WAITING FOR TREATMENT AS A RESULT OF THE COVID-19 PANDEMIC. D. Ludwig, F. Higgs, N. Allotey, S. Begum, J. Burton
272 [GO] 2022―Jun―28 POS1317 HOW CAN WE ASSESS CARDIOVASCULAR RISK IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS? PRELIMINARY RESULTS REGARDING MEASUREMENTS OF CAROTID INTIMA-MEDIA THICKNESS DURING THE COVID-19 PANDEMIC. M. Gruca, K. Orczyk, J. Zamojska, K. Niewiadomska-Jarosik, J. Stanczyk, E. Smolewska
273 [GO] 2022―Jun―28 POS1257 READING THE WAVES: IDENTIFYING DISTINCT PHENOTYPES OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN IN A SINGLE CANADIAN CENTER DURING THE 2020-2021 COVID-19 PANDEMIC T. Renson, P. Miettunen, S. Parsons, M. Dhalla, N. Johnson, N. Luca, et al. (+5)
274 [GO] 2022―Jun―28 POS1206 UNDERSTANDING THE LANDSCAPE OF RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH IL-6 INHIBITORS DURING THE COVID-19 PANDEMIC D. Baldock, E. Baynton, A. Kamaruddin
275 [GO] 2022―Jun―28 POS0609 STRESS-ASSOCIATED INCREASES IN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND FLARES DURING THE COVID-19 PANDEMIC D. Furst, N. T. Morris, A. Q. Pham, T. Woodworth, D. Elashoff, J. Brook, V. Ranganath
276 [GO] 2022―Jun―28 POS0375 EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS IN TELECONSULTATION DURING THE FIRST WAVE OF THE COVID-19 PANDEMIC J. Avouac, A. Moltó, C. Frantz, S. Wanono, E. Descamps, O. Fogel, et al. (+4)
277 [GO] 2022―Jun―28 AB1106 HOW HAS THE COVID-19 PANDEMIC AFFECTED OUR RHEUMATOLOGY PATIENTS USING BIOLOGICAL/TARGETED DMARDS? S. Gulle, Y. Erez, A. Karakas, T. Yüce İnel, S. B. Kocaer, T. Demirci Yildirim, et al. (+4)
278 [GO] 2022―Jun―28 AB1096 THE INFLUENCE OF THE BEHAVIORAL RESTRICTION OF COVID-19 PANDEMIC FOR THE FRAILTY OF PATIENTS WITH RHEUMATOID ARTHRITIS M. Tada, Y. Yamada, K. Mandai, Y. Matsumoto, N. Hidaka
279 [GO] 2022―Jun―28 POS1226 CLINICAL FACTORS ASSOCIATED WITH A POSITIVE SARS-CoV-19 TEST AND WITH FREQUENT TESTING DURING THE COVID-19 PANDEMIC IN >10.000 PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. RESULTS FROM A NATIONWIDE SURVEY FROM THE DANISH DANBIO REGISTRY B. Glintborg, D. V. Jensen, L. Terslev, O. Hendricks, M. Østergaard, S. H. Rasmussen, et al. (+14)
280 [GO] 2022―Jun―28 POS1572-PARE HELPER’S WAY OF WORKING IN ORS BRANCH - NIS DURING THE COVID-19 PANDEMIC IN 2021 D. Jankovic, V. Filipovic
281 [GO] 2022―Jun―28 AB1103 THE EFFECT OF COVID-19 PANDEMIC IN A LARGE SERIES OF PATIENTS WITH TAKAYASU ARTERITIS A. Karakas, T. Yuce Inel, F. Onen, İ. Sari
282 [GO] 2022―Jun―28 POS1235 WORKING FROM HOME IN PATIENTS WITH RMDs DURING THE COVID-19 PANDEMIC IN EUROPE. RESULTS FROM THE REUMAVID STUDY (PHASE 1 AND 2) M. Garrido-Cumbrera, V. Navarro-Compán, L. Christen, J. Correa-Fernández, H. Marzo-Ortega
283 [GO] 2022―Jun―28 AB1443 INCIDENCE OF RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC IN KOREA: A NATIONWIDE CLAIMS STUDY S. M. Ahn, S. Hong, C. K. Lee, B. Yoo, J. S. Oh, Y. G. Kim
284 [GO] 2022―Jun―28 AB1091 THE IMPACT OF COVID-19 PANDEMIC ON DISEASE MONITORING AND MONITORING FOR ADVERSE CLINICAL OUTCOMES IN THOSE ON BIOLOGIC THERAPY. B. Preece, E. Thomas
285 [GO] 2022―Jun―28 AB1089 PSYCHOSOCIAL IMPACTS OF THE COVID-19 PANDEMIC ON ETHIOPIAN AND CANADIAN RHEUMATOLOGY PATIENTS C. Hitchon, D. Dacosta, B. Abdissa Adugna, S. Bernatsky, I. Colmegna, B. Demelash, et al. (+5)
286 [GO] 2022―Jun―28 AB1117 THE IMPACT OF THE COVID-19 PANDEMIC ON HEALTH AND LIFESTYLE IN INDIVIDUALS WITH KNEE PAIN, A HALLOA STUDY E. Sunesson, C. Sylwander, E. Haglund, M. Andersson, I. Larsson
287 [GO] 2022―Jun―28 AB1410 IMPACT OF COVID-19 PANDEMIC ON HEALTHCARE RESOURCE USE AND CLINICAL OUTCOMES IN A COHORT OF PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES- AN INTERIM ANALYSIS FROM THE PER-MAS PROJECT. F. Trentin, G. Fulvio, G. Andreozzi, C. Cigolini, M. Da Rio, V. Dell’Oste, et al. (+17)
288 [GO] 2022―Jun―28 AB1401 IMPACT OF THE COVID-19 PANDEMIC ON HEALTHCARE UTILIZATIONS OF RMD PATIENTS IN EUROPE. RESULTS FROM THE REUMAVID STUDY (PHASE 1 AND 2) M. Garrido-Cumbrera, H. Marzo-Ortega, J. Correa-Fernández, L. Christen, V. Navarro-Compán
289 [GO] 2022―Jun―28 POS0920 THE EFFECT OF COVID-19 PANDEMIC ON IDIOPATHIC INFLAMMATORY MYOSITIS PATIENTS - A SINGLE CENTRE’S EXPERIENCES T. G. Béldi, A. Vincze, B. Miltényi-Szabó, Z. Varga, M. Nagy-Vincze, Z. Griger
290 [GO] 2022―Jun―28 AB0681 The 2-year impact of COVID-19 pandemic on muscle strength and physical performance in patients with systemic sclerosis: a cohort study L. Denardi Dória, R. Cavalheiro do Espírito Santo, L. Santos, D. Nóbrega de Moraes, É. Pena, J. Katarina Schoer Portes, et al. (+5)
291 [GO] 2022―Jun―28 POS1190 IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: DISRUPTIONS IN CARE AND SELF-REPORTED OUTCOMES A. M. Fouad, S. F. Elotla, E. Nourhan Elameen, A. E. Mohamed
292 [GO] 2022―Jun―28 POS1209 THE IMPACT OF THE COVID-19 PANDEMIC ON WORK PRODUCTIVITY IN PATIENTS WITH SPONDYLOARTHRITIS: RESULTS FROM THE DUTCH SpA-Net REGISTRY C. Webers, A. Van Tubergen, H. Vonkeman, A. Boonen
293 [GO] 2022―Jun―28 POS0378 EVALUATION OF THE USE OF VIDEO CONSULTATION IN GERMAN RHEUMATOLOGY CARE BEFORE AND DURING THE COVID-19 PANDEMIC WAVES J. Reiter, G. Chehab, P. Aries, F. Muehlensiepen, M. Welcker, A. Voormann, et al. (+3)
294 [GO] 2022―Jun―28 AB0691 SYSTEMIC SCLEROSIS AT THE TIME OF COVID-19 PANDEMIC: A BIBLIOMETRIC STUDY B. Doskaliuk, R. Yatsyshyn, I. Stoika, K. Fedorovych, O. Hotsaniuk, O. Drogomeretska
295 [GO] 2022―Jun―28 AB1185 PATIENT-REPORTED EXPERIENCE IN IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) IN THECONTEXT OF THE COVID-19 PANDEMIC: ACCESSIBILITY AND CONTINUITY OF CARE. J. P. Baldivieso, E. Ramirez, M. Uriarte-Ecenarro, C. Valero, E. Velasco, I. Llorente, et al. (+3)
296 [GO] 2022―Jun―28 AB1116 RESULTS OF PRESCRIBING BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND JANUS KINASE INHIBITORS FOR RHEUMATOID ARTHRITIS DURING THE COVID-19 PANDEMIC: DATA FROM A TELEPHONE SURVEY OF 254 PATIENTS. A. Potapova, A. Karateev, E. Pogozheva, E. Matianova, A. Bobkova, A. Semashko, et al. (+4)
297 [GO] 2022―Jun―28 POS1499-HPR ANKYLOSING SPONDYLITIS AND TELE-YOGA DURING COVID-19 PANDEMIC: PRELİMİNARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL Y. Acar, N. Ilcin, İ. Sari
298 [GO] 2022―Jun―28 POS1197 REMOTE AND PHYSICAL CONSULTATIONS DURING THE FIRST 15 MONTHS OF THE COVID-19 PANDEMIC: USE AND PATIENT-SATISFACTION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES FOLLOWED IN THE DANBIO REGISTRY B. Glintborg, D. V. Jensen, L. Terslev, O. Hendricks, M. Østergaard, S. H. Rasmussen, et al. (+14)
299 [GO] 2022―Jun―28 AB1121 HOW FEARS AND HOPES HAVE EVOLVED IN PATIENTS WITH RMDs THROUGHOUT THE COVID-19 PANDEMIC? RESULTS FROM THE REUMAVID STUDY (PHASE 1 AND 2) M. Garrido-Cumbrera, H. Marzo-Ortega, L. Christen, J. Correa-Fernández, E. Mateus, L. Grange, et al. (+7)
300 [GO] 2022―Jun―28 AB1162 THE LINK BETWEEN INFLAMMATION AND THROMBOSIS: CLINICAL AND IMMUNOHISTOCHEMICAL CHARACTERIZATION OF PULMONARY ARTERIAL THROMBOSIS IN COVID-19 PATIENTS L. Quartuccio, A. Sonaglia, L. Casarotto, D. Mcgonagle, C. DI Loreto, E. Pegolo
301 [GO] 2022―Jun―28 AB1134 BIBLIOMETRIC NETWORK ANALYSIS ON TOCILIZUMAB TREATMENT FOR COVID-19 PATIENTS L. Cascella, F. Monaco, D. Nocerino, A. Infernuso, V. Cascella, F. Del Prato, et al. (+2)
302 [GO] 2022―Jun―28 AB0020 COMPARATIVE DESCRIPTION OF CYTOKINES AND MATRIX METALLOPROTEINASES IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHROSIS UNDER A STRICT FOLLOW-UP COMPARED WITH COVID-19 PATIENTS S. Navarrete, L. D. Gutiérrez-Castañeda, P. K. Bautista-Niño, J. A. Rubio-Rubio, G. S. Rodríguez-Vargas, P. Santos-Moreno, et al. (+6)
303 [GO] 2022―Jun―28 POS1240 HIGH PREVALENCE OF SERUM AUTOANTIBODIES IN SEVERELY ILL COVID-19 PATIENTS HOSPITALIZED IN THE INTENSIVE CARE UNIT. K. Bitzogli, E. Jahaj, A. D. Bakasis, E. Kapsogeorgou, A. Goules, I. Stergiou, et al. (+7)
304 [GO] 2022―Jun―28 POS1231 PREDICTORS OF MORTALITY IN SEVERE AND CRITICAL COVID-19 PATIENTS WHO RECEIVED ANAKINRA M. Bektaş, M. İ. Kiliç
305 [GO] 2022―Jun―28 AB1178 THE COMPARISON OF EXECUTIVE FUNCTIONS OF RECOVERED COVID-19 PATIENTS WITH HEALTHY CONTROLS C. Cakir, Y. Ulus, A. Bilgici
306 [GO] 2022―Jun―28 POS1216 POTENTIAL PREDICTORS OF OUTCOME FOR ANAKINRA TREATMENT IN COVID-19 PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME S. Amikishiyev, R. Deniz, M. G. Gunver, S. Aghamuradov, N. Koca, B. Ince, et al. (+10)
307 [GO] 2022―Jun―28 POS1268 PHASE II TRIAL OF ENPATORAN IN PATIENTS HOSPITALIZED WITH COVID-19 PNEUMONIA J. E. Mckinnon, J. Santiaguel, C. Murta, D. Yu, M. Khursheed, F. Moreau, et al. (+4)
308 [GO] 2022―Jun―28 POS1242 BARICITINIB AND PULSE STEROIDS COMBINED TREATMENT IN SEVERE COVID-19 PNEUMONIA: PRELIMINARY DATA FROM A RHEUMATOLOGIC EXPERIENCE IN INTENSIVE CARE UNIT F. Ferro, E. Elefante, N. Italiano, M. Moretti, G. La Rocca, R. Mozzo, et al. (+3)
309 [GO] 2022―Jun―28 AB0513 COVID-19 PREVENTION IN PATIENTS WITH MODERATE-TO-SEVERE LUPUS DURING THE PANDEMIC: RESULTS FROM THE BILAG-BIOLOGICS REGISTER (BILAG-BR) S. Dyball, M. Rodziewicz, E. Sutton, B. Parker, I. N. Bruce
310 [GO] 2022―Jun―28 AB1141 THE PATTERN OF POST COVID-19 REACTIVE ARTHRITIS N. Varghese, V. Salaru, V. Sadovici-Bobeica
311 [GO] 2022―Jun―28 AB1148 POST COVID-19 RHEUMATIC AND MUSCULOSKELETAL DISEASES N. Varghese, N. Loghin-Oprea, V. Sadovici-Bobeica
312 [GO] 2022―Jun―28 AB1127 ANTIOSTEOPOROTIC TREATMENT AND COVID-19 RISK: IS THERE AN ASSOCIATION? N. Grygorieva, M. Bystrytska, N. Zaverukha, A. Musiienko
313 [GO] 2022―Jun―28 POS1198 VACCINATION AGAINST COVID-19 SHOULD BE ENCOURAGED IN PATIENTS WITH RHEUMATIC DISEASE, AS MOST PATIENTS DEVELOP A SEROLOGICAL RESPONSE AGAINST THE VACCINE AND VACCINATION REDUCES SELF-IMPOSED ISOLATION AND SHIELDING BEHAVIOR C. Ammitzbøll, M. K. Thomsen, J. B. Andersen, L. E. Bartels, M. L. F. Hermansen, A. D. Johannesen, et al. (+6)
314 [GO] 2022―Jun―28 AB1160 IMPACT OF COVID-19 TREATMENTS ON PERIPHERAL CAPILLARY DENSITY EVALUATED BY NAILFOLD VIDEOCAPILLAROSCOPY E. Gotelli, A. Sulli, P. F. Bica, I. Schiavetti, T. Aloe’, M. Grosso, et al. (+5)
315 [GO] 2022―Jun―28 POS0410 THE ROLE OF IL-6 IN ENDOTHELIAL DYSFUNCTION: RHEUMATOID ARTHRITIS AND COVID-19, TWO PATHOGENIC MODELS IN COMPARISON A. I. Celia, C. Barbati, T. Colasanti, M. Speziali, G. Pellegrino, F. Natalucci, et al. (+8)
316 [GO] 2022―Jun―28 AB1516 A CASE OF SEVERE ANCA ASSOCIATED VASCULITIS AFTER COVID-19 VACCINATION I. Qaisar, K. Sunmboye
317 [GO] 2022―Jun―28 POS1281 DIFFERENT HUMORAL BUT SIMILAR CELLULAR RESPONSES OF PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES UNDER DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS AFTER COVID-19 VACCINATION I. Andreica, A. Blazquez-Navarro, J. Sokolar, M. Anft, U. Kiltz, S. Pfaender, et al. (+5)
318 [GO] 2022―Jun―28 AB1386 A SURVEY ON ACCEPTANCE OF COVID-19 VACCINATION AMONG PATIENTS WITH RHEUMATIC DISEASES -A SINGLE CENTER EXPERIENCE IN MALAYSIA C. R. Ng, W. S. Wong
319 [GO] 2022―Jun―28 AB1100 COVID-19 VACCINATION IN A REAL-LIFE SETTING OF A RHEUMATOLOGICAL OUTPATIENT CENTER S. G. Werner, L. Moll, A. Uhlenberg-Moll, S. Mettler, H. E. Langer
320 [GO] 2022―Jun―28 POS1260 COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY P. Sen, N. R, A. Nune, J. B. Lilleker, V. Agarwal, S. Kardes, et al. (+23)
321 [GO] 2022―Jun―28 POS1250 EVALUATION AFTER COVID-19 VACCINATION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME: A RETROSPECTIVE COHORT STUDY. Ö. Karakaş, A. Erden, B. Armagan, S. C. Güven, E. Atalar, B. Polat, et al. (+2)
322 [GO] 2022―Jun―28 POS0738 IMMUNOGENICITY AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME G. M. Verstappen, L. De Wolff, S. Arends, H. M. Heiermann, Y. Van Sleen, A. Visser, et al. (+7)
323 [GO] 2022―Jun―28 POS1232 LONG-TERM OUTCOMES OF COVID-19 VACCINATION IN PATIENTS WITH RARE AND COMPLEX CONNECTIVE TISSUE DISEASES: AN AD-INTERIM ANALYSIS OF ERN-ReCONNET VACCINATE STUDY F. Di Cianni, C. Cardelli, N. Italiano, E. Laurino, M. Moretti, R. Depascale, et al. (+37)
324 [GO] 2022―Jun―28 AB1155 PAUSING METHOTREXATE IMPROVES IMMUNOGENICITY OF COVID-19 VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES A. N. Arumahandi de Silva, L. M. Frommert, F. Albach, J. Klotsche, V. Scholz, A. Ten Hagen, et al. (+7)
325 [GO] 2022―Jun―28 POS1262 COVID-19 VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES -RESULTS OF 2,134 CASES ANALYSIS I. Gaydukova, V. Mazurov, O. Inamova, E. Gaydukova
326 [GO] 2022―Jun―28 POS1247 THE EFFECT OF IMMUNOSUPPRESSIVE AGENTS ON ANTIBODY FORMATION AFTER COVID-19 VACCINATION IN RHEUMATOID ARTHRITIS PATIENTS E. Kang, Y. G. Kim, J. S. Oh, S. Hong, C. K. Lee, B. Yoo, S. M. Ahn
327 [GO] 2022―Jun―28 POS1207 SEROCONVERSION AFTER A THIRD COVID-19 VACCINATION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH (ULTRA-)LOW DOSE RITUXIMAB WITH A PREVIOUS INSUFFICIENT HUMORAL RESPONSE IS DEPENDENT ON RITUXIMAB DOSAGE C. Van der Togt, D. Ten Cate, B. Van den Bemt, J. Rahamat-Langendoen, N. Den Broeder, A. Den Broeder
328 [GO] 2022―Jun―28 AB1085 COVID-19 VACCINATION INTENTION AMONG TUNISIAN HEALTH CARE WORKERS O. Hamdi, M. Boudokhane, Z. Teyeb, I. Abdelaali, T. Jomni, S. Belakhal, M. H. Dogui
329 [GO] 2022―Jun―28 AB0930 Psoriatic arthritis disease flares: is Covid-19 vaccination just an innocent bystander? R. Bixio, I. Gavioli, D. Bertelle, F. Pistillo, D. Rotta, E. Bertoldo, et al. (+3)
330 [GO] 2022―Jun―28 AB1088 COVID-19 VACCINATION OF SPONDYLOARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: REAL-LIFE DATA T. Demirci Yildirim, C. Akleylek, H. Cinakli, D. Yildirim, S. Hakbilen, B. N. Coşkun, et al. (+22)
331 [GO] 2022―Jun―28 POS1214 COVID-19 VACCINATION RATE AND SAFETY PROFILE IN PATIENTS AFFECTED BY MIXED CRYOGLOBULINEMIC VASCULITIS. C. Vacchi, S. Testoni, M. Visentini, R. Zani, G. Lauletta, L. Gragnani, et al. (+13)
332 [GO] 2022―Jun―28 POS1208 EQUITY CONSIDERATIONS IN COVID-19 VACCINATION STUDIES OF INDIVIDUALS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES H. Wang, O. Dewidar, S. Whittle, E. Ghogomu, G. Hazlewood, L. Mbuagbaw, et al. (+4)
333 [GO] 2022―Jun―28 POS1278 EXCELLENT PROGNOSIS OF RHEUMATIC MANIFESTATIONS FOLLOWING COVID-19 VACCINATION: 7 MONTHS FOLLOW-UP DATA M. Gasparotto, S. Bindoli, R. Padoan, E. Zanatta, P. Sfriso, A. Doria, L. Iaccarino
334 [GO] 2022―Jun―28 AB1095 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AFTER COVID-19 VACCINATION: A CASE REPORT D. Abdel Mohsen, R. A. Elziaty, A. A. Abdalkader
335 [GO] 2022―Jun―28 AB1511 SLE ONSET POST COVID-19 VACCINATION: COINCIDENTAL OR ASSOCIATION? C. R. Ng, C. E. Goh
336 [GO] 2022―Jun―28 AB1102 A RARE CASE OF ACUTE INFLAMMATORY DEMYELINATING POLYRADICULOPATHY FOLLOWING THE SECOND DOSE OF PFIZER COVID-19 VACCINE V. Courant, M. Silva, S. Grewal
337 [GO] 2022―Jun―28 POS1224 RHEUMATOID ARTHRITIS DISEASE ACTIVITY ASSESSED BY PATIENT-REPORTED OUTCOMES AND FLOW CYTOMETRY BEFORE AND AFTER AN ADDITIONAL DOSE OF COVID-19 VACCINE S. Tedeschi, J. Stratton, J. Ellrodt, M. G. Whelan, K. Hayashi, K. Yoshida, et al. (+6)
338 [GO] 2022―Jun―28 POS1245 REVERSAL OF DECLINE IN HUMORAL RESPONSE TO BNT162b2 mRNA COVID-19 VACCINE AFTER BOOSTER ADMINISTRATION IN AUTOIMMUNE INFLAMMATORY RHEUMATOID DISEASES (AIRD) PATIENTS Y. Braun-Moscovici, M. Kaplan, M. Braun, R. Daood, D. Markovits, S. Giryes, et al. (+10)
339 [GO] 2022―Jun―28 POS1274 A SINGLE CENTER COVID-19 VACCINE EXPERIENCE IN FAMILIAL MEDITERRANEAN FEVER PATIENTS S. C. Güven, Ö. Karakaş, E. Atalar, H. E. Konak, P. Akyüz Dağli, E. Kayacan Erdogan, et al. (+8)
340 [GO] 2022―Jun―28 AB1115 COVID-19 VACCINE HESITANCY AMONG RHEUMATOID ARTHRITIS PATIENTS ON BIOLOGICS E. Hannech, S. Boussaid, S. Rekik, S. Jemmali, S. Rahmouni, H. Ajlani, et al. (+2)
341 [GO] 2022―Jun―28 POS1227 TIME BETWEEN SECOND AND THIRD DOSES INFLUENCES RESPONSE TO COVID-19 VACCINE IN AUTO-IMMUNE DISEASE PATIENTS TREATED WITH RITUXIMAB WITHOUT RESPONSE TO TWO DOSES. S. Bitoun, J. Avouac, J. Henry, R. Ghossan, O. Al Tabaa, R. Belkhir, et al. (+4)
342 [GO] 2022―Jun―28 POS1220 HUMORAL IMMUNE RESPONSE AGAINST BNT162b2 mRNA COVID-19 VACCINE IN JAPANESE RHEUMATIC DISEASE PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY: A MONOCENTRIC STUDY K. Sugihara, R. Wakiya, H. Shimada, T. Kameda, S. Nakashima, M. Kato, et al. (+4)
343 [GO] 2022―Jun―28 POS1285 IMMUNOGENICITY AND SAFETY OF THE CHADOX 1 COVID-19 VACCINE IN PATIENTS WITH AUTOIMMUNE DISEASES AND HEALTHY CONTROLS: DATA FROM SAFER STUDY K. Lysie Libardi Lira Machado, O. A. Martins Filho, E. Reis Neto, S. T. Miyamoto, I. Ribeiro Moulaz, L. Lorenzoni Grillo, et al. (+36)
344 [GO] 2022―Jun―28 AB1150 IMMUNOGENICITY AND SAFETY OF THE CORONOVAC AND BNT162b2 COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES AND HEALTHY ADULTS: COMPARISON OF DIFFERENT VACCINES S. Batibay, R. Koçak Ulucaköy, Z. Günendi, I. Fidan, G. Bozdayi, F. N. Göğüş
345 [GO] 2022―Jun―28 AB0629 Glomerulonephritis associated with ANCA after COVID-19 vaccine: a systematic review A. Laskova, B. Mohammed, F. Ali, B. Syritsa
346 [GO] 2022―Jun―28 AB1183 COVID-19 VACCINE: HESITANCY, ACCEPTANCE AND TOLERANCE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS M. Ghali, F. Fhima, M. Ardhaoui, N. Ben Chekaya, J. Mahbouba, S. Zrour, et al. (+3)
347 [GO] 2022―Jun―28 POS1273 EVALUATION OF THE SAFETY PROFILE OF COVID-19 VACCINES IN CHILD PATIENTS USING BIOLOGICAL THERAPY B. Sözeri, R. E. Yigit
348 [GO] 2022―Jun―28 AB1086 VACCINE HESITANCY AGAINST COVID-19 VACCINES IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES AND EFFECT OF SPECIALIST COUNSELLING ON VACCINE HESITANT PATIENTS WILLINGNESS TO TAKE VACCINE K. Kunalchandwar@gmail.Com, K. Kishor, J. Dixit, P. Dogga, D. Ekbote, P. Kumar, U. Dhakad
349 [GO] 2022―Jun―28 POS1210 SAFETY AND IMMUNOGENICITY OF COVID-19 VACCINES IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE C. Hitchon, R. Marrie, C. N. Bernstein, J. Kim, S. Obrien
350 [GO] 2022―Jun―28 AB1111 NO INCREASED RISK OF ADVERSE EVENTS OF THE WHO-VALIDATED COVID-19 VACCINES IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH BIOLOGICS M. Yasmine, W. Triki, H. Ferjani, D. Ben Nessib, K. Maatallah, D. Kaffel, W. Hamdi
351 [GO] 2022―Jun―28 AB1093 SAFETY OF COVID-19 VACCINES IN PATIENTS WITH RHEUMATOID ARTHRITIS (PRELIMINARY DATA). A. Kulikov, N. Muravyeva, B. Belov
352 [GO] 2022―Jun―28 POS0776 IMMUNOGENICITY AND SAFETY OF INACTIVATED AND mRNA COVID-19 VACCINES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS H. So, T. K. Li, V. Chan, L. S. Tam, P. K. Chan
353 [GO] 2022―Jun―28 POS1248 URIC ACID AND COVID-19: PATTERN OF CHANGES AND ASSOCIATION WITH PROGNOSIS A. Sydorova, O. Iaremenko
354 [GO] 2022―Jun―28 AB1120 PSYCHOLOGICAL ASSESSMENT IN PATIENTS WITH CHRONIC RHEUMATIC, SYSTEMIC AUTOIMMUNE, OR AUTOINFLAMMATORY DISEASES PRESENTED WITH COVID-19: THE MentCOVRMD STUDY. M. M. Farhat, M. Horn, G. Vaiva, E. Drumez, R. Seror, V. Gaud-Listrat, et al. (+8)
355 [GO] 2022―Jun―28 AB1099 CORONAVIRUS INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (CASE SERIES). I. Menshikova, A. Shilina, Y. Pak, I. Kolosova
356 [GO] 2022―Jun―28 AB1081 FLARES OF RHEUMATOID ARTHRITIS FOLLOWING CORONAVIRUS VACCINATION R. Hayward, Z. Farah
357 [GO] 2022―Jun―28 POS0391 TRENDS IN THE DIAGNOSIS OF MYOSITIS AND ASSOCIATION WITH THE CORONAVIRUS-19 PANDEMIC AND VACCINES: DATA FROM THE VENETO RARE DISEASE REGISTRY, 2014-2021 A. Giollo, M. Zen, M. Gatto, E. Zanatta, L. Iaccarino, A. Doria
358 [GO] 2022―Jun―28 AB1172 POSTER: SARS-COV 2 INFECTION AND ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS PATIENTS D. Anghel, O. G. Petrache, C. Jurcut, A. Mihai, M. M. Negru, A. Ghiațău
359 [GO] 2022―Jun―28 AB1403 IMPACT OF THE SARS-COV 2 PANDEMIC AND RELATED EPIDEMIOLOGICAL RESTRICTIONS ON THE CARE OF PATIENTS WITH OSTEOPOROSIS - EXPERIENCES OF A HUNGARIAN CENTRE Z. Kardos
360 [GO] 2022―Jun―28 POS1233 DIFFICULTIES AND MENTAL IMPACT OF THE SARS-CoV- 2 PANDEMIC IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A NATIONWIDE PATIENT ASSOCIATION STUDY M. Scherlinger, N. Zein, J. E. Gottenberg, M. Riviere, J. F. Kleinmann, J. Sibilia, L. Arnaud
361 [GO] 2022―Jun―28 AB1154 HUMORAL AND CELLULAR RESPONSE TO A THIRD BOOSTER DOSE SARS-CoV- 2 VACCINATION IN PATIENTS WITH AUTOIMMUNE DISEASE: A CASE SERIES T. Dimitroulas, A. Tychala, K. Defteraiou, E. Katsimpourlia, E. Sidiropoulou, M. Papachristou, et al. (+2)
362 [GO] 2022―Jun―28 AB1501 EFFECT OF SARS-COV-19 PANDEMIC ON RHEUMATOLOGY TRAINING IN INDIA K. Kunalchandwar@gmail.com, K. Kishor, P. Dogga, D. Ekbote, J. Dixit, P. Kumar, U. Dhakad
363 [GO] 2022―Jun―28 AB1168 CLINICAL AND SEROLOGICAL EVOLUTION OF RHEUMATIC PATIENTS INFECTED BY SARS-COV-2 M. De la Rubia Navarro, J. Ivorra Cortés, E. Grau García, L. Gonzalez Puig, R. Negueroles Albuixech, I. Martínez Cordellat, et al. (+13)
364 [GO] 2022―Jun―28 POS1316 PERFORMANCE OF THE KOBAYASHI SCORE AND MODIFIED KOBAYASHI SCORE IN PREDICTING RESISTANCE TO INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH PEDIATRIC INFLAMMATORY MULTISYSTEM SYNDROME ASSOCIATED WITH SARS-CoV-2. N. Cybulska, K. Jozkow, K. Orczyk, A. Stasiak, E. Smolewska
365 [GO] 2022―Jun―28 POS1282 PEDIATRIC INFLAMMATORY MULTISYSTEM SYNDROME TEMPORALLY-ASSOCIATED WITH SARS-CoV-2 - A PORTUGUESE SINGLE CENTRE CASE SERIES B. Santos, I. Cardoso, S. Miranda, F. Aguiar, M. Rodrigues, I. Brito
366 [GO] 2022―Jun―28 POS1219 SARS-COV-2 COURSE AND OUTCOME IN PATIENTS WITH SYSTEMIC AUTOINFLAMMATORY DISEASES (SAID) TREATED WITH IL-1 INHIBITORS AND COLCHICINE S. Bindoli, S. Della Mora, A. Doria, P. Sfriso
367 [GO] 2022―Jun―28 POS1296 T-CELL RESPONSE MEASURED BY INTERFERON-γ RELEASE ASSAY AS A NOVEL TOOL FOR BETTER UNDERSTANDING OF SARS-CoV-2 IMMUNITY: THE PRELIMINARY RESULTS OF A PROSPECTIVE STUDY IN PEDIATRIC PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS. K. Kapten, K. Orczyk, E. Smolewska
368 [GO] 2022―Jun―28 AB1094 SAFETY AND EFFICACY OF VACCINES FOR SARS-CoV-2 IN PATIENTS WITH RHEUMATIC AND IMMUNE-MEDIATED INFLAMMATORY DISEASES: DATA FROM THE ARGENTINEAN REGISTRY SAR-CoVAC C. A. Isnardi, K. Roberts, R. Quintana, J. Kreimer, C. Echeverria, P. C. Luna, et al. (+54)
369 [GO] 2022―Jun―28 AB1144 COGNITIVE AND PSYCHOSOCIAL OUTCOME IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME FOLLOWING SARS-CoV-2 INFECTION D. Gosar, M. Zajc Avramovič, N. Emersic, M. Šušterič, M. M. Šömen, D. Osredkar, T. Avcin
370 [GO] 2022―Jun―28 POS1204 SARS-CoV-2 INFECTION AFTER VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA M. Cosatti, M. E. D´ Angelo, I. E. Petkovic, M. D. L. A. Correa, D. Zelaya, M. S. Gálvez Elkin, et al. (+37)
371 [GO] 2022―Jun―28 AB1112 SARS-COV-2 INFECTION AND IT VACCINATION IN AUTOINMUNE DISEASE-ASSOCIATED INTERSTICIAL LUNG DISEASE A. Garcia Studer, M. Rojas-Giménez, M. Velloso Feijoo, C. M. Romero-Barco, F. Godoy-Navarrete, N. Mena-Vázquez
372 [GO] 2022―Jun―28 POS1200 DIFFERENCES BETWEEN THE FIRST AND THE SECOND WAVE OF SARS-COV-2 INFECTION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES IN ARGENTINA: DATA FROM THE SAR-COVID REGISTRY A. Bertoli, L. Muñoz, M. J. López Pérez, L. Sanchez Freytes, M. S. Castaño, V. Saurit, et al. (+47)
373 [GO] 2022―Jun―28 POS1238 GLUCOCORTICOIDS, RITUXIMAB AND THE PRESENCE OF INTERSTITIAL LUNG DISEASE ARE ASSOCIATED WITH POOR OUTCOMES OF THE SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL REGISTRY SAR-COVID. A. B. Gómez Vara, T. Barbich, C. A. Isnardi, E. E. Schneeberger, G. Citera, V. V. Castro Coello, et al. (+46)
374 [GO] 2022―Jun―28 POS1251 INCIDENCE AND OUTCOMES OF SARS-CoV-2 INFECTION IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: A POPULATION-BASED STUDY OF MORE THAN FOUR MILLION INHABITANTS IN THE LAZIO ITALIAN REGION E. De Lorenzis, P. Parente, G. Natalello, S. Soldati, S. L. Bosello, A. Barbara, et al. (+12)
375 [GO] 2022―Jun―28 AB1113 THE IMPACT OF SARS-COV-2 INFECTION ON DISEASE ACTIVITY AND CLINICAL RESPONSE TO BIOLOGICAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS B. Samões, A. Martins, D. Santos Oliveira, F. R. Martins, R. Nicolau, M. Rato, et al. (+3)
376 [GO] 2022―Jun―28 AB0107 IMPACT OF SARS-CoV-2 INFECTION ON THE DISEASE ACTIVITY OF PATIENTS WITH PSORIATIC ARTHRITIS UNDER bDMARDs: REAL LIFE DATA R. Nicolau, A. Martins, D. Santos Oliveira, B. Samões, F. R. Martins, M. Rato, et al. (+3)
377 [GO] 2022―Jun―28 POS1263 PRE-EXPOSURE PROPHYLAXIS FOR SARS-CoV-2 INFECTION WITH SUBCUTANEOUS CASIRIVIMAB/IMDEVIMAB IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES. F. Fagni, K. Schmidt, D. Bohr, L. Valor, F. Hartmann, K. Tascilar, et al. (+6)
378 [GO] 2022―Jun―28 POS1215 IMMUNE CORRELATES AND CLINICAL COURSE OF PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING VACCINATION WITH ANTI SARS-CoV-2 mRNA BASED VACCINES: RESULTS FROM A PROSPECTIVE, OBSERVATIONAL AND CONTROLLED STUDY K. Schmiedeberg, I. A. Abela, N. B. Pikor, N. Vuilleumier, M. Schwarzmueller, S. Epp, et al. (+8)
379 [GO] 2022―Jun―28 POS1217 ANTI-TNF THERAPY FOR IMMUNE MEDIATED INFLAMMATORY DISEASES MAY BE ASSOCIATED WITH LOWER ANTIBODY LEVELS AND VIRUS NEUTRALIZATION EFFICACY FOLLOWING SARS-CoV-2 mRNA VACCINATION N. Finkelstein, R. M. Dayam, J. Law, R. Goetgebuer, G. Chao, K. T. Abe, et al. (+25)
380 [GO] 2022―Jun―28 POS1243 ACCELERATED WANING OF PROTECTIVE IMMUNITY AFTER SARS-CoV-2 mRNA VACCINATION IN PATIENTS TREATED WITH BIOLOGICAL AND TARGETED SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS S. Tobudic, E. Simader, T. Deimel, P. Mandl, H. Haslacher, T. Perkmann, et al. (+11)
381 [GO] 2022―Jun―28 POS1237 SARS-CoV-2 mRNA VACCINE IMMUNOGENICITY IN CHRONIC INFLAMMATORY ARTHRITIS ON DMARD THERAPY N. Darwish, S. Jhaveri, U. Yoganathan, H. Bakillah, K. Chun, T. Wasser, J. Freeman
382 [GO] 2022―Jun―28 AB1119 GLUCOCORTICOIDS’ TREATMENT IMPAIRS THE MEDIUM-TERM IMMUNOGENIC RESPONSE TO SARS-CoV-2 mRNA VACCINES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. S. Garcia-Cirera, J. Calvet, A. Berenguer-Llergo, E. Pradenas, M. Llop Vilaltella, C. Galisteo, et al. (+2)
383 [GO] 2022―Jun―28 AB1137 USE OF TOCILIZUMAB IN CRITICALLY ILL SARS-COV-2 PATIENTS CARE- PROGNOSTIC FACTORS OF TREATMENT EFFECTIVENESS AND TREATMENT RESULTS Z. Kardos, M. Szabó, Z. Baráth, Á. Miksi, Á. Kozma, G. A. József, Z. Szekanecz
384 [GO] 2022―Jun―28 AB1165 THE ROLE OF MOLECULAR MIMICRY IN SARS-CoV-2 RELATED AUTOIMMUNE RHEUMATIC DISEASES C. Liaskos, E. Patrikiou, L. Komorowski, C. Tsigalou, A. Tsirogianni, L. Sakkas, D. Bogdanos
385 [GO] 2022―Jun―28 AB1123 EFFICACY AND SAFETY OF SARS-CoV-2 THIRD VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO DID NOT RESPOND AFTER PRIMARY TWO-DOSE REGIMEN C. A. Isnardi, O. L. Cerda, E. E. Schneeberger, M. Landi, C. Calle Montoro, M. A. Alfaro, et al. (+22)
386 [GO] 2022―Jun―28 AB1190 SOURCES OF INFORMATION ABOUT SARS-CoV-2 USED BY PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES (CIRD) I. Andreica, I. Roman, X. Baraliakos, U. Kiltz, J. Braun
387 [GO] 2022―Jun―28 AB1135 RESPONSE TO SARS-COV-2 VACCINATION IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE DEPENDS ON IMMUNOSUPPRESSIVE REGIMEN: A MATCHED, PROSPECTIVE COHORT STUDY P. Mandl, S. Tobudic, H. Haslacher, D. Mrak, T. Nothnagl, T. Perkmann, et al. (+8)
388 [GO] 2022―Jun―28 AB1188 SARS-CoV-2 VACCINATION WILLINGNESS AND PREDICTORS IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES (CIRD) AND WITHOUT CIRD I. Andreica, I. Roman, X. Baraliakos, U. Kiltz, J. Braun
389 [GO] 2022―Jun―28 AB1163 ATTITUDES AND HESITANCY IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES TOWARDS SARS-CoV-2 VACCINATION: A SINGLE-CENTER STUDY FROM BULGARIA T. Georgiev, R. Moraliyska, S. Bogdanova-Petrova, G. Gerganov, P. Kabakchieva, S. Dimitrov, et al. (+2)
390 [GO] 2022―Jun―28 AB1169 IMMUNOMODULATORY EFFECTS OF SARS-CoV-2 VACCINATION: INCREASE OF REGULATORY T CELLS AFTER mRNA VACCINE F. La Gualana, F. Villani, G. Cusano, L. Gragnani, L. Stefanini, S. Santini, et al. (+4)
391 [GO] 2022―Jun―28 POS1196 SARS-CoV-2 VACCINE ACCEPTANCE AND ASSOCIATED PSYCHOLOGICAL FACTORS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES H. Sugawara, H. Doi, T. Iwasaki, Y. Nakayama, Y. Nishida, Y. Gon, et al. (+6)
392 [GO] 2022―Jun―28 AB1149 EVALUATION OF THE EFFICACY AND SAFETY OF THE SARS-CoV-2 VACCINE IN PATIENTS WITH CHRONIC INFLAMMATORY DISEASES TREATED WITH BIOLOGICAL THERAPY. J. Calvo Gutierrez, C. López-Medina, M. C. Ábalos-Aguilera, A. B. Pérez Jiménez, D. Ruíz-Vilchez, F. U. Pilar, et al. (+3)
393 [GO] 2022―Jun―28 POS1276 HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE IN RITUXIMAB-TREATED PATIENTS E. Flores-Fernández, I. Vázquez-Gómez, C. Valera-Ribera, P. Andújar-Brazal, E. Valls-Pascual, J. M. Nogueira Coito, et al. (+3)
394 [GO] 2022―Jun―28 AB1192 SARS-COV-2 VACCINE IN SPONDYLOARTHRITIS PATIENTS: OVERALL MODERATE/HIGH IMMUNOGENICITY IMPAIRED BY IMMUNOSUPPRESSANTS AND BIOLOGICAL THERAPY C. Saad, M. Rodrigues Silva, P. Degrava Sampaio-Barros, J. Moraes, C. Goldenstein-Schainberg, N. Aikawa, et al. (+8)
395 [GO] 2022―Jun―28 POS1212 SARS-CoV-2 VACCINE SAFETY IN ADOLESCENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES AND ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS S. Lawson-Tovey, A. Strangfeld, E. Mateus, L. Gossec, L. Carmona, P. Machado, et al. (+7)
396 [GO] 2022―Jun―28 POS1201 SAFETY OF SARS-COV-2 VACCINES IN PATIENTS WITH RHEUMATIC DISEASES: DATA FROM THE NATIONAL REGISTRY SAR-CoVAC FROM ARGENTINA M. Cosatti, M. E. D´ Angelo, I. E. Petkovic, N. Kogan, D. A. Pereira, Y. Tissera, et al. (+38)
397 [GO] 2022―Jun―28 AB1146 SARS-Cov-2 VIRAL LOAD IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASE, A RETROSPECTIVE COMPARATIVE STUDY O. Alsaed, Y. A. Y. Alrimawi, R. Saleh, M. Chaponda, P. Coyle, K. Becetti, et al. (+7)
398 [GO] 2022―Jun―28 POS1178 PRESCRIBING RITUXIMAB IN PATIENTS WITH AUTO-IMMUNE DISEASES AND ACQUIRED HYPOGAMMAGLOBULINEMIA: DESCRIPTION OF THE RISK OF SEVERE INFECTION IN 121 PATIENTS BEFORE THE SARS-Cov2 ERA B. Xavier, M. Lafaurie, E. Treiner, O. Walter, G. Pugnet, G. Martin-Blondel, et al. (+7)
399 [GO] 2022―Jun―28 AB1145 EVALUATION OF THE HUMORAL IMMUNE RESPONSE SECONDARY TO VACCINATION AGAINST SARS-CoV2 IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES P. M. Corbalán, M. Pera, G. V. Espasa, M. L. Leguizamón, A. L. Barbaglia, L. Gonzalez Lucero, et al. (+11)
400 [GO] 2022―Jun―28 POS1191 IMMUNE RESPONSES TO MRNA VACCINES AGAINST SARS-COV2 IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES C. Sieiro Santos, C. Moriano, E. Diez Alvarez, S. Calleja Antolín, I. González Fernández, C. Álvarez Castro, J. M. Garcia Ruiz de Morales
401 [GO] 2022―Jun―28 AB1170 IMPACT IN PRENATAL EVALUATION OF PREGNANT WOMEN WITH RHEUMATIC DISEASES BY THE SARS-COV2 PANDEMIC A. Y. Lujano Negrete, M. E. Corral Trujillo, C. M. Skinner Taylor, L. Pérez Barbosa, A. Aguilar-Leal, M. C. Rodriguez-Ruiz, et al. (+3)
402 [GO] 2022―Jun―28 AB1130 A REDUCTION IN NEW REFERRALS FOR RHEUMATOID ARTHRITIS, OSTEOARTHRITIS AND CRYSTAL ARTHRITIS COMPARED TO GCA DURING COVID19 PANDEMIC M. Tormo-Ratera, M. Mirza, R. Luqmani
403 [GO] 2022―Jun―28 POS1496-HPR HARD TIMES: ADAPTING A FATIGUE MANAGEMENT PROGRAMME IN A PANDEMIC J. Dobson, D. Dockrell, K. Berg, H. Harris
404 [GO] 2022―Jun―28 POS1241 THE IMPACT OF TELEMEDICINE CONSULTATIONS FOR RHEUMATOID ARTHRITIS, GIANT CELL ARTERITIS, OSTEOARTHRITIS AND CRYSTAL ARTHRITIS DURING COVID19 PANDEMIC M. Tormo-Ratera, M. Mirza, R. Luqmani
405 [GO] 2022―Jun―28 AB1028 REGRESSIVE BONE MINERAL DENSITY TRENDS SEEN WITH DELAY IN FOLLOW UP OF DENOSUMAB TREATMENT DUE TO THE PANDEMIC INDUCED LOCKDOWN - A SINGLE CENTRE INDIAN EXPERIENCE. A. K. Aggarwal, N. Aggarwal, H. Sharma
406 [GO] 2022―Jun―28 AB1108 IMPACT OF THE FIRST WAVE OF THE COVID 19 PANDEMIC ON HEALTHCARE ACCESSIBILITY, DISEASE BEHAVIOUR, ANXIETY, AND PHYSICAL ACTIVITY IN RHEUMATIC DISEASE PATIENTS: AN ONLINE SURVEY AND POTENTIAL SOLUTIONS S. Yadav, R. Samant
407 [GO] 2022―Jun―28 POS0357-PARE EXPLORING THE IMPACT OF THE PANDEMIC ON ITALIAN RHEUMATIC DISEASE PATIENTS: A PATIENT ADVOCACY SURVEY A. Celano, D. Cafiero, S. Lopatriello, F. Tedone
408 [GO] 2022―Jun―28 AB1090 IMPACT OF THE COVID19 PANDEMIC ON THE SOCIAL BEHAVIOR OF PATIENTS WITH RHEUMATIC DISEASES L. Cano Garcia, S. Manrique Arija, M. Vera Rodríguez, R. Redondo, C. M. Romero-Barco, N. Mena-Vázquez
409 [GO] 2022―Jun―28 POS1544-HPR RHEUMATOID ARTHRITIS CONTROL USING SYNCHRONOUS TELEMEDICINE MODALITY IN THE PANDEMIC PERIOD L. J. Cajas Santana, D. Cajas
410 [GO] 2022―Jun―28 POS0358-PARE THE IRISH ‘WEAR RED’ FOR VASCULITIS CAMPAIGN - LAUNCHING AN ANNUAL AWARENESS CAMPAIGN IN A RESTRICTED PANDEMIC WORLD. S. Skeffington
411 [GO] 2022―Jun―28 POS1502-HPR A PHYSICAL EXERCISE PROGRAM FOR THE MANAGEMENT OF FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AT THE TIME OF PANDEMIC: A PILOT STUDY E. Elefante, C. Tani, V. Signorini, C. Stagnaro, L. Lunardi, D. Zucchi, et al. (+4)
412 [GO] 2022―Jun―28 POS1503-HPR THE VALUE OF REMOTE CONSULTATIONS WITH A PHYSIOTHERAPIST, SPECIALISED IN AXIAL SPONDYLOARTHRITIS DURING THE COVID 19 PANDEMIC: EVALUATION OF A MEMBER-SUPPORT PROJECT WITH THE NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY. E. Clarke, J. Hamilton, S. Dickinson
413 [GO] 2022―Jun―28 POS1530-HPR RHEUMATIC MUSCULOSKELETAL DISEASES (RMDs) DURING THE FIRST WAVE OF THE COVID19 PANDEMIC: PATIENTS’ POINT OF VIEW ON THE ROLE OF TELEMEDICINE K. El Aoufy, M. R. Melis, M. Balzani, S. Guiducci, S. Bellando Randone, S. Bambi, et al. (+2)
414 [GO] 2022―Jun―28 POS1494-HPR INCIDENCE OF PSYCHIATRIC DISORDERS AND FIBROMYALGIA IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS DURING COVID 19 PANDEMIC: THE ROLE OF TELEMEDICINE. R. Foti, G. Amato, Y. Dal Bosco, C. Gagliano, A. Longo, R. Falsaperla, et al. (+4)
415 [GO] 2022―Jun―28 POS1249 EFFICACY AND SAFETY OF ChAdOx1 nCoV-19/AZD1222 AND mRNA-1273 VACCINES: A COMPARATIVE STUDY IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES Y. J. Chen, W. N. Huang, H. H. Chen, H. W. Chen, P. L. Cheng, J. P. Chen, et al. (+7)
416 [GO] 2022―Jun―28 AB1101 PREVALENCE OF LONG COVID IN RHEUMATIC DISEASE PATIENTS: ANALYSIS OF SAR COVID REGISTRY C. A. Gonzalez Gomez, M. Cosatti, V. V. Castro Coello, M. Haye, Y. Tissera, A. A. Reyes, et al. (+45)
417 [GO] 2022―Jun―27 OP0253 COVID-19 ADMISSIONS AND MORTALITY IN PATIENTS WITH EARLY INFLAMMATORY ARTHRITIS: RESULTS FROM A NATIONAL COHORT M. Adas, M. Russell, E. Cook, E. Alveyn, S. Oyebanjo, P. Amlani-Hatcher, et al. (+3)
418 [GO] 2022―Jun―27 OP0173 INCIDENCE OF COVID-19 INFECTION AND HOSPITALISATION ACCORDING TO VACCINATION STATUS AND DMARD TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONWIDE MATCHED COHORT STUDY FROM DENMARK R. Cordtz, S. Kristensen, R. Westermann, K. Duch, F. Pearce, J. Lindhardsen, et al. (+3)
419 [GO] 2022―Jun―27 OP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES P. M. Machado, M. Schaefer, S. Mahil, N. Dand, M. Gianfrancesco, S. Lawson-Tovey, et al. (+48)
420 [GO] 2022―Jun―27 OP0211-HPR EXPERIENCES DURING THE COVID-19 PANDEMIC AMONG PEOPLE WITH INFLAMMATORY ARTHRITIS. “REOPENING OF SOCIETY IS HARDER THAN LOCK-DOWN” - A QUALITATIVE INTERVIEW STUDY L. Lund, M. Løwe, O. Hendricks, K. Schreiber, B. Glintborg, R. Petersen, et al. (+3)
421 [GO] 2022―Jun―27 OP0219 HIGH INCIDENCE OF MIS-C AND OTHER AUTOIMMUNE DISEASES AFTER SARS-COV-2 INFECTION COMPARED TO COVID-19 VACCINATION IN PEDIATRIC POPULATION FROM SOUTH CENTRAL EUROPE M. Bizjak, N. Emersic, M. Zajc Avramovič, T. Vesel Tajnšek, G. Markelj, S. Della Paolera, et al. (+5)
422 [GO] 2022―Jun―27 OP0179 CHARACTERISTICS AND OUTCOMES OF SARS-CoV-2 BREAKTHROUGH INFECTIONS AMONG DOUBLE AND TRIPLE VACCINATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES R. Hasseli, B. F. Hoyer, H. M. Lorenz, A. Pfeil, A. Regierer, J. Richter, et al. (+7)
423 [GO] 2022―Jun―27 OP0192 SEROLOGICAL RESPONSE AND SAFETY OF A THREE-DOSE SARS-CoV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY I. Jyssum, A. T. Tveter, J. Sexton, I. E. Christensen, T. T. Tran, S. Mjaaland, et al. (+14)
424 [GO] 2022―Jun―27 OP0176 THE PERSISTENCE OF ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-CoV-2 VACCINES IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES USING IMMUNOSUPPRESSIVE THERAPY, COMPARED TO HEALTHY CONTROLS I. Egeland Christensen, I. Jyssum, A. T. Tveter, J. Sexton, T. T. Tran, S. Mjaaland, et al. (+13)
425 [GO] 2022―Jun―27 OP0178 COVID-19 BREAKTHROUGH INFECTIONS IN VACCINATED PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES AND CONTROLS - DATA FROM TWO PROSPECTIVE COHORT STUDIES L. Boekel, E. Stalman, L. Wieske, F. Hooijberg, Y. Besten, M. Leeuw, et al. (+16)
426 [GO] 2022―Jun―27 OP0254 FACTORS ASSOCIATED WITH THE SEVERITY OF COVID-19 INFECTION IN PATIENTS WITH SPONDYLOARTHRITIS: RESULTS OF THE FRENCH RMD COVID-19 COHORT L. Perrot, L. Boyer, R. M. Flipo, H. Marotte, E. Pertuiset, C. Miceli Richard, et al. (+6)
427 [GO] 2022―Jun―27 OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY S. A. Yeoh, M. Gianfrancesco, S. Lawson-Tovey, K. Hyrich, A. Strangfeld, L. Gossec, et al. (+30)
428 [GO] 2022―Jun―27 OP0248 SEVERE COVID-19 OUTCOMES AMONG PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: A POPULATION-BASED STUDY S. Marozoff, Z. A. Fazal, J. Tan, N. Lu, A. Hoens, D. Lacaille, et al. (+5)
429 [GO] 2022―Jun―27 OP0251 IMPACT OF INTERSTITIAL LUNG DISEASE ON SEVERE COVID-19 OUTCOMES FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A MULTICENTER STUDY E. Gilbert, G. Figueroa-Parra, M. Valenzuela-Almada, S. Vallejo, M. R. Neville, N. Patel, et al. (+12)
430 [GO] 2022―Jun―27 OP0247 RISK FACTORS FOR SEVERE COVID-19 OUTCOMES: A STUDY OF IMMUNE-MEDIATED INFLAMMATORY DISEASES, THERAPIES AND COMORBIDITIES IN A LARGE US HEALTHCARE SYSTEM P. J. Mease, Q. Wei, M. Chiorean, L. Iles-Shih, J. Hadlock
431 [GO] 2022―Jun―27 OP0061 TIGHT CONTROL IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TARGETED THERAPIES ACROSS THE COVID-19 PANDEMIC ERA A. F. Luppino, G. Cincinelli, F. Ingegnoli, A. Orenti, E. G. Favalli, P. Boracchi, R. Caporali
432 [GO] 2022―Jun―27 OP0133 THE DECREASE OF MUSCLE MASS BY THE BEHAVIORAL RESTRICTION OF COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATOID ARTHRITIS M. Tada, Y. Yamada, K. Mandai, Y. Matsumoto, N. Hidaka
433 [GO] 2022―Jun―27 OP0197 POST-TRAUMATIC STRESS DISORDER AND SYMPTOMS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES DURING THE COVID-19 PANDEMIC: PRELIMINARY RESULTS FROM THE PERMAS STUDY G. Fulvio, V. Pedrinelli, G. Andreozzi, F. Trentin, S. Fantasia, S. Fonzetti, et al. (+18)
434 [GO] 2022―Jun―27 OP0175 TYPE OF mRNA COVID-19 VACCINE AND TREATMENT INFLUENCE ANTIBODY KINETICS IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES C. E. Raptis, D. O. Andrey, C. Polysopoulos, C. Berger, A. Ciurea, P. Lescuyer, et al. (+10)
435 [GO] 2022―Jun―27 OP0174 T-CELL RESPONSE AFTER COVID-19 VACCINE IS NOT IMPAIRED BY EARLY RITUXIMAB TREATMENT OR BELIMUMAB IN SYSTEMIC AUTOIMMUNE DISORDERS G. De Marchi, M. Fabris, R. Domenis, S. Guella, N. Cabas, F. Caponnetto, et al. (+4)
436 [GO] 2022―Jun―27 OP0172 THE IMPACT OF IMMUNOMODULATING TREATMENT ON THE IMMUNOGENICITY OF COVID-19 VACCINES IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES COMPARED TO HEALTHY CONTROLS. A SWEDISH NATIONWIDE STUDY (COVID19-REUMA) M. Frodlund, K. Chatzidionysiou, A. Södergren, E. Klingberg, A. Bengtsson, L. Klareskog, M. C. Kapetanovic
437 [GO] 2022―Jun―14 Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series George E Fragoulis, Christos Koutsianas, Kalliopi Fragiadaki, Ilias Mariolis, Stylianos Panopoulos, Christina Tsalapaki, et al. (+5)
438 [GO] 2022―Jun―10 Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
439 [GO] 2022―Apr―13 BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study Amir Bieber, Iftach Sagy, Lena Novack, Shay Brikman, Ran Abuhasira, Snait Ayalon, et al. (+3)
440 [GO] 2022―Apr―13 Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine Josefina Durán, Paula Isabel Burgos, Nicole Le Corre, Cinthya Ruiz Tagle, Constanza Martinez-Valdebenito, Mauricio Castro, et al. (+3)
441 [GO] 2022―Apr―08 Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE) Arthur Mageau, Valentine Marie Ferré, Tiphaine Goulenok, Charlotte Charpentier, Nicole Delory, Chrystel Francois, et al. (+4)
442 [GO] 2022―Apr―07 In the shadow of antibodies: how T cells defend against COVID-19 David S Pisetsky, Kevin L Winthrop
443 [GO] 2022―Mrz―25 Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases Lianne Kearsley-Fleet, Min-Lee Chang, Saskia Lawson-Tovey, Ruth Costello, Šárka Fingerhutová, Natálie Švestková, et al. (+19)
444 [GO] 2022―Mrz―18 Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study Peter Mandl, Selma Tobudic, Helmut Haslacher, Thomas Karonitsch, Daniel Mrak, Thomas Nothnagl, et al. (+9)
445 [GO] 2022―Mrz―14 Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Fredrik N Albach, Jens Klotsche, Veronika Scholz, Lara Maria Jeworowski, et al. (+7)
446 [GO] 2022―Mrz―11 Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination Jie Lu, Yuwei He, Robert Terkeltaub, Mingshu Sun, Zijing Ran, Xinmiao Xu, et al. (+10)
447 [GO] 2022―Mrz―11 Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases Nádia Emi Aikawa, Leonard de Vinci Kanda Kupa, Ana Cristina Medeiros-Ribeiro, Carla Goncalves Schahin Saad, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, et al. (+24)
448 [GO] 2022―Feb―23 Efficacy of COVID-19 vaccines in patients taking immunosuppressants Chen Shen, Malcolm Risk, Elena Schiopu, Salim S Hayek, Tiankai Xie, Lynn Holevinski, et al. (+3)
449 [GO] 2022―Feb―23 EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update Robert B M Landewé, Féline P B Kroon, Alessia Alunno, Aurélie Najm, Johannes WJ Bijlsma, Gerd-Rüdiger R Burmester, et al. (+22)
450 [GO] 2022―Feb―22 Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial Carlo Scognamiglio Renner Araujo, Ana Cristina Medeiros-Ribeiro, Carla G S Saad, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, Andrea Yukie Shimabuco, et al. (+10)
451 [GO] 2022―Feb―16 Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance Manuel Francisco Ugarte-Gil, Graciela S Alarcón, Zara Izadi, Ali Duarte-García, Cristina Reátegui-Sokolova, Ann Elaine Clarke, et al. (+52)
452 [GO] 2022―Feb―15 Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine Sara K Tedeschi, Jacklyn Stratton, Jack Elias Ellrodt, Mary Grace Whelan, Keigo Hayashi, Kazuki Yoshida, et al. (+6)
453 [GO] 2022―Feb―10 Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19 Fatema Tuz Zahra, Lorenza Bellusci, Gabrielle Grubbs, Hana Golding, Surender Khurana
454 [GO] 2022―Feb―08 Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort Sakir Ahmed, Pankti Mehta, Aby Paul, S Anu, Somy Cherian, Veena Shenoy, et al. (+4)
455 [GO] 2022―Feb―08 Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis Ana Cristina Medeiros-Ribeiro, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, Andrea Yukie Shimabuco, Henrique Carriço da Silva, Carla G S Saad, et al. (+12)
456 [GO] 2022―Feb―04 EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients’ questions Johannes WJ Bijlsma
457 [GO] 2022―Jan―27 Has the gout epidemic peaked in the UK? A nationwide cohort study using data from the Clinical Practice Research Datalink, from 1997 to across the COVID-19 pandemic in 2021 Abhishek Abhishek, Laila J Tata, Mamas Mamas, Anthony J Avery
458 [GO] 2022―Jan―17 Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series Mayan Teles, Caoilfhionn M Connolly, Sarah Frey, Teresa Po-Yu Chiang, Jennifer J Alejo, Brian J Boyarsky, et al. (+6)
459 [GO] 2022―Jan―13 Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial Michael Bonelli, Daniel Mrak, Selma Tobudic, Daniela Sieghart, Maximilian Koblischke, Peter Mandl, et al. (+18)
460 [GO] 2022―Jan―10 Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis Claudius Speer, Maximilian Töllner, Louise Benning, Katrin Klein, Marie Bartenschlager, Christian Nusshag, et al. (+9)
461 [GO] 2021―Dez―31 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry Pedro M Machado, Saskia Lawson-Tovey, Anja Strangfeld, Elsa F Mateus, Kimme L Hyrich, Laure Gossec, et al. (+25)
462 [GO] 2021―Dez―10 Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study Arthur Mageau, Thomas Papo, Stephane Ruckly, Andrey Strukov, Damien van Gysel, Karim Sacre, Jean-François Timsit
463 [GO] 2021―Dez―07 Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations Féline P B Kroon, Aurélie Najm, Alessia Alunno, Jan W Schoones, Robert B M Landewé, Pedro M Machado, Victoria Navarro-Compán
464 [GO] 2021―Nov―29 Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors Dimitra Dimopoulou, George Vartzelis, Foteini Dasoula, Maria Tsolia, Despoina Maritsi
465 [GO] 2021―Nov―29 Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis Elisabeth Simader, Selma Tobudic, Peter Mandl, Helmuth Haslacher, Thomas Perkmann, Thomas Nothnagl, et al. (+8)
466 [GO] 2021―Nov―26 Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases Francesco Ursini, Piero Ruscitti, Vincenzo Raimondo, Rossella De Angelis, Fabio Cacciapaglia, Erika Pigatto, et al. (+27)
467 [GO] 2021―Nov―25 Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines Yong Fan, Yan Geng, Yu Wang, Xuerong Deng, Guangtao Li, Juan Zhao, et al. (+10)
468 [GO] 2021―Nov―24 Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 Marcella Visentini, Laura Gragnani, Stefano Angelo Santini, Teresa Urraro, Annalisa Villa, Monica Monti, et al. (+12)
469 [GO] 2021―Nov―24 Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease David Simon, Koray Tascilar, Filippo Fagni, Katja Schmidt, Gerhard Krönke, Arnd Kleyer, et al. (+8)
470 [GO] 2021―Nov―22 Response to: Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’ by Trahtemberg et al Marvin J Fritzler, Uriel Trahtemberg
471 [GO] 2021―Nov―22 Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19? Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Johan Askling
472 [GO] 2021―Nov―22 Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’ by Trahtemberg et al Yudong Liu
473 [GO] 2021―Nov―10 Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases Charalampos Papagoras, George E Fragoulis, Nikoleta Zioga, Theodora Simopoulou, Kleopatra Deftereou, Eleni Kalavri, et al. (+25)
474 [GO] 2021―Okt―10 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 Alessia Alunno, Aurélie Najm, Pedro M Machado, Heidi Bertheussen, Gerd-Rüdiger R Burmester, Francesco Carubbi, et al. (+18)
475 [GO] 2021―Okt―05 BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus Quentin Moyon, Delphine Sterlin, Makoto Miyara, François Anna, Alexis Mathian, Raphael Lhote, et al. (+13)
476 [GO] 2021―Sep―23 B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics Renaud Felten, Pierre-Marie Duret, Elodie Bauer, Nathanael Sedmak, Julien H Djossou, Massiva Bensalem, et al. (+23)
477 [GO] 2021―Sep―23 Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series Caoilfhionn M Connolly, Teresa Po-Yu Chiang, Brian J Boyarsky, Jake A Ruddy, Mayan Teles, Jennifer L Alejo, et al. (+7)
478 [GO] 2021―Sep―13 SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future Kevin L Winthrop, Richard J Whitley, Daniel Aletaha
479 [GO] 2021―Sep―07 Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series Caoilfhionn M Connolly, Mayan Teles, Sarah Frey, Brian J Boyarsky, Jennifer L Alejo, William A Werbel, et al. (+5)
480 [GO] 2021―Sep―06 Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases Claire Cook, Naomi J Patel, Kristin M. D’Silva, Tiffany Y -T Hsu, Michael DiIorio, Lauren Prisco, et al. (+6)
481 [GO] 2021―Sep―06 SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases Saskia Lawson-Tovey, Kimme L Hyrich, Laure Gossec, Anja Strangfeld, Loreto Carmona, Bernd Raffeiner, et al. (+8)
482 [GO] 2021―Aug―24 Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases Teresa Po-Yu Chiang, Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Jennifer L Alejo, William A Werbel, et al. (+5)
483 [GO] 2021―Aug―23 Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry” by Sparks et al Elisa Gremese, Gianfranco Ferraccioli
484 [GO] 2021―Aug―23 Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al Zachary S Wallace, Jeffrey A Sparks, Philip C Robinson, Pedro M Machado, Jinoos Yazdany
485 [GO] 2021―Aug―13 Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry” by Sparks et al Ronald F van Vollenhoven, Sander W Tas, Michael T Nurmohamed
486 [GO] 2021―Aug―13 Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Philip C Robinson, Pedro M Machado, Jinoos Yazdany
487 [GO] 2021―Aug―06 Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression Maria Prendecki, Candice Clarke, Helena Edwards, Stacey McIntyre, Paige Mortimer, Sarah Gleeson, et al. (+10)
488 [GO] 2021―Aug―02 Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer Pier Luigi Meroni, Maria Orietta Borghi
489 [GO] 2021―Jul―20 Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System Maximilian Pistor, Andreas G F Hoepner, Yanan Lin, Simon Jung, Claudio L Bassetti, Andrew Chan, et al. (+2)
490 [GO] 2021―Jul―20 SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity Daniel Mrak, Selma Tobudic, Maximilian Koblischke, Marianne Graninger, Helga Radner, Daniela Sieghart, et al. (+12)
491 [GO] 2021―Jul―16 Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report Basil Golding, Youri Lee, Hana Golding, Surender Khurana
492 [GO] 2021―Jul―02 Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey’ Fernando Montero, Isabel Castrejón, Julia Martínez-Barrio, Juan Carlos Nieto-González, Javier Rivera, José María Álvaro-Gracia, Juan Molina Collada
493 [GO] 2021―Jul―02 Response to ‘Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’’ by Montero et al Alessandro Tomelleri, Lorenzo Dagna, Corrado Campochiaro
494 [GO] 2021―Jun―29 Unexpected impact of COVID-19 lockdown on spinal mobility and health perception in spondyloarthritis Sophie De Mits, Ann-Sophie De Craemer, Liselotte Deroo, Thomas Renson, Filip E Van den Bosch, Philippe Carron, Dirk Elewaut
495 [GO] 2021―Jun―25 Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis Serena Bugatti, Ludovico De Stefano, Silvia Balduzzi, Maria Immacolata Greco, Terenzj Luvaro, Irene Cassaniti, et al. (+9)
496 [GO] 2021―Jun―23 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study’’ by Klopfenstein et al Robert BM Landewé, Sofia Ramiro, Rémy L M Mostard
497 [GO] 2021―Jun―23 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Timothée Klopfenstein, Vincent Gendrin, Thierry Conrozier, Aurélie Gerazime, Marc Puyraveau, Souheil Zayet
498 [GO] 2021―Jun―22 Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City Medha Barbhaiya, Jonah M. Levine, Vivian P. Bykerk, Deanna Jannat-Khah, Lisa A. Mandl
499 [GO] 2021―Jun―18 Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2 Yolanda Braun-Moscovici, Marielle Kaplan, Maya Braun, Doron Markovits, Samy Giryes, Kohava Toledano, et al. (+3)
500 [GO] 2021―Jun―14 Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study Victoria Furer, Tali Eviatar, Devy Zisman, Hagit Peleg, Daphna Paran, David Levartovsky, et al. (+23)
501 [GO] 2021―Jun―07 Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals Oleg Melikhov, Tatiana Kruglova, Karine Lytkina, Georgy Melkonyan, Elena Prokhorovich, Gleb Putsman, et al. (+4)
502 [GO] 2021―Mai―28 Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Milena A Gianfrancesco, Zara Izadi, Kimme L Hyrich, et al. (+58)
503 [GO] 2021―Mai―28 SARS-COV-2 vaccination after stem cell transplantation for scleroderma Doron Rimar, Gleb slobodin, Alona Paz, Israel Henig, Tsila Zuckerman
504 [GO] 2021―Mai―26 POS1464-HPR ASSESSMENT OF EMOTIONAL WELL-BEING IN RHEUMATIC PATIENTS DURING COVID-19 LOCKDOWN THROUGH A WEB-BASED SURVEY APPROACH C. Iannuccelli, B. Lucchino, C. Gioia, A. Gattamelata, F. Giardina, M. DI Franco, et al. (+2)
505 [GO] 2021―Mai―26 POS1468-HPR THE IMPACT OF COVID-19 ON RHEUMATOLOGY HEALTH CARE WORKERS AND THEIR SCIENTIFIC OUTPUT: HEAVY LIES THE CROWN ON FEMALE RHEUMATOLOGISTS C. Kirchler, M. R. Andrews, E. Mosor, K. Thaler, T. Stamm, R. Fritsch-Stork, C. Duftner
506 [GO] 2021―Mai―26 AB0690 HOW DID COVID-19 AFFECT PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES TREATED WITH DMARDs - EXPERIENCE FROM A ROMANIAN RHEUMATOLOGY HOSPITAL A. Trandafir, I. Saulescu, A. Balanescu, D. Opris-Belinski, V. Bojinca, F. Berghea, et al. (+10)
507 [GO] 2021―Mai―26 POS1466-HPR IMPACT OF COVID-19 PANDEMIC ON ADHERENCE BEHAVIOR OF LATIN-AMERICAN PATIENTS WITH RHEUMATIC DISEASES I. A. Moreno-Arquieta, G. G. Sánchez Mendieta, D. E. Flores Alvarado, J. A. Esquivel Valerio, D. Á. Galarza-Delgado
508 [GO] 2021―Mai―26 POS1463-HPR IMPACT OF COVID-19 PANDEMIC ON DISEASE ACTIVITY AND EMOTIONAL WELL-BEING AMONG RHEUMATOID ARTHRITIS PATIENTS: A TELEMEDICINE STUDY B. Lucchino, C. Iannuccelli, C. Gioia, G. Dolcini, M. DI Franco
509 [GO] 2021―Mai―26 AB0668 THE ONSET OF RHEUMATOID ARTHRITIS AFTER COVID-19 - COINCIDENCE OR CONNECTED? V. Derksen, T. Kissel, F. Lamers-Karnebeek, A. Van der Bijl, A. C. Venhuizen, T. Huizinga, et al. (+3)
510 [GO] 2021―Mai―26 AB0702 PITFALLS IN THE DIAGNOSIS OF COVID-19 - EXPERIENCES FROM A RHEUMATOLOGY OUTPATIENT CLINIC S. G. Werner, H. E. Langer, P. Höhenrieder, R. Chatelain
511 [GO] 2021―Mai―26 Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease Rebecca H Haberman, Ramin Herati, David Simon, Marie Samanovic, Rebecca B Blank, Michael Tuen, et al. (+20)
512 [GO] 2021―Mai―26 AB0694 COVID-19 İNFECTION IN PATIENTS WITH RHEUMATIC DISEASES: TWO CENTERS EXPERIENCE A. Şahin, M. A. Gedikli, M. E. Derin, B. Karakaş, B. Karataş, N. Çabuk Çelik, İ. Yalçin
513 [GO] 2021―Mai―26 POS1458-HPR DIGITAL RHEUMATOLOGY IN THE ERA OF COVID-19: RESULTS OF A NATIONAL PATIENT AND PHYSICIAN SURVEY A. Kernder, H. Morf, P. Klemm, D. Vossen, M. Meyer, I. Haase, et al. (+7)
514 [GO] 2021―Mai―26 Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group Francesco Ursini, Piero Ruscitti, Salvatore D'Angelo, Fabio Cacciapaglia, Rossella De Angelis, Corrado Campochiaro, et al. (+14)
515 [GO] 2021―Mai―26 POS1491-HPR MENTAL HEALTH OUTCOMES AMONG HEALTH CARE WORKERS DURING THE CORONAVIRUS-19 PANDEMIC O. Hamdi, M. Sellami, S. Miladi, A. Fazaa, L. Souabni, K. Ouenniche, et al. (+4)
516 [GO] 2021―Mai―26 POS1422 CORRELATES OF TESTING POSITIVE FOR SARS-COV-2 IN PATIENTS WITH RHEUMATIC AD MUSCULOSKELETAL DISEASES N. Singh, I. Huang, M. Singleton, A. Bays, J. Sabo, S. Chung, et al. (+7)
517 [GO] 2021―Mai―26 POS1496-HPR IS NUTRITIONAL FOLLOW-UP IN PATIENTS LIVING WITH RHEUMATOID ARTHRITIS BETTER WITH TELECONSULTATION? - EXPERIENCE BEFORE AND AFTER PANDEMIC I. Mozo, M. Marquez, O. Valencia
518 [GO] 2021―Mai―26 Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19 Bernardo D'Onofrio, Ludovico De Stefano, Bianca Lucia Palermo, Blerina Xoxi, Antonio Manzo, Carlomaurizio Montecucco, Serena Bugatti
519 [GO] 2021―Mai―26 AB0673 THE ROUTINE HEALTH CARE OF PATIENTS WITH RHEUMATIC DISEASES DURING THE PANDEMIC OF COVID-19 S. Mariem, M. Yasmine, S. Miladi, A. Fazaa, L. Souebni, K. Ouenniche, et al. (+4)
520 [GO] 2021―Mai―26 AB0682 RHEUMATOLOGY TEACHING IN TIMES OF COVID-19 Y. Chang, J. Nicholls
521 [GO] 2021―Mai―26 AB0681 HOW COMMON IS COVID-19 IN CHILDREN, YOUNG PEOPLE AND ADULTS WITH RHEUMATIC DISEASES? RESULTS FROM THE INTERNATIONAL COVID-19 EUROPEAN PATIENT REGISTRY S. Shoop-Worrall, S. Verstappen, W. Costello, S. Angevare, Y. Uziel, C. Wouters, et al. (+2)
522 [GO] 2021―Mai―26 AB0674 RAPID ADOPTION OF TELEMEDICINE IN RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY S. A. Yeoh, K. Young, M. Putman, E. Graef, F. Berenbaum, R. Conway, et al. (+13)
523 [GO] 2021―Mai―26 AB0670 THE COURSE AND OUTCOMES OF COVID-19 IN PATIENTS WITH ANCA-ASSOCIATED SYSTEMIC VASCULITIS, RECEIVING ANTI-B CELL THERAPY WITH RITUXIMAB T. Beketova, V. Babak, M. Suprun
524 [GO] 2021―Mai―26 AB0695 PATTERN OF COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES UNDERGOING BIOLOGICAL THERAPY: A COHORT EXPERIENCE C. Ancuta, C. Pomirleanu, G. Strugariu, L. Petrariu, E. Ancuta, C. Bran, et al. (+2)
525 [GO] 2021―Mai―26 AB0705 SHORT-TERM OUTCOMES OF COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES WHO ARE TREATED BY BIOLOGICAL AND TARGETED SYNTHETIC DMARDS: OBSERVATIONAL SINGLE-CENTER STUDY E. Luchikhina, D. Karateev, O. Semenova, O. Matveychuk, T. Kuznetsova
526 [GO] 2021―Mai―26 AB0689 INCIDENCE AND SEVERITY OF COVID-19 IN PATIENTS WITH SPONDYLOARTHRITIS IN ARGENTINA: EXPERIENCE IN A COUNTRY WITH STRICT ISOLATION V. Martire, C. Airoldi, M. S. Gálvez Elkin, M. Machado Escobar, N. Callahuara, V. Duarte, et al. (+22)
527 [GO] 2021―Mai―26 AB0658 FEAR OF COVID-19 IN POSTPARTUM WOMEN WITH RHEUMATIC DISEASE L. G. Espinosa Banuelos, M. E. Corral Trujillo, C. M. Skinner Taylor, L. Pérez Barbosa, R. A. Rodriguez Chavez, A. Y. Lujano Negrete, et al. (+3)
528 [GO] 2021―Mai―26 AB0653 COURSE OF COVID-19 INFECTION IN A SERIES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS C. Cetin, N. Aliyeva, Y. Yalçinkaya, A. Gül, M. Inanc, B. Artim-Esen
529 [GO] 2021―Mai―26 AB0703 THE COURSE OF COVID-19 INFECTION IN PATIENTS WITH ARTHRITIS RECEIVING TARGETED DMARDS E. Koltsova, G. Lukina, E. Shmidt, K. Lytkina, E. Rozochkina, E. Zhilyaev
530 [GO] 2021―Mai―26 AB0688 SEVERITY OF COVID-19 INFECTION IN RHEUMATIC IMMUNE-MEDIATEDINFLAMMATORY DISEASES. STUDY IN A SINGLE UNIVERSITY HOSPITAL D. Martínez-López, D. Prieto-Peña, L. Sanchez-Bilbao, A. Herrero-Morant, C. Álvarez-Reguera, M. Trigueros-Vazquez, et al. (+2)
531 [GO] 2021―Mai―26 AB0692 REACTIVE ARTHRITIS ASSOCIATED WITH COVID-19 INFECTION: A REVIEW F. Alkindi, K. Alseiari, K. Al Naqbi
532 [GO] 2021―Mai―26 AB0667 A PROSPECTIVE STUDY INTO COVID-19 LIKE SYMPTOMS IN PATIENTS WITH AND WITHOUT IMMUNE MEDIATED INFLAMMATORY DISEASES OR IMMUNOMODULATING DRUGS L. van Ouwerkerk, A. Van der Meulen, M. Ninaber, Y. K. O. Teng, T. Huizinga, C. Allaart
533 [GO] 2021―Mai―26 AB0655 RHEUMATOID ARTHRITIS ACTIVITY BEFORE AND AFTER COVID-19 LOCKDOWN PERIOD M. Jordhani, D. Ruci, F. Skana, E. Memlika
534 [GO] 2021―Mai―26 AB0872-HPR IMPACT OF COVID-19 ON A PHYSICAL ACTIVITY FEASIBILITY PILOT STUDY: THE PIPPRA EXPERIENCE L. Larkin, A. Moses, S. Gallagher, A. Fraser, B. A. Esbensen, J. Green, et al. (+2)
535 [GO] 2021―Mai―26 AB0687 EFFECT OF COVID-19 ON PATIENTS ATTENDING AMBULATORY DEEP VENOUS THROMBOSIS OUT-PATIENT CLINIC: A RETROSPECTIVE, COHORT ANALYSIS[KI1] [KI1]101 CHARACTERS T. Hill, K. P. Iyengar, A. Nune
536 [GO] 2021―Mai―26 AB0685 IMPACT OF COVID-19 ON PATIENTS WITH RHEUMATIC DISEASES: EXPERIENCE OF THE DEPARTMENT OF RHEUMATOLOGY OF THE UNIVERSITY HOSPITAL OF IBN ROCHD OF CASABLANCA H. El Moutaouakil, Z. El Ouali, K. Nassar, S. Janani
537 [GO] 2021―Mai―26 AB0664 THE PSYCHOLOGICAL STATE OF THE PATIENTS WITH RHEUMATIC DISEASES AND HOSPITAL WORKERS DURING THE CORONAVIRUS DISEASE (COVID-19) OUTBREAK T. Lisitsyna, D. Veltishchev, A. Borisova, E. Nasonov, A. Lila
538 [GO] 2021―Mai―26 AB0651 CASE-REPORT: ORGANIZING PNEUMONIA IN A PREGNANT WOMAN WITH RHEUMATOID ARTHRITIS DURING COVID-19 PANDEMIC A. Cornillie, C. Grivegnee
539 [GO] 2021―Mai―26 AB0657 PERCEIVED STRESS AND FOOD INSECURITY IN PREGNANT AND POSTPARTUM WOMEN WITH RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC L. G. Espinosa Banuelos, P. R. Ancer Rodríguez, M. G. Herrera López, C. M. Skinner Taylor, L. Pérez Barbosa, R. Moyeda Martinez, et al. (+4)
540 [GO] 2021―Mai―26 AB0868-HPR ADHERENCE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATIC DISEASES DURING COVID-19 PANDEMIC I. A. Moreno-Arquieta, G. G. Sánchez Mendieta, D. E. Flores Alvarado, J. A. Esquivel Valerio, D. Á. Galarza-Delgado
541 [GO] 2021―Mai―26 AB0877-HPR EXERCISE COMPLIANCE AND DISEASE STATUS IN PATIENTS WITH RHEUMATIC DISEASES DURING COVID-19 PANDEMIC G. G. Pala, Z. Tuna, N. G. Tore, S. Bayram, F. Sarİ, M. A. Ozturk, D. Oskay
542 [GO] 2021―Mai―26 AB0903-HPR DURATION OF TELEPHONE CONSULTATIONS AMONGST RHEUMATOLOGY PRACTITIONERS IN A DISTRICT GENERAL HOSPITAL - ADAPTING TO REMOTE CONSULTATION IN A COVID-19 PANDEMIC L. Parker, F. Coldstream
543 [GO] 2021―Mai―26 AB0908-HPR SIGNED, SEALED, DELIVERED: PHARMACISTS ACHIEVING BETTER CARE CLOSER TO HOME IN RHEUMATOLOGY HIGH COST DRUG MANAGEMENT DURING THE COVID-19 PANDEMIC S. Gohil
544 [GO] 2021―Mai―26 AB0920-PARE WHAT WE LEARNED DURING COVID-19 PANDEMIC J. Grygielska
545 [GO] 2021―Mai―26 AB0677 GENDER DIFFERENCES ON THE IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, L. Christen, L. Carmona, J. Correa-Fernández, S. Sanz-Gómez, et al. (+10)
546 [GO] 2021―Mai―26 AB0708 HIGH DRUG RETENTION RATES DESPITE B/TSDMARD INTERRUPTIONS IN COVID-19 PANDEMIC CHAOS S. Gulle, Y. Erez, A. Karakas, T. Yüce İnel, S. B. Kocaer, T. Demirci Yildirim, et al. (+4)
547 [GO] 2021―Mai―26 AB0907-HPR UNEXPECTED DIFFERENCE IN ACCEPTANCE OF TELECONSULTATION BETWEEN PATIENTS WITH LUPUS AND RHEUMATOID ARTHRITIS WHO UNDERWENT TO A DEVELOPED AND IMPLEMENTED TELEMEDICINE INNOVATIVE PROGRAM AFTER THE DECLARATION OF QUARANTINE DUE TO THE COVID-19 PANDEMIC IN COLOMBIA S. M. Hernández-Zambrano, R. A. Castiblanco-Montañez, J. Chavez-Chavez, D. P. Rivera-Triana, A. Aza, L. Villarreal, et al. (+3)
548 [GO] 2021―Mai―26 AB0500 IMPACT OF COVID-19 PANDEMIC IN OVERALL HEALTH AND FUNCTIONING IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE REUMAVID STUDY (PHASE 1) D. Benavent, M. Garrido-Cumbrera, C. Plasencia, L. Christen, H. Marzo-Ortega, J. Correa-Fernández, et al. (+3)
549 [GO] 2021―Mai―26 AB0921-PARE PRACTICES AND BEHAVIORS DURING THE COVID-19 PANDEMIC IN PATIENTS WHO PARTIALLY ATTEND TO AN EDUCATIONAL PROGRAM ON RHEUMATOID ARTHRITIS. A CROSS-SECTIONAL SURVEY F. Rodriguez, D. Buitrago-Garcia, G. Sánchez, P. Santos-Moreno
550 [GO] 2021―Mai―26 AB0669 DEPRESSION AND ANXIETY MIGHT NOT BE INCREASED DURING COVID-19 PANDEMIC IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS E. Erpek, D. Solmaz, D. Bayraktar, G. Duran, G. Kabadayi, E. Durak Ediboglu, et al. (+8)
551 [GO] 2021―Mai―26 AB0676 FEARS AND HOPES DURING THE COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, L. Christen, L. Carmona, J. Correa-Fernández, S. Sanz-Gómez, et al. (+10)
552 [GO] 2021―Mai―26 AB0901-HPR SOCIAL AND PSYCHOLOGICAL IMPACT OF THE CONTAINEMENT DURING COVID-19 PANDEMIC ON PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES T. El Joumani, H. Rkain, T. Fatima Zahrae, H. Kenza, A. Radouan, N. Laila, et al. (+5)
553 [GO] 2021―Mai―26 AB0675 COUNTRY COMPARISON ON THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, L. Christen, L. Carmona, J. Correa-Fernández, S. Sanz-Gómez, et al. (+10)
554 [GO] 2021―Mai―26 AB0661 EFFECT OF COVID-19 PANDEMIC ON SLEEP DISORDERS IN PATIENTS WITH INFLAMMATORY ARTHRITIS F. Ingegnoli, M. Buoli, C. Posio, R. DI Taranto, R. Caporali
555 [GO] 2021―Mai―26 AB0899-HPR THE IMPACT OF CORONAVIRUS (COVID-19) PANDEMIC ON THERAPEUTIC MAINTENANCE IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES T. El Joumani, H. Rkain, T. Fatima Zahrae, H. Kenza, A. Radouan, N. Laila, et al. (+5)
556 [GO] 2021―Mai―26 AB0665 SWITCHING INTRAVENOUS ABATACEPT AND TOCILIZUMAB TO SUBCUTANEOUS INJECTIONS DURING THE COVID-19 PANDEMIC: A FRENCH EXPERIENCE A. Combier, S. Wanono, L. Poiroux, C. Frantz, E. Descamps, O. Fogel, et al. (+5)
557 [GO] 2021―Mai―26 AB0910-HPR LEVELS OF DEPRESSION AND ANXIETY DURING COVID-19 PANDEMIC: AT WHAT DEGREE ARE HEALTH CARE WORKERS AFFECTED IN TUNISIA? K. Ben Abdelghani, O. Hamdi, S. Miladi, M. Sellami, K. Ouenniche, L. Souabni, et al. (+4)
558 [GO] 2021―Mai―26 AB0902-HPR COVID-19 PANDEMIC: KNOWLEDGE, BELIEVES AND FEARS IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES IN A DEVELOPING COUNTRY T. El Joumani, H. Rkain, T. Fatima Zahrae, H. Kenza, A. Radouan, N. Laila, et al. (+5)
559 [GO] 2021―Mai―26 AB0707 RHEUMATOLOGY PATIENT CARE IN THE COVID-19 PANDEMIC: TELEMEDICINE, DELEGATION, PATIENT SATISFACTION AND VACCINATION BEHAVIOUR T. Thiele, S. Beider, H. Kühl, G. Miehlke, A. Cossmann, A. Holz, et al. (+5)
560 [GO] 2021―Mai―26 AB0683 OSTEOARTHRITIS PAIN AND COVID-19 PANDEMIC: THE LOCKDOWN IMPACT F. Orsini, O. De Lucia, F. Ingegnoli, G. Cincinelli, G. Armentaro, R. DI Taranto, R. Caporali
561 [GO] 2021―Mai―26 AB0898-HPR WICH FACTORS ARE RELATED TO PAINFUL EXPERIENCE IN PATIENTS AFFECTED BY CHRONIC INFLAMMATORY RHEUMATIC DISEASE DURING THE COVID-19 PANDEMIC? T. El Joumani, H. Rkain, T. Fatima Zahrae, H. Kenza, R. Abouqal, N. Laila, et al. (+5)
562 [GO] 2021―Mai―26 AB0696 ANTI-PHOSPHOLIPID AUTOANTIBODIES IN COVID-19 PATIENTS M. Jordhani, D. Ruci, V. Ruci
563 [GO] 2021―Mai―26 AB0700 TOCILIZUMAB DID NOT REDUCE MORTALITY IN SEVERE COVID-19 PATIENTS BUT CAUSED THROMBOCYTOSIS Z. Öztürk, S. M. Türk, D. Karataş, Ü. Erkorkmaz, K. Özmen Süner, H. Dheir, et al. (+3)
564 [GO] 2021―Mai―26 AB0679 NAILFOLD VIDEOCAPILLAROSCOPY RESULTS IN COVID-19 PATIENTS RECOVERED FROM DIFFERENT DISEASE SEVERITY E. Gotelli, P. F. Bica, T. Aloe’, A. Sulli, M. Grosso, C. Pizzorni, et al. (+5)
565 [GO] 2021―Mai―26 AB0697 ANTI-SARS-COV-2 ANTIBODIES AND AUTOANTIBODIES IN COVID-19 PATIENTS SURVIVED AFTER ICU ADMISSION, 6 MONTHS LATER K. Bitzogli, E. Magira, L. Chatzis, E. Jahaj, H. Alexopoulos, M. Dalakas, et al. (+3)
566 [GO] 2021―Mai―26 AB0706 ASSOCIATED RISK FACTORS AND OUTCOMES IN HOSPITALISED COVID-19 PATIENTS WITH BIOLOGICS AND JAK-INHIBITORS: A REPORT FROM A CENTER SPECIALISED IN IMMUNE-MEDIATED DISEASES A. M. Anzola Alfaro, L. R. Caballero Motta, J. C. Nieto González, L. Menchen Viso, O. Baniandrés, C. Lobo Rodríguez, et al. (+3)
567 [GO] 2021―Mai―26 AB0710 ANISOCYTOSIS INDEX AS AN EARLY PREDICATOR OF HOSPITAL MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA FROM A LEVEL III HOSPITAL. LIMA PERU J. Ravelo
568 [GO] 2021―Mai―26 AB0666 PROGNOSTIC VALUE OF SERUM KREBS VON DEN LUNGEN-6 GLYCOPROTEIN CIRCULATING LEVELS IN COVID-19 PNEUMONIA: A PROSPECTIVE COHORT STUDY D. Lobo Prat, I. Castellví, D. Castillo, S. Orozco, A. Mariscal, L. Martínez-Martínez, et al. (+12)
569 [GO] 2021―Mai―26 AB0660 COVID-19 SHARES CLINICAL FEATURES WITH ANTI-MELANOMA DIFFERENTIATION ASSOCIATED PROTEIN 5 POSITIVE DERMATOMYOSITIS AND ADULT STILL’S DISEASE Y. Kondo, Y. Kaneko, H. Takei, H. Tamai, T. Takeuchi
570 [GO] 2021―Mai―26 AB0680 SARCOPENIA RATE IN COVID-19 SURVIVORS D. Levy, M. Giannini, W. Oulehri, M. Riou, C. Marcot, A. Meyer, B. Geny
571 [GO] 2021―Mai―26 AB0652 FERRITIN IS ASSOCIATED WITH THE SEVERITY OF LUNG INVOLVEMENT BUT NOT WITH WORSE PROGNOSIS IN PATIENTS WITH COVID-19: DATA FROM TWO ITALIAN COVID-19 UNITS F. Carubbi, A. Alunno, L. Salvati, C. Ferri, D. Grassi
572 [GO] 2021―Mai―26 AB0709 CHARACTERIZATION OF NAILFOLD CAPILLAROSCOPY IN COVID-19: A CASE CONTROL STUDY P. E. Bermudez Bermejo, R. Jimenez-Soto, A. Sanchez Rodríguez, A. Turrent, D. Mercado Velasco, I. Bravo-Lee, et al. (+3)
573 [GO] 2021―Mai―26 AB0704 TELEMEDICINE AT THE TIME OF COVID-19: THE EXPERIENCE WITH RA PATIENTS TREATED WITH JAK-INHIBITORS C. Garufi, F. R. Spinelli, S. Mancuso, F. Ceccarelli, F. Conti
574 [GO] 2021―Mai―26 AB0698 CORONAVIRUS 19 DISEASE VACCINE: PERCEPTIONS AND INTENTIONS OF TUNISIAN PATIENTS WITH RHEUMATOID ARTHRITIS K. Ben Abdelghani, H. Boussaa, S. Miladi, M. Sellami, L. Souabni, K. Ouenniche, et al. (+4)
575 [GO] 2021―Mai―26 AB0693 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DURING CORONAVIRUS 19 PANDEMIC: WHAT DO TUNISIAN RHEUMATOLOGISTS THINK? H. Ferjani, H. Boussaa, K. Maatallah, H. Khalfalli, D. Kaffel, W. Hamdi
576 [GO] 2021―Mai―26 AB0386 CORONAVIRUS INFECTION AND VASCULITIS: IDENTIFYING ASSOCIATIONS MINING THE BIOMEDICAL LITERATURE A. Rodriguez-Pla, R. Cartin-Ceba
577 [GO] 2021―Mai―26 AB0691 ANALYSIS OF SARS-COV-2 ANTIBODIES IN NON-COVID-19 PATIENTS: COMPARISON BETWEEN SYSTEMIC SCLEROSIS PATIENTS AND HEALTHY CONTROLS L. Giardullo, C. Rotondo, A. Corrado, N. Maruotti, R. Colia, A. Altomare, et al. (+3)
578 [GO] 2021―Mai―26 AB0671 NO EVIDENCE OF SARS-COV-2 IN THE KNEE JOINT: A CADAVER STUDY M. Grassi, V. Giorgi, M. Nebuloni, P. Zerbi, M. R. Gismondo, F. Salaffi, et al. (+3)
579 [GO] 2021―Mai―26 AB0739 MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2 INFECTION AND E.COLI SEPSIS: THE POTENTIAL ROLE OF PROCALCITONINE AS A RAPID DIAGNOSTIC BIOMARKER TO DISTINGUISH TWO DIFFERENT PHASES OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME M. Gilio, S. B. Morella, F. Picaro, C. Acierno, D. Palazzo, A. Erezanu, et al. (+3)
580 [GO] 2021―Mai―26 AB0656 SARS-CoV-2 INFECTION IN PATIENTS WITH RHEUMATIC DISEASE: A TERTIARY SINGLE-CENTER EXPERIENCE A. Halbac, B. Balan, C. Tamas, M. M. Tamas, I. Felea, I. Filipescu, et al. (+4)
581 [GO] 2021―Mai―26 AB0662 IMPACT OF THE SARS-CoV-2 PANDEMIC IN A POPULATION OF PATIENTS FOLLOWED IN A RHEUMATOLOGY DEPARTMENT S. Lahrichi, K. Nassar, S. Janani
582 [GO] 2021―Mai―26 AB0663 COMPARING METHODS FOR DETERMINING ANTIBODIES TO SARS-CoV-2 USING A RAPID TEST AND ENZYME-LINKED IMMUNOSORBENT ASSAY G. Gridneva, E. Aronova, S. Glukhova, M. Cherkasova, B. Belov, K. Nurbaeva, E. Salyanova
583 [GO] 2021―Mai―26 AB0672 PSYCHOLOGIC STATE OF PATIENTS WITH RHEUMATIC DISEASES AFTER THE OUTBREAK OF SARS-COV2 M. Yasmine, S. Mariem, S. Miladi, A. Fazaa, L. Souebni, K. Ouenniche, et al. (+4)
584 [GO] 2021―Mai―26 AB0654 TOCILIZUMAB IS PROTECTIVE AGAINST SARS-COV2 INFECTION OR NOT? F. Fayed, E. Abdelkarim
585 [GO] 2021―Mai―26 AB0699 RETROSPECTIVE ANALYSIS OF 52 SARS-COV2 POSITIVE PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE: A SINGLE CENTER EXPERIENCE Y. Karabulut
586 [GO] 2021―Mai―26 AB0684 LESS THAN 20% OF PATIENTS WITH A CHRONIC INFLAMMATORY RHEUMATIC DISEASE CHANGED THEIR IMMUNOSUPPRESSIVE MEDICATION BECAUSE OF THE COVID 19 PANDEMIC I. Andreica, R. Jast, G. Rezniczek, U. Kiltz, D. Kiefer, B. Buehring, et al. (+2)
587 [GO] 2021―Mai―26 AB0905-HPR TELEMEDICINE IN RHEUMATOLOGY AT TIME OF COVID PANDEMIC G. Cuomo, F. Masini, K. Gjeloshi, D. Lubrano, L. E. Adinolfi, C. Romano
588 [GO] 2021―Mai―26 AB0926-PARE IMPACT OF COVID 19 PANDEMIC ON TUNISIAN SPA PATIENTS: PSYCHOLOGICAL STATE AND TREATMENT ADHERENCE M. Rachdi, A. Feki, Z. Gassara, S. Ben Jemaa, M. Ghali, M. Ezzeddine, et al. (+4)
589 [GO] 2021―Mai―26 AB0879-HPR MOTIVATION OF HEALTHCARE PROVIDERS DURING COVID19 PANDEMIC OUTBREAK C. Cobilinschi, A. Constantinescu, I. Draniceanu, A. Balanescu, V. Bojinca, C. L. Constantinescu, et al. (+7)
590 [GO] 2021―Mai―25 POS0047 OUTCOMES IN INFLAMMATORY ARTHROPATHY PATIENTS HOSPITALIZED FOR COVID-19 T. Collins, V. Patel, A. Babajanians, S. Kubomoto
591 [GO] 2021―Mai―25 OP0288 MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY Z. Izadi, M. Gianfrancesco, K. Hyrich, A. Strangfeld, L. Gossec, L. Carmona, et al. (+27)
592 [GO] 2021―Mai―25 OP0282 RITUXIMAB ASSOCIATED WITH SEVERE COVID-19 AMONG PATIENTS WITH INFLAMMATORY ARTHRITIDES: A 1-YEAR MULTICENTER STUDY IN 1116 SUCCESSIVE PATIENTS RECEIVING BIOLOGIC AGENTS R. Felten, P. M. Duret, E. Bauer, M. Ardizzone, H. J. Djossou, J. H. Salmon, et al. (+9)
593 [GO] 2021―Mai―25 OP0314 DOCK8 MUTATIONS IN COVID-19 AND MIS-C CYTOKINE STORM SYNDROME R. Cron, M. Zhang, D. Absher, J. Bridges, A. Schnell, P. Bhatraju, et al. (+5)
594 [GO] 2021―Mai―25 OP0284 OUTCOME OF COVID-19 IN PATIENTS WITH RHEUMATIC AND INFLAMMATORY DISEASES TREATED WITH RITUXIMAB: DATA FROM DE FRENCH RMD COVID-19 COHORT J. Avouac, E. Drumez, E. Hachulla, R. Seror, S. Georgin-Lavialle, S. El Mahou, et al. (+17)
595 [GO] 2021―Mai―25 OP0324-PARE PATIENT INFORMATION IN TIMES OF CRISIS: LESSONS LEARNED FROM COVID-19 COMMUNICATION IN RHEUMATOLOGY M. M. Bakker, T. Luttikhuis, I. Jansen, J. Rademakers, M. De Wit, A. Boonen, P. Putrik
596 [GO] 2021―Mai―25 POS0053 RHEUMATOID ARTHRITIS AND THE RISK OF COVID-19 DIAGNOSIS, HOSPITALISATION AND DEATH: A POPULATION-BASED MULTI-STATE COHORT ANALYSIS INCLUDING 5,586,565 PEOPLE IN CATALONIA, SPAIN A. Vivekanantham, E. Burn, S. Fernandez-Bertolin, M. Aragon, T. Duarte-Salles, D. Prieto-Alhambra
597 [GO] 2021―Mai―25 OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE J. Sparks, Z. Wallace, A. Seet, M. Gianfrancesco, Z. Izadi, K. Hyrich, et al. (+36)
598 [GO] 2021―Mai―25 OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA) M. F. Ugarte-Gil, G. S. Alarcon, A. Seet, Z. Izadi, C. Reategui Sokolova, A. E. Clarke, et al. (+44)
599 [GO] 2021―Mai―25 POS0051 THE IMPACT OF COVID-19 ON RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY K. Young, S. A. Yeoh, M. Putman, E. Graef, F. Berenbaum, R. Conway, et al. (+13)
600 [GO] 2021―Mai―25 OP0082-PARE THE EFFECT COVID-19 HAS ON THE MENTAL HEALTH OF PEOPLE LIVING WITH RHEUMATIC DISEASES. FROM DATA TO INTERVENTIONS. S. Mingolla, A. Celano, M. Santopietro
601 [GO] 2021―Mai―25 OP0285 COVID-19 HOSPITALIZATIONS, ICU ADMISSION, AND DEATH AMONG PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) - A POPULATION-BASED STUDY L. Eder, R. Croxford, A. Drucker, A. Mendel, K. Bindee, Z. Touma, et al. (+5)
602 [GO] 2021―Mai―25 OP0283 DOES TNF-INHIBITION DECREASE THE RISK OF SEVERE COVID-19 IN RMD-PATIENTS? R. Hasseli, B. F. Hoyer, A. Krause, H. M. Lorenz, A. Pfeil, A. Regierer, et al. (+7)
603 [GO] 2021―Mai―25 POS0054 THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS PATIENTS FROM THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR) A. M. Hoffmann-Vold, C. Brunborg, F. Tirelli, P. Carreira, N. Del Papa, A. Mekinian, et al. (+15)
604 [GO] 2021―Mai―25 POS1258 MISSING THE WINDOW OF OPPORTUNITY: EARLY ARTHRITIS CLINICS IN TIMES OF COVID-19 B. D’onofrio, L. De Stefano, B. L. Palermo, B. Xoxi, A. Manzo, C. Montecucco, S. Bugatti
605 [GO] 2021―Mai―25 POS1257 HYPOGAMMAGLOBULINEMIA IS A SIGNIFICANT RISK FACTOR FOR MORTALITY IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND COVID-19 B. Ince, M. Bektas, N. Koca, B. F. Agargun, S. Zarali, D. Y. Guzey, et al. (+4)
606 [GO] 2021―Mai―25 POS1251 ROLE OF SYSTEMIC AUTOINMUNE CONDITIONS IN HOSPITAL ADMISSIONS RELATED TO COVID-19 I. Perez-Sancristobal, L. Lopez Pedraza, M. P. Álvarez Hernandez, J. I. Colomer, A. Madrid García, B. Fernandez, et al. (+5)
607 [GO] 2021―Mai―25 OP0274-PARE EVALUATION OF PATIENT SATISFACTION FOR TELEHEALTH (PHONE AND VIDEO) IN RHEUMATOLOGY OUTPATIENTS DURING COVID-19 PANDEMIC Y. Oh, A. Hennessey, L. Young, D. Yates, C. Barrett
608 [GO] 2021―Mai―25 OP0264-HPR “I LITERALLY CONVINCED MYSELF I WAS GOING TO CATCH IT AND DIE”: LIVED EXPERIENCES OF THE COVID-19 PANDEMIC BY PEOPLE WITH RHEUMATIC DISEASES FROM FOUR EUROPEAN COUNTRIES R. J. O. Ferreira, C. Costa, A. Marques, A. J. Barata Cavaleiro, S. Makri, K. Parperis, et al. (+5)
609 [GO] 2021―Mai―25 POS0056 ANXIETY AND CONCERNS RELATED TO THE WORK SITUATION DURING THE COVID-19 PANDEMIC IN >5,000 PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE FOLLOWED IN THE DANISH DANBIO REGISTRY, RESULTS FROM A NATIONWIDE QUESTIONNAIRE B. Glintborg, D. V. Jensen, S. Engel, L. Terslev, M. Pfeiffer Jensen, O. Hendricks, et al. (+15)
610 [GO] 2021―Mai―25 OP0265-HPR IMPACT OF COVID-19 PANDEMIC ON RHEUMATOLOGY PATIENTS IN NORTHERN IRELAND - A WEB BASED CROSS-SECTIONAL SURVEY P. McKee, A. Irvine, C. Riddell, E. Ball
611 [GO] 2021―Mai―25 POS0152-HPR REMOTE CLINICAL MANAGEMENT: INCORPORATING ELECTRONIC ASSESSMENT OF PATIENTS WITH RHEUMATIC DISEASES INTO STANDARD CLINICAL PATHWAYS DURING THE COVID-19 PANDEMIC: A PILOT STUDY T. Malley, J. Jackman, S. Manderson, L. Saldana Pena, E. Evans, J. Barrett, et al. (+2)
612 [GO] 2021―Mai―25 LB0001 MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION L. Pupim, T. S. Wang, K. Hudock, J. Denson, N. Fourie, L. Hercilla Vasquez, et al. (+12)
613 [GO] 2021―Mai―25 OP0281 EXCESS GIANT CELL ARTERITIS CASES ARE ASSOCIATED WITH PEAKS IN COVID-19 PREVALENCE B. Mulhearn, J. Ellis, S. Skeoch, J. Pauling, S. Tansley
614 [GO] 2021―Mai―25 POS1237 ALGORITHM IDENTIFYING CHRONIC INFLAMMATORY DISEASES TREATED BY BIOTHERAPY AND/OR TARGETED SYNTHETIC TREATMENTS IN OUTPATIENT CARE IN FRANCE: FEASIBILITY, PRELIMINARY RESULTS, AND IMPACT OF COVID-19 P. Richette, M. Allez, V. Descamps, L. Perra, S. Pilet, M. Maravic
615 [GO] 2021―Mai―25 POS1228 THE ROLE OF CHEST CT IN UNDERSTANDING INTERSTITIAL LUNG DISEASE (ILD): SYSTEMIC SCLEROSIS (SSc). VERSUS COVID-19 M. Orlandi, N. Landini, G. Sambataro, C. Nardi, C. Bruni, S. Bellando-Randone, et al. (+25)
616 [GO] 2021―Mai―25 POS0050 ARE PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) MORE LIKELY TO RECEIVE COVID-19 TESTS AND TEST POSITIVE FOR SARS-COV-2? A MATCHED POPULATION-BASED STUDY L. Eder, R. Croxford, A. Drucker, A. Mendel, K. Bindee, Z. Touma, et al. (+5)
617 [GO] 2021―Mai―25 LB0003 IMMUNOGENICITY AND SAFETY OF THE BNT162b2 mRNA COVID-19 VACCINE IN ADULT PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND GENERAL POPULATION: A MULTICENTER STUDY V. Furer, T. Eviatar, D. Zisman, H. Peleg, D. Paran, D. Levartovsky, et al. (+23)
618 [GO] 2021―Mai―25 OP0009-PARE SUCCESSFUL PATIENT EDUCATION ON COVID-19 VACCINE SAFETY IN A LARGE RHEUMATOLOGY COHORT USING INTERACTIVE MOBILE-PHONE VIDEO TECHNOLOGY: CONTEXT, RESULTS, AND NEXT STEPS L. Rajagopala, M. Ford, M. Jasim, D. Mulherin, S. Venkatachalam, T. Sheeran, J. Bateman
619 [GO] 2021―Mai―25 LB0002 COVID-19 VACCINE SAFETY IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASE P. M. Machado, S. Lawson-Tovey, K. Hyrich, L. Carmona, L. Gossec, E. Mateus, et al. (+17)
620 [GO] 2021―Mai―25 POS1223 RAS GUANYL RELEASING PROTEIN 1 (RASGRP1) IN PERIPHERAL B CELLS LINKS RA TO COVID-19 S. Hannawi, F. Alqutami, M. Y. Hachim
621 [GO] 2021―Mai―25 OP0287 IMMUNOMODULATORY THERAPIES FOR SEVERE FORMS OF COVID-19: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER A. Alunno, A. Najm, X. Mariette, J. Emmel, L. Mason, G. De Marco, et al. (+2)
622 [GO] 2021―Mai―25 POS1177 REVAMPING BIOLOGIC THERAPY DURING COVID-19 S. Ahmed Narikkoottungal, A. Siddiqui, A. Constantin, S. Farrow, K. Ahmed
623 [GO] 2021―Mai―25 POS0052 PATHOPHYSIOLOGY OF ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER A. Najm, A. Alunno, X. Mariette, B. Terrier, G. De Marco, L. Mason, et al. (+3)
624 [GO] 2021―Mai―25 OP0313 PRELIMINARY CRITERIA FOR MACROPHAGE ACTIVATION SYNDROME ASSOCIATED WITH CORONAVIRUS DISEASE-19 S. Amikishiyev, M. G. Gunver, M. Bektas, S. Aghamuradov, B. Ince, N. Koca, et al. (+24)
625 [GO] 2021―Mai―25 POS1163 CHARACTERISTICS AND OUTCOMES IN A REAL-WORLD COHORT OF RHEUMATOID ARTHRITIS PATIENTS WITH COVID-19 Y. Ye, X. Yue, W. Krueger, L. Wegrzyn
626 [GO] 2021―Mai―25 POS0349 SEQUENCE COMPLEMENTARITY BETWEEN SARS-CoV-2 GENOME AND HUMAN NONCODING RNAS ASSOCIATED WITH IMMUNOLOGICAL DISORDERS: AN IN SILICO PIVOTAL STUDY R. Talotta, S. Bahrami, M. J. Laska
627 [GO] 2021―Mai―25 POS0049 SARS-COV-2 INFECTION IN CHILDREN WITH RHEUMATIC DISEASE: EXPERIENCE OF A TERTIARY REFERRAL CENTER B. Sözeri, F. Demir, S. Kalin, C. Hasbal Akkuş
628 [GO] 2021―Mai―25 POS0055 SARS-COV-2 OUTBREAK IN AUTOIMMUNE DISEASES: THE EURO-COVIMID STUDY D. Saadoun, M. Vieira, M. Vautier, X. Baraliakos, I. Andreica, J. A. P. Da Silva, et al. (+16)
629 [GO] 2021―Mai―25 OP0075 EVALUATION OF A VIRTUAL REALITY TEACHING CONCEPT FOR MEDICAL STUDENTS DURING THE SARS-COV-2 PANDEMIC A. Pfeil, F. Marcus, T. Hoffmann, P. Klemm, P. Oelzner, U. Müller-Ladner, et al. (+6)
630 [GO] 2021―Mai―25 OP0323-PARE “CELEBRATING THE 50TH ANNIVERSARY OF OUR ORGANISATION IN TIMES OF PANDEMIC: HOW WE USED DIGITAL TOOLS TO OVERCOME CHALLENGES AND DIFFICULTIES AND CAME INTO CONTACT WITH MORE PARTICIPANTS AND VIEWERS THAN EVER ENVISAGED!” C. Elling-Audersch
631 [GO] 2021―Mai―25 POS1235 ASSESSMENT OF RISK FACTORS FOR HOSPITALIZATION OF AUTOIMMUNE AND RHEUMATIC DISEASE PATIENTS WITH COVID-19 - A SINGLE CENTRE OBSERVATIONAL STUDY J. M N, P. Dekate, S. Vontari, R. Dudam
632 [GO] 2021―Mai―25 POS1264 IMMUNE-MEDIATED DISEASES (IMID) AND CORONAVIRUS DISEASE 2019 (COVID-19): RESULTS FROM AN OBSERVATIONAL RETROSPECTIVE MULTICENTER STUDY R. Dos-Santos, C. Calviño, I. Bastón, R. Ferreiro, F. Montero, C. Gonzalez, et al. (+3)
633 [GO] 2021―Mai―25 POS1190 EXPECTATIONS AND POTENTIAL CONCERNS OF PATIENTS WITH AUTOIMMUNE AND RHEUMATIC DISEASES REGARDING VACCINATION AGAINST SARS-CoV-2 (COVID-19): THE WORLDWIDE ONLINE VAXICOV STUDY R. Felten, M. Dubois, M. F. Ugarte-Gil, J. Fort, L. Pijnenburg, A. Chaudier, et al. (+10)
634 [GO] 2021―Mai―25 POS1172 COVID-19 ACROSS RHEUMATOLOGY: A BIBLIOMETRIC STUDY B. Doskaliuk, R. Yatsyshyn, I. Stoika, K. Fedorovych, O. Drogomeretska, O. Hotsaniuk, Y. Delva
635 [GO] 2021―Mai―25 POS1210 PREVALENCE OF COVID-19 AMONG PATIENTS WITH RHEUMATIC DISEASES: AN OBSERVATIONAL SURVEY DURING THE TWO WAVES IN ITALY S. Fasano, I. Pantano, D. Mauro, D. Capocotta, D. Iacono, E. Gaggiano, et al. (+6)
636 [GO] 2021―Mai―25 POS1211 IDENTIFICATION OF COMMON FUNCTIONAL PATHWAYS IN PATIENTS WITH LUPUS AND COVID-19 BY TIME-SERIES ANALYSIS Y. LI, S. X. Zhang, J. Qiao, Q. Wang, S. Song, R. Zhao, et al. (+7)
637 [GO] 2021―Mai―25 POS1168 SELF-REPORTED SARS-CoV2 TESTING AND COVID-19 DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS IN A SWISS OBSERVATIONAL COHORT E. Papagiannoulis, A. Ciurea, D. Dan, A. Finckh, B. Gilbert, I. Von Loga, et al. (+3)
638 [GO] 2021―Mai―25 POS1263 COVID-19 FROM THE PATIENTS’S PERSPECTIVE: PRELIMINARY RESULTS OF ONLINE SURVEY D. Karateev, P. Pchelnikova, E. Luchikhina, T. Boboshko
639 [GO] 2021―Mai―25 POS1162 PREDICTORS OF HOSPITALISATION IN PATIENTS WITH RHEUMATIC DISEASE AND COVID-19 IN IRELAND: DATA FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY R. Conway, E. Nikiphorou, C. Demetriou, C. Low, K. Leamy, J. Ryan, et al. (+11)
640 [GO] 2021―Mai―25 POS1201 Incidence and outcome of COVID-19 in ANCA-associated vasculitis: impact of COVID-19 in patients undergoing rituximab for maintenance E. Treppo, M. Binutti, G. Del Frate, S. De Vita, L. Quartuccio
641 [GO] 2021―Mai―25 POS1181 CLINICAL COURSE OF COVID-19 IN CHILDREN WITH RHEUMATIC DISEASE UNDER BIOLOGIC THERAPY F. Demir, K. Ulu, Ş. Çağlayan, T. Coşkuner, B. Sözeri
642 [GO] 2021―Mai―25 POS1202 EXPERIENCE WITH COVID-19 IN GERMAN PAEDIATRIC RHEUMATOLOGY CENTRES A. Klein, D. Windschall, W. Emminger, R. Berendes, J. Kuemmerle-Deschner, R. Trauzeddel, et al. (+10)
643 [GO] 2021―Mai―25 POS1233 USE OF BARICITINIB AND TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 IN HOSPITALIZED PATIENTS D. X. Xibille Friedmann, S. M. Carrillo Vazquez
644 [GO] 2021―Mai―25 POS1246 COVID-19 IN ITALIAN PATIENTS WITH RHEUMATIC AUTOIMMUNE SYSTEMIC DISEASES: RESULTS OF A NATIONWIDE SURVEY STUDY C. Ferri, D. Giuggioli, V. Raimondo, L. Dagna, V. Riccieri, E. Zanatta, et al. (+60)
645 [GO] 2021―Mai―25 POS1242 FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH RHEUMATIC DISEASES AND COVID-19 IN MEXICO D. Alpizar-Rodriguez, F. Irazoque-Palazuelos, T. S. Rodriguez-Reyne, E. Zamora, D. X. Xibille Friedmann, A. Castillo Ortiz, et al. (+24)
646 [GO] 2021―Mai―25 POS1193 CLINICAL FEATURES AND THE COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER A. Avanoglu Guler, T. Yüce İnel, H. Karadeniz, R. Bilici Salman, H. Satiş, H. Küçük, et al. (+6)
647 [GO] 2021―Mai―25 POS1259 FAVOURABLE SHORT-TERM COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER USING BIOLOGIC AGENTS N. Aliyeva, B. Ç. Yalçin Dulundu, S. Amikishiyev, S. Aghamuradov, M. Bektaş, B. Ince, et al. (+5)
648 [GO] 2021―Mai―25 POS1247 CLINICAL FEATURES AND OUTCOMES OF COVID-19 IN PATIENTS WITH IGG4-RELATED DISEASE. A COLLABORATIVE EUROPEAN MULTI-CENTRE STUDY G. A. Ramirez, M. Lanzillotta, M. Ebbo, A. Fernandez-Codina, G. Mancuso, F. Martínez-Valle, et al. (+5)
649 [GO] 2021―Mai―25 POS1227 IMPACT OF A PRE-EXISTING INTERSTITIAL LUNG DISEASE ON SEVERITY OF COVID-19 IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES P. A. Juge, E. Hachulla, C. Richez, E. Drumez, A. Duhamel, R. Borie, P. Dieudé
650 [GO] 2021―Mai―25 POS1252 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES ON CHRONIC USE OF HYDROXYCHLOROQUINE IN A LARGE BRAZILIAN COHORT - A 24-WEEK PROSPECTIVE STUDY G. Salviato Pileggi, G. Ferreira, A. P. Gomides, E. Reis Neto, M. Abreu, C. Albuquerque, et al. (+33)
651 [GO] 2021―Mai―25 POS1188 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTINE REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY ALLIANCE) A. A. Reyes, G. Alle, R. Tanten, M. Scolnik, E. Soriano, G. Berbotto, et al. (+21)
652 [GO] 2021―Mai―25 POS1245 MORTALITY OF COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON TO THE GENERAL POPULATION IN MÉXICO M. U. Martínez-Martínez, F. Irazoque-Palazuelos, T. S. Rodriguez-Reyne, E. Zamora, A. Castillo Ortiz, B. E. Zazueta, et al. (+13)
653 [GO] 2021―Mai―25 POS1266 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: SURVEY-BASED ASSESSMENT OF THE RISK OF HOSPITALIZATION D. Karateev, P. Pchelnikova, E. Luchikhina, T. Boboshko
654 [GO] 2021―Mai―25 POS1226 THE COURSE OF CORONAVIRUS DISEASE 2019 (COVID-19) IN PATIENTS WITH SJOGREN’S SYNDROME TREATED WITH ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB) E. Sokol, A. Torgashina, B. Chalcev, J. Khvan, O. Golovina
655 [GO] 2021―Mai―25 POS1232 COVID-19 IN PATIENTS WITH SYSTEMIC SCLEROSIS: ONE RHEUMATOLOGY CENTER EXPERIENCE M. Starovoytova, O. Desinova, L. P. Ananyeva, O. Koneva, L. Garzanova, O. Ovsyannikova, et al. (+3)
656 [GO] 2021―Mai―25 POS1161 A CITIZEN SCIENCE APPROACH TO CAPTURE POOR MENTAL HEALTH RELATED TO COVID-19 IN RHEUMATIC PATIENTS AFTER CONFINEMENT DURING PANDEMIC IN ITALY F. Ingegnoli, M. Buoli, C. Posio, R. DI Taranto, A. Lo Muscio, E. Cumbo, et al. (+2)
657 [GO] 2021―Mai―25 POS1254 INCIDENCE AND OUTCOME OF COVID-19 IN ROUTINE RHEUMATOLOGY CARE: DATA FROM A SINGLE OUTPATIENT CENTER IN GERMANY S. G. Werner, P. Höhenrieder, R. Chatelain, H. E. Langer
658 [GO] 2021―Mai―25 POS1184 AUTOIMMUNE SYSTEMIC DISEASES AND COVID-19 INFECTION S. Monov, R. Shumnalieva, D. Monova
659 [GO] 2021―Mai―25 POS1198 THE ROLE OF SOCS3 IN COLCHICINE ANTI-INFLAMMATORY EFFECT ON COVID-19 INFECTION M. Y. Hachim, F. Alqutami, S. Hannawi
660 [GO] 2021―Mai―25 POS1215 INFLUENCE OF CONFINEMENT CARRIED OUT BY PATIENTS WITH AUTOIMMUNE AND IMMUNE- MEDIATED INFLAMMATORY DISEASE WITH BIOLOGICAL TREATMENT ON COVID-19 INFECTION J. Font-Urgelles, S. Mínguez, B. Rodríguez-Diez, L. Creus-Vila, M. Esquius Rafat, X. Fusta Novell, et al. (+5)
661 [GO] 2021―Mai―25 POS1183 OUTCOMES OF COVID-19 INFECTION AMONG CHILDREN AND YOUNG PEOPLE WITH PRE-EXISTING RHEUMATIC AND MUSCULOSKELETAL DISEASES L. Kearsley-Fleet, S. Lawson-Tovey, R. E. Costello, A. Belot, F. Aeschlimann, I. Melki, et al. (+15)
662 [GO] 2021―Mai―25 POS1230 OUTCOME FOLLOWING COVID-19 INFECTION IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS A. Antovic, B. Lövström, A. Hugelius, O. Borjesson, A. Bruchfeld, I. Gunnarsson
663 [GO] 2021―Mai―25 POS1231 COVID-19 INFECTION IN RHEUMATIC IMMUNE-MEDIATED INFLAMMATORY DISEASES. EPIDEMIOLOGICAL STUDY IN A SINGLE UNIVERSITY HOSPITAL D. Martínez-López, D. Prieto-Peña, L. Sanchez-Bilbao, A. Herrero-Morant, C. Álvarez-Reguera, M. Trigueros-Vazquez, et al. (+2)
664 [GO] 2021―Mai―25 POS1234 IMPACT OF THE CHANGE IN ADMINISTRATION ROUTE OF TOCILIZUMAB AND ABATACEPT, DUE TO THE COVID-19 LOCKDOWN ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS L. Diebold, T. Wirth, V. Pradel, N. Balandraud, E. Fockens, C. Paris, et al. (+3)
665 [GO] 2021―Mai―25 POS1189 THE IMPACT OF TELEMEDICINE AND COVID-19 ON A TERTIARY RHEUMATOLOGY SERVICE: A RETROSPECTIVE AUDIT W. Zhu, T. De Silva, L. Eades, S. Morton, S. Ayoub, E. F. Morand, A. Antony
666 [GO] 2021―Mai―25 POS1236 IMPACT OF COVID-19 ON INITIATION AND RENEWAL OF BIOTHERAPIES AND TARGETED SYNTHETIC TREATMENTS P. Richette, M. Allez, V. Descamps, L. Perra, S. Pilet, M. Maravic
667 [GO] 2021―Mai―25 POS1205 THE IMPACT OF COVID-19 ON PATIENT MANAGEMENT AND PRESCRIBING STRATEGY ACROSS THE EU AND US: A REAL-WORLD SURVEY OF RHEUMATOLOGISTS, DERMATOLOGISTS, AND GASTROENTEROLOGISTS E. Holdsworth, R. Lukanova, M. Hughes, J. Hall, J. Austin, G. Taylor-Stokes, J. Piercy
668 [GO] 2021―Mai―25 POS1192 BEHAVIOR AND FEELINGS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DURING LOCKDOWN MEASURES FOR THE COVID-19 OUTBREAK G. De Marchi, D. Azzolina, E. Maresio, D. Colatutto, M. Binutti, M. Monte, et al. (+7)
669 [GO] 2021―Mai―25 POS1222 FACTORS ASSOCIATED WITH USE OF TELEMEDICINE FOR FOLLOW-UP OF LUPUS NEPHRITIS IN THE COVID-19 OUTBREAK H. So, E. Chow, T. K. LI, I. T. Cheng, S. L. Lau, C. C. Szeto, L. S. Tam
670 [GO] 2021―Mai―25 POS1164 USE OF TELEMEDICINE FOR FOLLOW-UP OF SLE PATIENTS WITH NEPHRITIS IN THE COVID-19 OUTBREAK (“TeleSLE”): THE 6-MONTH RESULTS OF A RANDOMIZED CONTROLLED TRIAL H. So, E. Chow, T. K. LI, S. L. Lau, I. T. Cheng, C. C. Szeto, L. S. Tam
671 [GO] 2021―Mai―25 POS1207 REAL WORLD POPULATION-BASED ASSESSMENT OF COVID-19 OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS USING BIOLOGIC OR SYNTHETIC DMARDs L. Wegrzyn, K. Winthrop, S. Kim, Y. Ye, C. Huisingh, W. Krueger, et al. (+2)
672 [GO] 2021―Mai―25 POS1186 EFFECT OF SOCIO-ECONOMIC STATUS AND EDUCATIONAL LEVEL ON COVID-19 OUTCOMES IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA: DATA FROM THE SAR-COVID REGISTRY L. Sorrentino, J. Rebak, F. Maldonado, V. V. Castro Coello, A. Brigante, A. Hamaui, et al. (+22)
673 [GO] 2021―Mai―25 POS1166 UNDERSTANDING PRESCRIPTION BEHAVIOR ACROSS HEALTHCARE PROFESSIONALS IN TREATING KNEE OSTEOARTHRITIS BEFORE AND DURING THE 2020 COVID-19 PANDEMIC D. Baldock, E. Baynton, H. Hamdan
674 [GO] 2021―Mai―25 POS1173 A SHORT DELAY IN ARTHRITIS CARE IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY - LESSONS FROM THE CORONAVIRUS DISEASE 19 (COVID-19) PANDEMIC A. Giollo, E. Bertoldo, C. Benini, O. Viapiana, L. Idolazzi, G. Adami, et al. (+3)
675 [GO] 2021―Mai―25 POS1178 THE ROLE OF VIRTUAL TELEPHONE VISITS IN THE TIGHT CONTROL OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TARGETED THERAPIES DURING THE COVID-19 PANDEMIC F. Ingegnoli, G. Cincinelli, A. F. Luppino, E. Favalli, R. Caporali
676 [GO] 2021―Mai―25 POS1244 PRELIMINARY RESULTS OF LONG-TERM FOLLOW-UP OF THE HEALTH STATUS OF PATIENTS USING csDMARDs AND b/tsDMARDS FOR RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC F. Unlu Ozkan, K. Sari, I. Aktas
677 [GO] 2021―Mai―25 POS1265 CHALLENGES OF EGYPTIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DURING COVID-19 PANDEMIC S. Tharwat, S. Zohdy
678 [GO] 2021―Mai―25 POS1243 TELEMEDICINE AND MANAGEMENT OF THE PATIENT AFFECTED BY GIANT CELL ARTERITIS DURING THE COVID-19 PANDEMIC - TELEMACOV S. Parisi, M. C. Ditto, A. Laganà, C. L. Peroni, E. Fusaro
679 [GO] 2021―Mai―25 POS1213 IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN ON WELLBEING ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, L. Christen, L. Carmona, J. Correa-Fernández, S. Sanz-Gómez, et al. (+10)
680 [GO] 2021―Mai―25 POS1175 ASSESSMENT OF THE COVID-19 PANDEMIC FROM THE PERSPECTIVE OF PEOPLE WITH RHEUMATIC MUSCULOSKELETAL DISEASES IN EUROPE. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, J. Correa-Fernández, S. Sanz-Gómez, L. Christen, V. Navarro-Compán
681 [GO] 2021―Mai―25 POS1170 SELF-PROTECTION STRATEGIES, HEALTH BEHAVIOR AND DISEASE ACTIVITY DURING THE FIRST WAVE, RE-OPENING AND SECOND WAVE OF THE COVID-19 PANDEMIC IN >7000 DANISH PATIENTS WITH INFLAMMATORY ARTHRITIS B. Glintborg, D. V. Jensen, S. Engel, L. Terslev, M. Pfeiffer Jensen, O. Hendricks, et al. (+15)
682 [GO] 2021―Mai―25 POS1249 MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN DURING THE COVID-19 PANDEMIC IN TURKEY: FIRST REPORT FROM THE EASTERN MEDITERRANEAN Y. Ozsurekci, S. Gürlevik, S. Kesici, U. Kaya Akca, P. D. Oygar, K. Aykac, et al. (+12)
683 [GO] 2021―Mai―25 POS1169 IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION H. Bower, T. Frisell, D. DI Giuseppe, B. Delcoigne, G. M. Alenius, E. Baecklund, et al. (+10)
684 [GO] 2021―Mai―25 POS1241 THE IMPACT OF THE COVID-19 PANDEMIC ON PHYSICAL FUNCTIONING AND MENTAL WELLBEING IN 824 PATIENTS WITH RHEUMATIC DISEASE OVER 8 MONTHS: PHYSICAL FUNCTIONING DECLINES N. Cleaton, S. Raizada, T. Sheeran, J. Bateman
685 [GO] 2021―Mai―25 POS1167 REVIEW OF THE IMPACT OF COVID-19 PANDEMIC ON RHEUMATOLOGY SERVICES AT A LARGE TERTIARY CARE CENTRE IN WALES, UK R. Asif, N. Elndari, A. Negi
686 [GO] 2021―Mai―25 POS1185 IMPACT OF LOCKDOWN DURING COVID-19 PANDEMIC ON THE ONSET OF POST-TRAUMATIC STRESS DISORDER (PTSD) IN SYSTEMIC SCLEROSIS PATIENTS: A CASE-CONTROL STUDY D. M. Reza Beigi, G. Pellegrino, A. Lorello, C. Angelelli, K. Stefanantoni, F. Conti, V. Riccieri
687 [GO] 2021―Mai―25 POS1171 THE COVID-19 PANDEMIC PROMPTS ISOLATION AND BEHAVIORAL CHANGES IN PATIENTS WITH CHRONIC RHEUMATIC DISEASES LEADING TO REDUCED PHYSICAL ACTIVITY, INCREASED PAIN, DISEASE ACTIVITY, AND LOW SEROPREVALENCE OF SARS-CoV2 ANTIBODIES C. Ammitzbøll, J. B. Andersen, S. R. Vils, C. M. Jørgensen, E. M. Hauge, C. Erikstrup, et al. (+3)
688 [GO] 2021―Mai―25 POS1182 MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS DURING THE COVID-19 PANDEMIC: EVIDENCE FROM THE ITALIAN EPICENTER F. Ingegnoli, A. F. Luppino, G. Cincinelli, E. Favalli, R. Caporali
689 [GO] 2021―Mai―25 POS1261 DISEASE ACTIVITY AND PAIN LEVELS ARE NOT INFLUENCED BY THE CURRENT COVID19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES IN GERMANY - DATA FROM THE GERMAN COVID-19 PATIENT SURVEY R. Hasseli, U. Müller-Ladner, T. Schmeiser, H. M. Lorenz, A. Krause, H. Schulze-Koops, et al. (+7)
690 [GO] 2021―Mai―25 POS1250 VITAMIN D DEFICIENCY IS MAINLY ASSOCIATED WITH SEVERE LUNG INVOLVEMENT, LONGER DISEASE DURATION AND RISK OF DEATH IN ELDERLY COVID-19 PATIENTS A. Sulli, E. Gotelli, A. Casabella, M. Grosso, C. Schenone, C. Pizzorni, et al. (+4)
691 [GO] 2021―Mai―25 POS1224 RHEUMATIC MANIFESTATIONS IN COVID-19 PATIENTS - SINGLE-CENTER EXPERIENCE AMIDST THE PANDEMIC S. Bogdanova-Petrova, T. Georgiev, G. Gerganov, S. Hristova, S. Dimitrov, T. Shivacheva
692 [GO] 2021―Mai―25 POS1256 SINGLE DOSE TOCILIZUMAB PHARMACOKINETICS IN GLUCOCORTICOID PRE-TREATED COVID-19 PATIENTS DURING CYTOKINE STORM SYNDROME HYPERINFLAMMATORY EPISODE: LESS IS MORE N. Boone, S. Ramiro, D. J. Moes, R. Mostard, C. Magro Checa, C. Van Dongen, et al. (+6)
693 [GO] 2021―Mai―25 POS1214 THE DYNAMICS OF INFLAMMATORY MARKERS IN COVID-19 PATIENTS TREATED WITH LEVILIMAB N. Lomakin, B. Bakirov, G. Musaev, D. Protsenko, O. Moiseeva, E. Pasechnik, et al. (+13)
694 [GO] 2021―Mai―25 POS1209 SUCCESSFUL TREATMENT OF SEVERE COVID-19 PNEUMONIA AND CYTOKINE RELEASE WITH SIMULTANEOUS TOCILIZUMAB AND ANAKINRA WITH ONE-MONTH FOLLOW-UP H. Haibel, J. L. Vahldiek, S. Angermair, M. Schumann, B. Siegmund, D. Poddubnyy, T. Schneider
695 [GO] 2021―Mai―25 POS1176 THE IMPACT OF COVID-19 QUARANTINE ON MENTAL HEALTH OF PATIENTS WITH FIBROMYALGIA F. Ingegnoli, M. Buoli, C. Posio, R. DI Taranto, R. Caporali
696 [GO] 2021―Mai―25 POS1262 A COHORT STUDY OF COVID-19 RELATED MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN AND ADOLESCENTS FROM MULTIPLE TERTIARY CARE CENTRES IN SOUTH INDIA A. Tiwari, A. Rauf, S. Kesavan, M. Kappanayil, S. Sivadas, S. Balan, P. Chickermane
697 [GO] 2021―Mai―25 POS1197 IN DEPTH IDENTIFICATION OF RISK FACTORS FOR SEVERE COVID-19, REQUIRING HOSPITALIZATION, IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: RESULTS OF A DUTCH NESTED CASE CONTROL STUDY (PRELIMINARY RESULTS) M. Opdam, S. Benoy, L. M. Verhoef, S. Van Bijnen, F. Lamers-Karnebeek, R. A. M. Traksel, et al. (+3)
698 [GO] 2021―Mai―25 POS1191 COVID-19 STRESS: DOES IT AUGMENT PAIN IN PEOPLE WITH FIBROMYALGIA AND MIGHT PSYCHOLOGICAL FLEXIBILITY PROTECT AGAINST THIS INFLUENCE? T. Koppert, J. W. G. Jacobs, M. Lumley, R. Geenen
699 [GO] 2021―Mai―25 POS1187 WILLINGNESS TO GET THE COVID-19 VACCINE AMONG PATIENTS WITH RHEUMATIC DISEASES, HEALTH WORKERS AND GENERAL POPULATION B. Yurttas, B. C. Poyraz, N. Süt, A. Ozdede, M. Oztas, Ö. F. Tabak, et al. (+2)
700 [GO] 2021―Mai―25 POS1268 COVID-19 VACCINE HESITANCY AMONG RHEUMATOLOGY PATIENTS RECEIVING INFLUENZA VACCINE V. Valerio, H. C. Shen, E. Field, E. G. Mcdonald, A. Turner, S. Bernatsky, et al. (+2)
701 [GO] 2021―Mai―25 POS1248 SAFETY PROFILE OF PFIZER-BIONTECH COVID-19 VACCINE IN PATIENTS WITH RHEUMATIC DISEASES: PRELIMINARY ASSESSMENT G. Cuomo, M. Atteno, C. Naclerio, L. E. Adinolfi, C. Romano
702 [GO] 2021―Mai―25 POS1196 COVID-19 VACCINE WILLINGNESS IN RA? RESULTS FROM THE RA LOUVAIN BRUSSELS COHORT T. Sokolova, V. Pirson, T. Xavier, E. Curraj, L. Bricman, E. Sapart, et al. (+4)
703 [GO] 2021―Mai―25 POS1220 PREGNANT AND POSTPARTUM WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES AND COVID-19: A CASE SERIES R. A. Rodriguez Chavez, C. M. Skinner Taylor, L. Pérez Barbosa, G. Figueroa-Parra, J. E. Compeán-Villegas, L. G. Espinosa Banuelos, et al. (+4)
704 [GO] 2021―Mai―25 POS1174 HYPERINFLAMMATION AND CLINICAL OUTCOMES FOR PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES HOSPITALIZED FOR COVID-19: A COMPARATIVE COHORT STUDY T. Hsu, K. D’silva, N. Serling-Boyd, J. Wang, A. Mueller, X. Fu, et al. (+10)
705 [GO] 2021―Mai―25 POS1238 ANTIPHOSPHOLIPID ANTIBODIES AND COVID-19: TREND OVER TIME S. Mancuso, S. Truglia, A. Capozzi, F. Pasquali, S. Recalchi, G. Riitano, et al. (+6)
706 [GO] 2021―Mai―25 POS1314 JUVENILE IDIOPATHIC ARTHRITIS IN THE CONTEXT OF THE CORONAVIRUS DISEASE 19 PANDEMIC: IMPACT ON THE DECREASE IN TREATMENT AND THE RETURN TO SCHOOL B. Quéré, I. Lemelle, A. Lohse, P. Pillet, J. Molimard, O. Richer, et al. (+8)
707 [GO] 2021―Mai―25 POS1195 ASSESSING ANTIBODY STATUS FOR SARS-CoV-2 IN PEOPLE WITH CORONAVIRUS INFECTION: A TIME COURSE STUDY IN PEOPLE WITH AUTOIMMUNE CONDITIONS K. Biddle, S. Koushesh, A. Blundell, D. Clark, S. Krishna, N. Sofat
708 [GO] 2021―Mai―25 POS1206 SEROPREVALENCE OF SARS-CoV-2 ANTIBODIES IN AUTOIMMUNE INFLAMMATORY RHEUMATOLOGIC PATIENTS T. Eviatar, D. Levartovsky, V. Furer, A. Polachek, O. Elalouf, M. Zisapel, et al. (+6)
709 [GO] 2021―Mai―25 POS1212 SARS-CoV-2 INFECTION AMONG PATIENTS WITH BEHÇET’S SYNDROME I. Mattioli, A. Bettiol, M. L. Urban, E. Silvestri, D. Malandrino, A. Palermo, et al. (+3)
710 [GO] 2021―Mai―25 POS1267 CLINICAL COURSE OF NEW SARS-COV-2 INFECTION IN CHILDREN WITH RHEUMATIC DISEASES: RETROSPECTIVE STUDY OF SINGLE PEDIATRIC RHEUMATOLOGY CENTER I. Nikishina, Z. Kolkhidova, V. Matkava, A. Shapovalenko, S. Arsenyeva, M. Kaleda, et al. (+2)
711 [GO] 2021―Mai―25 POS1260 FACTORS ASSOCIATED WITH SEVERE SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES IN MADRID: RESULTS FROM REUMA-COVID SORCOM REGISTRY A. Boteanu, A. García Fernández, N. De la Torre, M. Pavia Pascual, O. Sanchez Pernaute, S. Recuero Diaz, et al. (+9)
712 [GO] 2021―Mai―25 POS1208 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE ARGENTINEAN SAR-COVID REGISTRY C. A. Isnardi, R. Quintana, K. Roberts, V. V. Castro Coello, A. A. Reyes, Y. Tissera, et al. (+15)
713 [GO] 2021―Mai―25 POS1194 THE EFFECT OF SARS-COV-2 ON THE COURSE AND THE TREATMENT OF RHEUMATIC INFLAMMATORY DISEASES. EXPERIENCE FORM THE NORTHWESTERN GREECE E. Pelechas, E. Kaltsonoudis, M. Migos, P. Karagianni, A. Kavvadias, P. Voulgari, A. Drosos
714 [GO] 2021―Mai―25 POS1229 ANTI-MDA5 AND ANTISYNTHETASE ANTIBODIES SCREENING IN SEVERE SARS-COV-2 PNEUMONIA. BE AWARE OF FALSE POSITIVE RESULTS A. Gil-Vila, J. Perurena-Prieto, C. Nolla-Fontana, O. Orozco-Galvez, M. Miarons-Font, A. Guillén del Castillo, et al. (+4)
715 [GO] 2021―Mai―25 POS1219 SARS-COV-2 VACCINE HESITANCY AMONG PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: A MESSAGE FOR RHEUMATOLOGISTS R. Priori, G. Pellegrino, S. Colafrancesco, C. Alessandri, F. Ceccarelli, M. DI Franco, et al. (+5)
716 [GO] 2021―Mai―25 POS1255 REACTOGENICITY OF SARS-COV-2 VACCINES IN PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASE M. Yang, P. Katz, D. Paez, A. Carvidi, M. Matloubian, M. Nakamura, L. S. Gensler
717 [GO] 2021―Mai―25 POS1180 TREATMENT COMPLIANCE OF PATIENTS WITH RHEUMATOID ARTHRITIS DURING THE FIRST WAVE OF THE SARS-CoV-2/COVID-19 PANDEMIC IN PORTUGAL: RESULTS FROM THE COVID IN RA (COVIDRA) SURVEY F. Araujo, N. Gonçalves, A. F. Mourão
718 [GO] 2021―Mai―25 POS1204 LOW POSITIVITY RATE IN ANTIBODY SARS-COV2 TESTS IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH RITUXIMAB. A CASE CONTROL STUDY OF A HIGH IMPACT SARS-COV2 INFECTION AREA. A. García Fernández, P. Morán Álvarez, J. Bachiller-Corral, M. Vázquez Díaz
719 [GO] 2021―Mai―25 POS1218 SAFETY AND EFFICACY OF ANAKINRA IN SEVERE SARS-COV2 INFECTION (COVID19) AT A TERTIARY HOSPITAL O. Rusinovich, A. Mora, E. Muñez, L. Delgado Tellez de Cepeda, N. De la Torre, M. Pavía, et al. (+4)
720 [GO] 2021―Mai―25 POS1199 CLINICAL MANIFESTATIONS OF SARS-CoV2 INFECTIONS IN CHILDREN AND ADOLESCENTS WITH RHEUMATIC AND MUSCULUSKELETAL DISEASES - SURVEY DATA FROM GERMANY C. Sengler, S. Eulert, M. Niewerth, T. Kallinich, H. Wittkowski, H. Girschick, et al. (+10)
721 [GO] 2021―Mai―25 POS1216 SYMPTOM RATES, ATTITUDES AND MEDICATION ADHERENCE OF RHEUMATIC AND MUSCULOSKELETAL DISEASE PATIENTS DURING THE SARS-CoV2 PANDEMIC K. Murray, S. Quinn, M. Turk, A. O’rourke, E. Molloy, L. O’neill, et al. (+3)
722 [GO] 2021―Mai―25 POS1221 SARS-COV2 SEROLOGY SCREENING IN SPONDYLOARTHRITIS PATIENTS IN NORTH-EASTERN ITALY: A PILOT STUDY A. Ortolan, C. Cosma, M. Lorenzin, G. Cozzi, A. Doria, M. Plebani, R. Ramonda
723 [GO] 2021―Mai―25 POS1217 THE PATTERN OF COVID 19 PANDEMIC AMONG PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES (AIIRD) F. Kharouf, T. Eviatar, M. Braun, E. Pokroy-Shapira, M. Brodavka, N. Agmon-Levin, et al. (+17)
724 [GO] 2021―Mai―25 POS1203 EFFECT OF THE COVID19 PANDEMIC ON RHEUMATOLOGIST PRESCRIPTION BEHAVIOUR OF NEW ADVANCED THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY D. De Cock, P. Durez, V. Badot, R. Westhovens, P. Verschueren
725 [GO] 2021―Mai―24 High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases Jake A Ruddy, Caoilfhionn Marie Connolly, Brian J Boyarsky, William A Werbel, Lisa Christopher-Stine, Jacqueline Garonzik-Wang, et al. (+2)
726 [GO] 2021―Mai―13 Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Rosenbaum et al Kimme L Hyrich, Martin Schäfer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F Mateus, et al. (+5)
727 [GO] 2021―Mai―13 Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ James Todd Rosenbaum, Michael H Weisman, Cassie Shafer, Elin Aslanyan, Richard A Howard, Kimberly Ogle, et al. (+4)
728 [GO] 2021―Mai―12 Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’ Desiree Tampe, Peter Korsten, Samy Hakroush, Martin Sebastian Winkler, Björn Tampe
729 [GO] 2021―Mai―12 Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’’ by Tampe et al Marcia A Friedman, Kevin L Winthrop
730 [GO] 2021―Mai―06 Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation Marlou T H F Janssen, Sofia Ramiro, Robert B M Landewé, César Magro-Checa, Rémy L M Mostard
731 [GO] 2021―Mai―06 SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response Michael Markus Bonelli, Daniel Mrak, Thomas Perkmann, Helmuth Haslacher, Daniel Aletaha
732 [GO] 2021―Mai―06 SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases David Simon, Koray Tascilar, Filippo Fagni, Gerhard Krönke, Arnd Kleyer, Christine Meder, et al. (+15)
733 [GO] 2021―Apr―27 Response to: ‘Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’’ by Roongta et al Veerle F A M Derksen, Diane van der Woude
734 [GO] 2021―Apr―27 EULAR COVID-19 registry: lessons learnt and future considerations Saskia Lawson-Tovey, Anja Strangfeld, Kimme L Hyrich, Loreto Carmona, Diana Rodrigues, Laure Gossec, et al. (+2)
735 [GO] 2021―Apr―27 Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’ Rashmi Roongta, Arghya Chattopadhyay, Alakendu Ghosh
736 [GO] 2021―Apr―27 Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’ Serena Bugatti, Silvia Balduzzi, Ludovico De Stefano, Antonio Manzo, Blerina Xoxi, Laura Bogliolo, et al. (+3)
737 [GO] 2021―Apr―27 Response to: ‘Correspondence on ‘EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs’’ by Bugatti et al Johannes W J Bijlsma
738 [GO] 2021―Apr―26 Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients Uriel Trahtemberg, Robert Rottapel, Claudia C Dos Santos, Arthur S Slutsky, Andrew Baker, Marvin J Fritzler
739 [GO] 2021―Apr―26 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Aimilios Kaklamanos, Panagiotis Karamichalos, Panayiotis G Vlachoyiannopoulos, Athanasios G Tzioufas
740 [GO] 2021―Apr―26 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos et al Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
741 [GO] 2021―Apr―13 Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy Francesca Ingegnoli, Gilberto Cincinelli, Angela Flavia Luppino, Ennio Giulio Favalli, Annalisa Orenti, Patrizia Boracchi, Roberto Caporali
742 [GO] 2021―Apr―13 Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs Lotte van Ouwerkerk, Andrea E van der Meulen-de Jong, Maarten K Ninaber, Y K Onno Teng, Tom WJ Huizinga, Cornelia F Allaart
743 [GO] 2021―Apr―09 Correspondence on ‘Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study’ Liang En Wee, Edwin Philip Conceicao, Jing Yuan Tan, Julian Thumboo, Indumathi Venkatachalam
744 [GO] 2021―Mrz―23 Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases Brian J Boyarsky, Jake A Ruddy, Caoilfhionn M Connolly, Michael T Ou, William A Werbel, Jacqueline M Garonzik-Wang, et al. (+2)
745 [GO] 2021―Mrz―19 Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Robin K Avery, William A Werbel, Dorry L Segev, et al. (+2)
746 [GO] 2021―Mrz―16 SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study Arthur Mageau, Geoffrey Aldebert, Damien Van Gysel, Thomas Papo, Jean-François Timsit, Karim Sacre
747 [GO] 2021―Mrz―10 Correspondence on ‘SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease’ Shanoj K C, Sakir Ahmed, Veena Shenoy, Aparna R Menon, Sanjo Saijan, Sageer AS Babu, Padmanabha Shenoy
748 [GO] 2021―Mrz―10 Response to: ‘Correspondence on ‘SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease’’ by Shanoj et al Kristin M D’Silva, Naomi Serling-Boyd, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary Scott Wallace
749 [GO] 2021―Mrz―05 Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab Marcia A Friedman, Kevin L Winthrop
750 [GO] 2021―Mrz―03 Rheumatology and COVID-19 at 1 year: facing the unknowns Leonard Calabrese, Kevin L Winthrop
751 [GO] 2021―Mrz―03 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Charles Josef S Smolen
752 [GO] 2021―Mrz―01 Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et al Martin Schäfer, Anja Strangfeld, Kimme L Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, et al. (+5)
753 [GO] 2021―Mrz―01 Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ Ben Mulhearn
754 [GO] 2021―Mrz―01 Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Veerle F A M Derksen, Theresa Kissel, Femke B G Lamers-Karnebeek, Arie E van der Bijl, Annemarie C Venhuizen, Tom W J Huizinga, et al. (+3)
755 [GO] 2021―Feb―23 Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Gerd-Marie Ahlenius, Eva Baecklund, et al. (+10)
756 [GO] 2021―Feb―23 SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists Roberta Priori, Greta Pellegrino, Serena Colafrancesco, Cristiano Alessandri, Fulvia Ceccarelli, Manuela Di Franco, et al. (+5)
757 [GO] 2021―Feb―18 Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’ by Arnaud and Devilliers Pedro M Machado, Martin Schäfer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, et al. (+5)
758 [GO] 2021―Feb―18 Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ Laurent Arnaud, Hervé Devilliers
759 [GO] 2021―Feb―16 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Maria De Santis, Antonio Voza, Victor Savevski, Salvatore Badalamenti, Maurizio Cecconi, Alberto Mantovani, Carlo Selmi
760 [GO] 2021―Feb―16 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by De Santis et al Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
761 [GO] 2021―Feb―16 Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider Alessia Alunno, Aurélie Najm, Xavier Mariette, Gabriele De Marco, Jenny Emmel, Laura Mason, et al. (+2)
762 [GO] 2021―Feb―15 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Pierre Charles
763 [GO] 2021―Feb―15 Response to: ’Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Charles Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
764 [GO] 2021―Feb―10 EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs Johannes WJ Bijlsma
765 [GO] 2021―Feb―07 EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19 Alessia Alunno, Aurélie Najm, Pedro M Machado, Heidi Bertheussen, Gerd R Burmester, Francesco Carubbi, et al. (+18)
766 [GO] 2021―Jan―29 PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic Julia Spierings, Voon Ong, Christopher P Denton
767 [GO] 2021―Jan―28 Correspondence on ‘Anti-inflammatory therapy for COVID-19 infection: the case for colchicine’ Carlo Perricone, Elena Bartoloni, Giacomo Cafaro, Roberto Caporali, Roberto Gerli
768 [GO] 2021―Jan―28 Response to: ‘Correspondence on ‘Anti-inflammatory therapy for COVID-19 infection: the case for colchicine’’ by Perricone et al Binita Shah, Aaron Z Reyes, Kelly A Hu, Jacob Teperman, Theresa L Wampler Muskardin, Jean-Claude Tardif, Michael H Pillinger
769 [GO] 2021―Jan―28 Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ Shamma Al Nokhatha, Neil MacEoin, Richard Conway
770 [GO] 2021―Jan―28 Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by Nokhatha et al Christian Dejaco, Johannes WJ Bijlsma, Frank Buttgereit
771 [GO] 2021―Jan―28 Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey Corrado Campochiaro, Giorgia Trignani, Alessandro Tomelleri, Stefano Cascinu, Lorenzo Dagna
772 [GO] 2021―Jan―27 Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Anja Strangfeld, Martin Schäfer, Milena A Gianfrancesco, Saskia Lawson-Tovey, Jean W Liew, Lotta Ljung, et al. (+31)
773 [GO] 2021―Jan―27 Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Lee Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
774 [GO] 2021―Jan―27 Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’ Young Ho Lee
775 [GO] 2021―Jan―27 Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’ Tomoyuki Kawada
776 [GO] 2021―Jan―27 Response to: ‘Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’’ by Kawada Silvia Piantoni, Laura Andreoli, Enrico Colombo, Monia Mendeni, Maria Laura Ghirardelli, Antonio Brucato, et al. (+5)
777 [GO] 2021―Jan―25 CO0004 OLDER AGE, CARDIOVASCULAR COMORBIDITY AND GLUCOCORTICOSTEROIDS ARE RISK FACTORS FOR COVID-19 HOSPITALISATION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: FIRST RESULTS OF THE GERMAN COVID-19-IRD REGISTRY A. Regierer, R. Hasseli, B. Hoyer, A. Krause, H. M. Lorenz, A. Pfeil, et al. (+7)
778 [GO] 2021―Jan―25 CO0001 MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPER-INFLAMMATION G. De Luca, G. Cavalli, C. Campochiaro, E. Della Torre, P. Angelillo, A. Tomelleri, et al. (+15)
779 [GO] 2021―Jan―25 CO0005 C-C CHEMOKINE RECEPTOR TYPE 5 AND ITS LIGANDS CCL4, 8 AND 11 CAN LINK COVID-19, RHEUMATOID ARTHRITIS AND HYDROXYCHLOROQUINE M. Y. Hachim, S. Hannawi
780 [GO] 2021―Jan―25 CO0002 LOSS OF SELF-TOLERANCE IN SARS-COV-2 INFECTION: IMMUNOLOGICAL ASSESSMENT OF A CONVALESCENT COHORT A. Paglionico, V. Varriano, B. Tolusso, S. Alivernini, L. Petricca, G. Natalello, et al. (+5)
781 [GO] 2021―Jan―25 C00006 PSYCHOLOGICAL IMPACT OF COVID 19 PANDEMIC ON PATIENTS WITH RHEUMATOLOGICAL DISORDERS - A WEB BASED CROSS-SECTIONAL MULTICENTRE SURVEY Y. G C, Y. P. Singh, S. Prasad, N. Srinivasulu, S. Kumar, S. R, et al. (+4)
782 [GO] 2021―Jan―21 Correspondence on ‘Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients’ Tanaz A Kermani
783 [GO] 2021―Jan―21 Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts Angel YS Wong, Brian MacKenna, Caroline E Morton, Anna Schultze, Alex J Walker, Krishnan Bhaskaran, et al. (+26)
784 [GO] 2021―Jan―15 Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ Sarthak Gupta, Shuichiro Nakabo, Jun Chu, Sarfaraz Hasni, Mariana J Kaplan
785 [GO] 2021―Jan―15 Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
786 [GO] 2021―Jan―15 Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’ Haiyan Yang, Jie Xu, Li Shi, Guangcai Duan, Yadong Wang
787 [GO] 2021―Jan―13 SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease Kristin M D’Silva, Naomi Serling-Boyd, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary S Wallace
788 [GO] 2021―Jan―07 Correspondence on ‘Preliminary predictive criteria for COVID-19 cytokine storm’ Desiree Tampe, Martin S Winkler, Peter Korsten, Samy Hakroush, Onnen Moerer, Björn Tampe
789 [GO] 2021―Jan―07 Response to: ‘Correspondence on ‘Preliminary predictive criteria for COVID-19 cytokine storm’’ by Tampe et al Roberto Caricchio, Marcello Gallucci, Chandra Dass, Xinyan Zhang, Stefania Gallucci, David Fleece, et al. (+2)
790 [GO] 2021―Jan―06 Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic-World Scleroderma Foundation preliminary advice for patient management’ Elena Snarskaya, Kseniia Vasileva
791 [GO] 2021―Jan―06 Response to: ‘Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management’’ by Snarskaya and Vasileva Cosimo Bruni, Marco Matucci-Cerinic
792 [GO] 2021―Jan―05 Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland Aron Hjalti Bjornsson, Gerdur Grondal, Mar Kristjansson, Thorunn Jonsdottir, Thorvardur Jon Love, Bjorn Gudbjornsson
793 [GO] 2020―Dez―22 Correspondence on ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’ Sibel Zehra Aydin, Elliot Hepworth, Peter Tugwell
794 [GO] 2020―Dez―22 Response to: ‘Correspondence on ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’’ by Aydin et al Dalifer Dayanira Freites Nuñez, Leticia Leon, Arkaitz Mucientes, Luis Rodriguez-Rodriguez, Judit Font Urgelles, Alfredo Madrid García, et al. (+4)
795 [GO] 2020―Dez―18 Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine Alexis Mathian, Matthieu Mahevas, Julien Rohmer, Mathilde Roumier, Fleur Cohen-Aubart, Blanca Amador-Borrero, et al. (+29)
796 [GO] 2020―Dez―18 Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management Marco Matucci-Cerinic, Cosimo Bruni, Yannick Allanore, Massimo Clementi, Lorenzo Dagna, Nemanja S Damjanov, et al. (+14)
797 [GO] 2020―Dez―18 Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic Hendrik Schulze-Koops, Christof Specker, Christof Iking-Konert, Julia Holle, Frank Moosig, Klaus Krueger
798 [GO] 2020―Dez―16 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study’’ by Calvo-Aranda et al Sofia Ramiro, Rémy Mostard, Robert BM Landewé
799 [GO] 2020―Dez―16 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Enrique Calvo-Aranda, Irene Cañamares-Orbis, Marta Novella-Navarro, Alvaro Martinez-Alcala, Maria del Carmen Ortega de la O, Ismael Escobar-Rodriguez, Fernando Manuel Sanchez-Aranda
800 [GO] 2020―Dez―08 Anti-inflammatory therapy for COVID-19 infection: the case for colchicine Aaron Z Reyes, Kelly A Hu, Jacob Teperman, Theresa L Wampler Muskardin, Jean-Claude Tardif, Binita Shah, Michael H Pillinger
801 [GO] 2020―Dez―02 Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients
802 [GO] 2020―Nov―30 Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic Naomi Serling-Boyd, Kristin M D’Silva, Tiffany YT Hsu, Rachel Wallwork, Xiaoqing Fu, Ellen M Gravallese, et al. (+5)
803 [GO] 2020―Nov―25 Response to: ‘Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al’ by Notz et al Alexis Mathian, Zahir Amoura
804 [GO] 2020―Nov―20 Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al ’ by Ventura et al Juliette Chommeloux, Marie Pouletty, Naim Ouldali, Mathieu Kerneis, Alexis Mathian, Raphaele Mestiri, et al. (+3)
805 [GO] 2020―Nov―17 COVID-19 cytokine storm: what is in a name? Peter A Nigrovic
806 [GO] 2020―Nov―12 Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’ Cloé Comarmond, Mathilde Leclercq, Gaëlle Leroux, Cindy Marques, Alexandre Le Joncour, Fanny Domont, et al. (+10)
807 [GO] 2020―Nov―12 Response to: ‘Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’ by Comarmond et al Alessandro Tomelleri, Silvia Sartorelli, Elena Marina Baldissera, Lorenzo Dagna, Corrado Campochiaro
808 [GO] 2020―Nov―11 Response to ‘Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’ by Ruyssen-Witrand et al Adrian Ciurea, Axel Finckh
809 [GO] 2020―Nov―11 Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’ Adeline Ruyssen-Witrand, Martin Soubrier, André Basch, Marie-Elise Truchetet, Raphaèle Seror
810 [GO] 2020―Nov―10 Response to ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Shi et al Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
811 [GO] 2020―Nov―10 Correspondence on ‘prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’ Jiyuan Shi, Ya Gao, Lili Zhang, Yang Zhao, Jianguo Xu, Jinhui Tian
812 [GO] 2020―Nov―06 Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries Christian Dejaco, Alessia Alunno, Johannes WJ Bijlsma, Annelies Boonen, Bernard Combe, Axel Finckh, et al. (+5)
813 [GO] 2020―Nov―03 Response to ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Gremese et al Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
814 [GO] 2020―Nov―03 Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’ Elisa Gremese, Giovanni Brondani, Luca Apollonio, Gianfranco Ferraccioli
815 [GO] 2020―Nov―02 Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area Rim Bourguiba, Marion Delplanque, Caroline Vinit, Léa Savey, Gilles Grateau, Veronique Hentgen, Sophie Georgin-lavialle
816 [GO] 2020―Okt―30 Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study Sergey Moiseev, Sergey Avdeev, Ekaterina Tao, Michail Brovko, Nikolay Bulanov, Anastasiia Zykova, et al. (+3)
817 [GO] 2020―Okt―30 Response to ‘Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study’ by Moiseev et al Sofia Ramiro, Robert B M Landewé, Rémy Mostard
818 [GO] 2020―Okt―30 Correspondence to ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’ Hendrik Schulze-Koops, Alla Skapenko, Andreas Krause, Klaus Krueger, Hanns-Martin Lorenz, Philipp Sewerin, et al. (+5)
819 [GO] 2020―Okt―30 Response to: ‘Correspondence on ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’’ by Schulze-Koops et al Dalifer Dayanira Freites Nuñez, Leticia Leon, Arkaitz Mucientes, Luis Rodriguez-Rodriguez, Judit Font Urgelles, Alfredo Madrid García, et al. (+4)
820 [GO] 2020―Okt―14 COVID-19 in Italian patients with rheumatic autoimmune systemic diseases Clodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, Poupak Fallahi, Alessandro Antonelli
821 [GO] 2020―Okt―14 Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic Kim Lauper, Johannes W J Bijlsma, Gerd R Burmester
822 [GO] 2020―Okt―13 Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
823 [GO] 2020―Okt―06 Response to ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID19): a multicentre cohort’’ by Mastrolia et al Charlotte Borocco, Marie Pouletty, Caroline Galeotti, Ulrich Meinzer, Albert Faye, Isabelle Koné-Paut, et al. (+2)
824 [GO] 2020―Okt―01 Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ Florence Jeny, Raphael Lhote, Gwenael Lorillon, Nicolas Belhomme, Grégory Pugnet, Raphaël Borie, et al. (+23)
825 [GO] 2020―Okt―01 Response to: ‘Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’’ by Jeny et al Andrea Hermina Györfi, Georg Schett, Jörg H W Distler
826 [GO] 2020―Sep―28 Tackling osteoarthritis during COVID-19 pandemic Francisco Airton Castro da Rocha, Lucas da Ponte Melo, Francis Berenbaum
827 [GO] 2020―Sep―25 Response to: ‘Correspondence to ‘Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases’’ by Wu et al Jose L Pablos, María Galindo, Ricardo Blanco, José M Alvaro-Gracia
828 [GO] 2020―Sep―25 Correspondence to ‘Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases’ Bo-Yao Wu, Chi-Ho Chan, James Cheng-Chung Wei
829 [GO] 2020―Sep―25 Preliminary predictive criteria for COVID-19 cytokine storm Roberto Caricchio, Marcello Gallucci, Chandra Dass, Xinyan Zhang, Stefania Gallucci, David Fleece, et al. (+2)
830 [GO] 2020―Sep―25 Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al Meredith J Ventura, Emmanuel Guajardo, Eva H Clark, Kalpana Bhairavarasu, Riyad Y Kherallah, Andrew R DiNardo, et al. (+4)
831 [GO] 2020―Sep―22 Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort Adrian Ciurea, Eleftherios Papagiannoulis, Kristina Bürki, Isabell von Loga, Raphael Micheroli, Burkhard Möller, et al. (+9)
832 [GO] 2020―Sep―22 Response to: ‘Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic’ by Lecler et al Sara Monti, Carlomaurizio Montecucco
833 [GO] 2020―Sep―21 Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case-control study’ Martin Sebastian Winkler, Peter Korsten, Claudia Binder, Björn Tampe
834 [GO] 2020―Sep―21 Correspondence to ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ Maria Vincenza Mastrolia, Rino Agostiniani, Chiara Azzari, Roberto Bernardini, Ugo Bottone, Giovanni Battista Calabri, et al. (+16)
835 [GO] 2020―Sep―15 Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients Fabio Cacciapaglia, Andreina Manfredi, Gianluca Erre, Matteo Piga, Garifallia Sakellariou, ombretta viapiana, et al. (+4)
836 [GO] 2020―Sep―15 Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): what does the future hold? Murugan Sudhakar, Pandiarajan Vignesh
837 [GO] 2020―Sep―09 Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences’ by Ruscitti et al’ by Chen et al Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, et al. (+10)
838 [GO] 2020―Sep―09 Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences’ by Ruscitti et al Acer I-Hung Chen, Sheng-Chieh Lin, James Cheng-Chung Wei
839 [GO] 2020―Sep―07 Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases Alessandro Giollo, Eugenia Bertoldo, Giovanni Adami, Adam J Cybulski, Angelo Fassio, Giovanni Orsolini, et al. (+4)
840 [GO] 2020―Sep―07 Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases’ by Giollo et al Kimme L Hyrich, Milena Gianfrancesco, Pedro M Machado, Jinoos Yazdany, Philip C Robinson
841 [GO] 2020―Sep―07 Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic Alireza Khabbazi, Hadiseh Kavandi, Roghayeh Paribanaem, Raha Khabbazi, Aida Malek Mahdavi
842 [GO] 2020―Sep―07 Education and treatment adherence during the COVID-19 pandemic. Response to: ‘Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic’ by Khabbazi et al Rita Angélica Pineda-Sic, Griselda Serna-Peña, Jesus Alberto Cardenas-de la Garza, Sergio A Torres-Castillo, Dionicio Angel Galarza-Delgado, Diana Elsa Flores-Alvarado
843 [GO] 2020―Sep―07 Response to: ‘Implications of SARS-CoV-2 infection for patients with rheumatic disease’ by Lin et al Alexis Mathian, Zahir Amoura
844 [GO] 2020―Sep―03 Response to ‘Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic’ by Chuah et al Alexis Mathian, Zahir Amoura
845 [GO] 2020―Sep―01 Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study’ by Potere et al’ by Buckley Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, et al. (+2)
846 [GO] 2020―Sep―01 Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study’ by Potere et al Leo Buckley
847 [GO] 2020―Aug―28 Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al Quirin Notz, Patrick Meybohm, Peter Kranke, Dirk Weismann, Christopher Lotz, Marc Schmalzing
848 [GO] 2020―Aug―28 Comment on ‘Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19’ by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France Emilie Sbidian, Laetitia Penso, Philippe Herlemont, Jérémie Botton, Bérangère Baricault, Laura Semenzato, et al. (+4)
849 [GO] 2020―Aug―28 Systemic lupus erythematosus and COVID-19: what we know so far Giuseppe A. Ramirez, Luca Moroni, Emanuel Della-Torre, Maria Gerosa, Lorenzo Beretta, Enrica P. Bozzolo, Lorenzo Dagna
850 [GO] 2020―Aug―27 Colchicine treatment in community healthcare setting to prevent severe COVID-19 Emanuel Della-Torre, Giuseppe A Ramirez, Lorenzo Dagna, Moreno Tresoldi
851 [GO] 2020―Aug―27 Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al Silvia Piantoni, Enrico Colombo, Roberto Furloni, Laura Andreoli, Antonio Brucato, Massimo Imazio, et al. (+2)
852 [GO] 2020―Aug―19 Correspondence to: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al Rachael Mary Flood, Richard Conway, Colm Kirby, Diana Gheta, David J Kane, Ronan H Mullan
853 [GO] 2020―Aug―19 Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed ‘window of opportunity’ Alessandro Giollo, Riccardo Bixio, Davide Gatti, Ombretta Viapiana, Luca Idolazzi, Christian Dejaco, Maurizio Rossini
854 [GO] 2020―Aug―19 High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab Edoardo Conticini, Federico Franchi, David Bennett, Serafina Valente, Maria A Mazzei, Elena Bargagli, et al. (+3)
855 [GO] 2020―Aug―19 Response to: ‘High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab’ by Conticini et al Sofia Ramiro, Rémy Mostard, Robert BM Landewé
856 [GO] 2020―Aug―19 Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: ‘Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study’ by Della-Torre et al’ by Cheng and Zhang Emanuel Della-Torre, Giovanni Landoni, Alberto Zangrillo, Lorenzo Dagna
857 [GO] 2020―Aug―19 Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study’ by Della-Torre et al Chao Cheng, Fangjie Zhang
858 [GO] 2020―Aug―18 Rheumatic diseases and COVID-19: a cohort of 17 patients under DMARDs. Response to: ‘Comment on: Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab’ by Messina et al Pierre-Marie Duret, Lionel Spielmann, Laurent Messer
859 [GO] 2020―Aug―18 Comment on: Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab Francesco Messina, Francesca Pampaloni, Stefano Piaserico
860 [GO] 2020―Aug―13 Implications of SARS-CoV-2 infection for patients with rheumatic disease Changsong Lin, Ziyu Wang, Jie Li, Xinyi Xia, Yun Liu, Qianghu Wang
861 [GO] 2020―Aug―12 Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study Jose L Pablos, María Galindo, Loreto Carmona, Ana Lledó, Miriam Retuerto, Ricardo Blanco, et al. (+9)
862 [GO] 2020―Aug―12 COVID-19 and how evidence of a new disease evolves Féline P B Kroon, Ted R Mikuls, Robert BM Landewé
863 [GO] 2020―Aug―12 COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson
864 [GO] 2020―Aug―11 Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic Seow Lin Chuah, Cheng Lay Teh, Sharifah Aishah Wan Mohd Akbar, Yaw Kiet Cheong, Benjamin Sachdev Manjit Singh
865 [GO] 2020―Aug―11 Case of adult large vessel vasculitis after SARS-CoV-2 infection Ryohei Oda, Takeshi Inagaki, Masahiro Ishikane, Masatoshi Hotta, Akira Shimomura, Mitsuhiro Sato, et al. (+6)
866 [GO] 2020―Aug―10 High oligoclonality of immunoglobulins in SARS-CoV2 positive patients Marie Kolopp-Sarda, Pierre Miossec
867 [GO] 2020―Aug―07 Impact of lockdown on rheumatology outpatient care in the age of COVID-19 Benjamin Sachdev Manjit Singh, Seow Lin Chuah, Yaw Kiet Cheong, Sharifah Aishah Wan, Cheng Lay Teh
868 [GO] 2020―Aug―07 Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist’ by Graef et al Chien Hsien Lo, Yu-Hsun Wang, Chin Feng Tsai, Kuei Chuan Chan, Li Ching Li, Tse Hsien Lo, et al. (+2)
869 [GO] 2020―Aug―07 Mild COVID-19 in ANCA-associated vasculitis treated with rituximab Silvia Suárez-Díaz, Claudia Morán-Castaño, Rubén Coto-Hernández, Lourdes Mozo-Avellaneda, Carlos Suárez-Cuervo, Luis Caminal-Montero
870 [GO] 2020―Aug―07 Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases Dalifer D Freites Nuñez, Leticia Leon, Arkaitz Mucientes, Luis Rodriguez-Rodriguez, Judit Font Urgelles, Alfredo Madrid García, et al. (+4)
871 [GO] 2020―Aug―07 Impact of the COVID-19 lockdown on the management and control of patients with GCA Roman Praliaud, Helene Greigert, Maxime Samson, Marianne Zeller, Mathieu Boulin, Philip Bielefeld, et al. (+3)
872 [GO] 2020―Aug―07 Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic Augustin Lecler, Delphine Villeneuve, Catherine Vignal, Thomas Sené
873 [GO] 2020―Aug―07 Response to: ‘Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist’ by Graef et al’ by Lo et al Ali Duarte-García, Elizabeth R Graef, Jean W Liew, Maximilian F Konig, Alfred Hyoungju Kim, Jeffrey A Sparks
874 [GO] 2020―Aug―07 No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany) Peer Aries, Christof Iking-Konert
875 [GO] 2020―Aug―05 Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus Yasushi Kondo, Yuko Kaneko, Tatsuhiro Oshige, Hiroyuki Fukui, Shuntaro Saito, Mikio Okayama, et al. (+5)
876 [GO] 2020―Aug―05 Response to: ‘Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus’ by Kondo et al Alexis Mathian, Zahir Amoura
877 [GO] 2020―Aug―05 COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs Khalil Ansarin, Ali Taghizadieh, Saeid Safiri, Aida Malek Mahdavi, Shirin Ranjbar, Soheil Teymouri, et al. (+2)
878 [GO] 2020―Aug―05 Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang et al Janine A Lamb, Spyridon Megremis, Hector Chinoy
879 [GO] 2020―Aug―05 Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future Yukai Wang, Guangzhou Du, Guohong Zhang, Marco Matucci-Cerinic, Daniel E Furst
880 [GO] 2020―Aug―05 Hydroxychloroquin ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis Mendel E Singer, David C Kaelber, Maria J Antonelli
881 [GO] 2020―Aug―05 Response to: ‘Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis’ by Singer et al Manuel Francisco Ugarte-Gil, Maximilian F Konig, Peter Korsten, Francis Berenbaum, Alfred Hyoungju Kim, Jeffrey A Sparks
882 [GO] 2020―Aug―05 Correspondence on: ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al Rosa Pino, Ana Carolina Izurieta, María Ríos-Barnés, Sílvia Ricart, Mariona F De Sevilla, Laura Monfort, et al. (+15)
883 [GO] 2020―Aug―05 Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al’ by Pino et al Naim Ouldali, Marie Pouletty, Johanna Lokmer, Cherine Benzouid, Constance Beyler, Anna Deho, et al. (+3)
884 [GO] 2020―Aug―04 To immunosuppress: whom, when and how? That is the question with COVID-19 Kevin L Winthrop, Xavier Mariette
885 [GO] 2020―Aug―04 Transient monoarthritis and psoriatic skin lesions following COVID-19 Ludovico De Stefano, Silvia Rossi, Carlomaurizio Montecucco, Serena Bugatti
886 [GO] 2020―Aug―04 Response to: ‘Presence of anti-phospholipid antibodies in COVID-19: a case series study’ by Amezcua-Guerra et al Alexis Mathian, Marc Pineton De Chambrun, Alain Combes, Zahir Amoura
887 [GO] 2020―Aug―04 Presence of antiphospholipid antibodies in COVID-19: case series study Luis M Amezcua-Guerra, Gustavo Rojas-Velasco, Malinalli Brianza-Padilla, Armando Vázquez-Rangel, Ricardo Márquez-Velasco, Francisco Baranda-Tovar, et al. (+6)
888 [GO] 2020―Aug―04 Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Benucci et al Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht Vallbracht, Rebecca Hasseli, Alla Skapenko
889 [GO] 2020―Jul―31 Rational use of tocilizumab in COVID-19 Siddharth Jain, Shefali Khanna Sharma
890 [GO] 2020―Jul―31 COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine Cheng Lay Teh, Yaw Kiet Cheong, Wan Rosmaiza Wan Musa, Sharifah Aishah Wan Mohd Akbar, Noraini Mat Husin, Suk Chyn Gun
891 [GO] 2020―Jul―31 More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia Gianfranco Ferraccioli
892 [GO] 2020―Jul―31 Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Fabio Ciceri, Alberto Zangrillo, Lorenzo Dagna
893 [GO] 2020―Jul―31 Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma Pier Leopoldo Capecchi, Pietro Enea Lazzerini
894 [GO] 2020―Jul―31 Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, et al. (+2)
895 [GO] 2020―Jul―30 Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience Asim Khan, Alice Cole, Naveen Bhadauria, Munzir El-Hassan, Daud Abdulla, Thomas Axon, et al. (+4)
896 [GO] 2020―Jul―30 Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al Ioana Andreica, David Kiefer, Guenther A Rezniczek, Robert Jast, Bjoern Buehring, Uta Kiltz, et al. (+2)
897 [GO] 2020―Jul―30 Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome Mirko Scarsi, Silvia Piantoni, Enrico Colombo, Paolo Airó, Donata Richini, Marco Miclini, et al. (+22)
898 [GO] 2020―Jul―28 Improving telemedicine and in-person management of rheumatic and autoimmune diseases,during and after COVID-19 pandemic outbreak. Definite need for more Rheumatologists. Response to: ‘Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?’ by Akpabio et al Francesco Caso, Antonio del Puente, Nicolò Girolimetto, Marco Tasso, Corrado Caso, Raffaele Scarpa, Luisa Costa
899 [GO] 2020―Jul―24 Response to: ‘Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in patients with rheumatism in Wuhan, China’’ by Chen et al Jixin Zhong, Cong Ye, Shaozhe Cai, Lingli Dong
900 [GO] 2020―Jul―24 Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in rheumatism patients in Wuhan, China’ Xiao-Huan Chen, Chih-Jung Yeh, Han-You Mo, James Cheng Chung Wei
901 [GO] 2020―Jul―24 Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia Sharifah Aishah Wan, Cheng Lay Teh, Benjamin Sachdev Manjit Singh, Yaw Kiet Cheong, Seow Lin Chuah, Ahmad Tirmizi Jobli
902 [GO] 2020―Jul―24 Response to: ‘Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia’ by Wan et al Jixin Zhong, Lingli Dong
903 [GO] 2020―Jul―24 Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia? Emine Duran, Levent Kilic, Gamze Durhan, Ahmet Çağkan Inkaya, Gulay Sain Guven, Gul Karakaya, et al. (+2)
904 [GO] 2020―Jul―22 Response to: ‘Should patients starting biologics be screened for COVID-19?’ by Cardenas-de la Garza et al Robert B M Landewé, Hendrik Schulze-Koops
905 [GO] 2020―Jul―21 COVID-19 and Behçet’s disease: clinical case series Gerard Espinosa, Olga Araujo, Sergi Amaro, Marta Bodro, Pedro Juan Moreno, Reinaldo Moreno, et al. (+2)
906 [GO] 2020―Jul―21 Comment on: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al Samet Karahan, Ali Cetinkaya, Kaniye Aydin, Hatice Aslan Sirakaya
907 [GO] 2020―Jul―21 COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre Natasha Cleaton, Sabrina Raizada, Nick Barkham, Srinivasan Venkatachalam, Tom Sheeran, Tochukwu Adizie, et al. (+3)
908 [GO] 2020―Jul―21 Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study Sofia Ramiro, Rémy L M Mostard, César Magro-Checa, Christel M P van Dongen, Tom Dormans, Jacqueline Buijs, et al. (+8)
909 [GO] 2020―Jul―21 Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, et al. (+10)
910 [GO] 2020―Jul―15 Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia Samy Hakroush, Jonas Franz, Jörg Larsen, Peter Korsten, Martin Sebastian Winkler, Björn Tampe
911 [GO] 2020―Jul―15 Response to: ‘Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India’ by Goyal et al Alexis Mathian, Zahir Amoura
912 [GO] 2020―Jul―15 Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India Mohit Goyal, Pravin Patil, Himanshu Pathak, Sham Santhanam, Anshul Goel, Vishnu Sharma, et al. (+16)
913 [GO] 2020―Jul―13 COVID-19 in patients with rheumatic diseases: what is the real mortality risk? Claudia Marques, Marcelo M Pinheiro, Edgard Torres Reis Neto, Andrea Tavares Dantas, Francinne Machado Ribeiro, Ana Karla G Melo
914 [GO] 2020―Jul―10 Rheumatic disease and COVID-19 Jean W Liew, Elizabeth R Graef
915 [GO] 2020―Jul―09 Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, et al. (+2)
916 [GO] 2020―Jul―09 Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest? Pedro Santos-Moreno, Diana Buitrago-Garcia, Laura Villarreal, Anggie Aza, Michael Cabrera, Wilberto Rivero, Adriana Rojas-Villarraga
917 [GO] 2020―Jul―09 Response to: ‘Emergency arising from patients’ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?’ by Santos-Mareno et al Jean W Liew, Elizabeth R Graef, Jeffrey A Sparks, Alfred Hyoungju Kim
918 [GO] 2020―Jul―06 Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD Maurizio Benucci, Arianna Damiani, Gianfranco Giannasi, Francesca Li Gobbi, Luca Quartuccio, Valentina Grossi, et al. (+2)
919 [GO] 2020―Jul―06 COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study Muserref Kasap Cuceoglu, Ezgi Deniz Batu, Yelda Bilginer, Seza Özen
920 [GO] 2020―Jul―06 Should patients starting biologics be screened for COVID-19? Jesus Alberto Cardenas-de la Garza, Rosa I Arvizu-Rivera, Dionicio Angel Galarza-Delgado
921 [GO] 2020―Jul―06 Comparative analysis of synovial inflammation after SARS-CoV-2 infection Stefano Alivernini, Antonella Cingolani, Marco Gessi, Annamaria Paglionico, Giuliana Pasciuto, Barbara Tolusso, et al. (+2)
922 [GO] 2020―Jul―06 Response to: ‘Comparative analysis of synovial inflammation after SARS-CoV-2 infection’ by Alivernini et al María-del-Carmen López-González, Vega Jovani, Esperanza Merino, Paloma Vela, Mariano Andrés
923 [GO] 2020―Jul―03 Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Angela Napolitano, Salvatore La Marca, et al. (+12)
924 [GO] 2020―Jul―02 Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey Marlene Plüß, Gamal Chehab, Peter Korsten
925 [GO] 2020―Jul―02 Response to: ‘Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey’ by Plüß et al Alexis Mathian, Zahir Amoura
926 [GO] 2020―Jul―01 COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic Richard Oluyinka Akintayo, Akpabio Akpabio, Asgar Kalla, Dzifa Dey, Angela Migowa, Hakeem Olaosebikan, et al. (+18)
927 [GO] 2020―Jun―30 Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis Andrea Hermina Györfi, Markus Kopp, Matthias May, Marcel Vetter, Michael Uder, Andreas E Kremer, et al. (+3)
928 [GO] 2020―Jun―30 Response to: ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ by Györfi et al Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson
929 [GO] 2020―Jun―30 Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases Laura Nuño, Marta Novella Navarro, Gema Bonilla, Karen Franco-Gómez, Pilar Aguado, Diana Peiteado, et al. (+11)
930 [GO] 2020―Jun―26 Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht, Rebecca Hasseli, Alla Skapenko
931 [GO] 2020―Jun―26 Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: ‘Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab’ by Schulze-Koops et al Sara Monti, Carlomaurizio Montecucco
932 [GO] 2020―Jun―26 Case of acute arthritis following SARS-CoV-2 infection Naoto Yokogawa, Naoto Minematsu, Harutaka Katano, Tadaki Suzuki
933 [GO] 2020―Jun―25 Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors Vega Jovani, Irene Calabuig, Maria Luisa Peral-Garrido, Ernesto Tovar-Sugrañes, María-del-Carmen López-González, Pilar Bernabeu, et al. (+9)
934 [GO] 2020―Jun―25 Response to: ‘Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors’ by Jovani et al Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary S Wallace
935 [GO] 2020―Jun―25 Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments Zoé Gendebien, Christian von Frenckell, Clio Ribbens, Béatrice André, Marie Thys, Marjorie Gangolf, et al. (+3)
936 [GO] 2020―Jun―25 Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic Pedro Santos-Moreno, Josefina Chavez-Chavez, Sandra Milena Hernández-Zambrano, Diana Patricia Rivera-Triana, Ruth Alexandra Castiblanco-Montañez, Anggie Aza, et al. (+3)
937 [GO] 2020―Jun―25 Response to: ‘Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic’ by Santos-Moreno et al Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
938 [GO] 2020―Jun―25 Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics Arielle Mendel, Sasha Bernatsky, Anca Askanase, Sang-Cheol Bae, Ann Elaine Clarke, Nathalie Costedoat-Chalumeau, et al. (+11)
939 [GO] 2020―Jun―24 Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19 Panayiotis G Vlachoyiannopoulos, Eleni Magira, Haris Alexopoulos, Edison Jahaj, Katerina Theophilopoulou, Anastasia Kotanidou, Athanasios G Tzioufas
940 [GO] 2020―Jun―24 Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak Ho So, Cheuk-Chun Szeto, Lai-Shan Tam
941 [GO] 2020―Jun―24 Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: ‘Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak’ by So et al Hendrik Schulze-Koops, Christof Specker, Klaus Krueger
942 [GO] 2020―Jun―23 Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience Rita Angélica Pineda-Sic, Dionicio Angel Galarza-Delgado, Griselda Serna-Peña, Sergio A Castillo-Torres, Diana Elsa Flores-Alvarado, Jorge A Esquivel-Valerio, Iván De Jesús Hernández-Galarza
943 [GO] 2020―Jun―23 Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience’ by Pineda-Sic et al Hendrik Schulze-Koops, Klaus Krueger, Christof Specker
944 [GO] 2020―Jun―22 Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al Carmen Magdalena Gamboa-Alonso, Gabriel Figueroa-Parra, Dionicio Angel Galarza-Delgado
945 [GO] 2020―Jun―19 Challenges and opportunities in telerheumatology in the COVID-19 era. Response to: ‘Online management of rheumatoid arthritis during COVID-19 pandemic’ by Zhang et al Gabriel Figueroa-Parra, Carmen Magdalena Gamboa-Alonso, Dionicio Angel Galarza-Delgado
946 [GO] 2020―Jun―19 Mounting data indicate that antimalarials do not prevent mild or severe COVID-19 in rheumatic patients. Response to: ‘The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients’ by Favalli et al Vasco C Romão, Ana Rita Cruz-Machado, João Eurico Fonseca
947 [GO] 2020―Jun―19 Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients Ennio Giulio Favalli, Orazio De Lucia, Martina Biggioggero, Nicoletta Del Papa, Roberto Caporali
948 [GO] 2020―Jun―16 Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot pot’ versus in US ‘hot pot’: similarity and difference Jun Zhao, Rongrong Pang, Jian Wu, Yanju Guo, Yang Yang, Libo Zhang, Xinyi Xia
949 [GO] 2020―Jun―16 Response to: ‘COVID-19 in patients with rheumatological diseases treated with Anti-TNF’ by Brito et al and ‘Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot pot’ versus in US ‘hot pot’: similarity and difference’ by Zhao et al Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary Scott Wallace
950 [GO] 2020―Jun―16 Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study Yao Huang, Zhe Chen, Yu Wang, Liang Han, Kai Qin, Wenya Huang, et al. (+8)
951 [GO] 2020―Jun―16 COVID-19 in patients with rheumatological diseases treated with anti-TNF Carlos Antunes Brito, José Gerardo Paiva, Fernando Nunes Pimentel, Rosinete Santos Guimarães, Mariana Ribeiro Moreira
952 [GO] 2020―Jun―12 Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases Jose L Pablos, Lydia Abasolo, Jose M Alvaro-Gracia, Francisco J Blanco, Ricardo Blanco, Isabel Castrejón, et al. (+9)
953 [GO] 2020―Jun―11 Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort Luisa Costa, Marco Tasso, Nadia Scotti, Erika Mostacciuolo, Nicolò Girolimetto, Francesca Foglia, et al. (+3)
954 [GO] 2020―Jun―11 Response to: ‘Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort’ by Costa et al Latika Gupta, Durga Prasanna Misra, Vishwesh Agarwal, Suma Balan, Vikas Agarwal
955 [GO] 2020―Jun―11 Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort Marie Pouletty, Charlotte Borocco, Naim Ouldali, Marion Caseris, Romain Basmaci, Noémie Lachaume, et al. (+22)
956 [GO] 2020―Jun―10 Biologics, spondylitis and COVID-19 James Todd Rosenbaum, Hedley Hamilton, Dongseok Choi, Michael H Weisman, John D Reveille, Kevin L Winthrop
957 [GO] 2020―Jun―08 Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak Jan Holubar, Moglie Le Quintrec, Hind Letaief, Jean Luc Faillie, Yves-Marie Pers, Christian Jorgensen
958 [GO] 2020―Jun―08 Response to: ‘Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak’ by Holubar et al Alexis Mathian, Zahir Amoura
959 [GO] 2020―Jun―05 Response to: ‘Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab’ by Avouac et al Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques Maria, et al. (+4)
960 [GO] 2020―Jun―05 Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies Carlos Sanchez-Piedra, Cesar Diaz-Torne, Javier Manero, José M Pego-Reigosa, Íñigo Rúa-Figueroa, Miguel A Gonzalez-Gay, et al. (+2)
961 [GO] 2020―Jun―05 COVID-19 infection in a patient with FMF: does colchicine have a protective effect? Senol Kobak
962 [GO] 2020―Jun―05 Telemedicine will not keep us apart in COVID-19 pandemic Simone Perniola, Stefano Alivernini, Valentina Varriano, Annamaria Paglionico, Giacomo Tanti, Pietro Rubortone, et al. (+7)
963 [GO] 2020―Jun―05 Telemedicine: a useful tool but not the holy grail. Response to: ‘Telemedicine will not keep us apart in the COVID-19 pandemic’ by Perniola et al Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
964 [GO] 2020―Jun―05 COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases Clementina López-Medina, Alejandro Escudero, Eduardo Collantes-Estevez
965 [GO] 2020―Jun―05 Candidate rheumatologic treatments for COVID-19. Response to: ‘COVID-19 infection in a patient with FMF: does colchicine have a protective effect?’ by Kobak Sara Monti, Carlomaurizio Montecucco
966 [GO] 2020―Jun―05 Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab Jérôme Avouac, Paolo Airó, Nicolas Carlier, Marco Matucci-Cerinic, Yannick Allanore
967 [GO] 2020―Jun―05 EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 Robert BM Landewé, Pedro M Machado, Féline Kroon, Hans WJ Bijlsma, Gerd R Burmester, Loreto Carmona, et al. (+13)
968 [GO] 2020―Jun―05 Response to: ‘COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases’ by Lopez-Medina et al Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
969 [GO] 2020―Jun―03 COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy Sophie Benoy, Rene Traksel, Peter Verhaegh, Jasper Broen
970 [GO] 2020―Mai―31 Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: ‘Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Carbillon et al Maximilian F Konig, Milena Gianfrancesco, Jinoos Yazdany, Philip C Robinson
971 [GO] 2020―Mai―31 Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine Lionel Carbillon, Amélie Benbara, Jeremy Boujenah
972 [GO] 2020―Mai―31 Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic George E Fragoulis, Gerasimos Evangelatos, Aikaterini Arida, Vasiliki-Kalliopi Bournia, Kalliopi Fragiadaki, Anastasios Karamanakos, et al. (+6)
973 [GO] 2020―Mai―31 No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: ‘Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis et al Hendrik Schulze-Koops, Klaus Krueger, Christof Specker
974 [GO] 2020―Mai―31 Patients with lupus with COVID-19: University of Michigan experience Beth Wallace, Laraine Washer, Wendy Marder, J Michelle Kahlenberg
975 [GO] 2020―Mai―31 Response to: ‘Patients with lupus with COVID-19: University of Michigan experience’ by Wallace et al Alexis Mathian, Zahir Amoura
976 [GO] 2020―Mai―29 Case series of acute arthritis during COVID-19 admission María-del-Carmen López-González, Maria Luisa Peral-Garrido, Irene Calabuig, Ernesto Tovar-Sugrañes, Vega Jovani, Pilar Bernabeu, et al. (+8)
977 [GO] 2020―Mai―29 Response to: ‘Case series of acute arthritis in COVID-19 admission’ by López-González et al Elizabeth R Graef, Jean W Liew, Alfred HJ Kim, Jeffrey A Sparks
978 [GO] 2020―Mai―29 Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Milena Gianfrancesco, Kimme L Hyrich, Sarah Al-Adely, Loreto Carmona, Maria I Danila, Laure Gossec, et al. (+22)
979 [GO] 2020―Mai―29 Correspondence regarding research letter to the editor by Mathian et al, ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’ Mandana Nikpour, Benjamin Teh, Ian P Wicks, Marc Pellegrini
980 [GO] 2020―Mai―29 Response to: Correspondence regarding research letter to the editor by Mathian et al, ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’’ by Nikpour et al Alexis Mathian, Zahir Amoura
981 [GO] 2020―Mai―28 Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study Carlo Salvarani, Gianluigi Bajocchi, Pamela Mancuso, Elena Galli, Francesco Muratore, Luigi Boiardi, et al. (+14)
982 [GO] 2020―Mai―26 Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’ Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Xiaoqing Fu, Ellen M Gravallese, et al. (+3)
983 [GO] 2020―Mai―25 Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ennio Giulio Favalli, Maria Gerosa, Antonella Murgo, Roberto Caporali
984 [GO] 2020―Mai―25 Response to: ‘Are patients with systemic lupus erythematosus at increased risk for COVID-19?’ by Favalli et al Alexis Mathian, Zahir Amoura
985 [GO] 2020―Mai―24 Online management of rheumatoid arthritis during COVID-19 pandemic Yang Zhang, Jian Wang, Liang Zhao, Jun Xiao, Zhanjun Shi
986 [GO] 2020―Mai―24 Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis Sara Monti, Paolo Delvino, Elisa Bellis, Alessandra Milanesi, Fabio Brandolino, Carlomaurizio Montecucco
987 [GO] 2020―Mai―23 COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
988 [GO] 2020―Mai―23 Response to ‘To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic’ by Parperis Francesca Romana Spinelli, Fulvia Ceccarelli, Manuela Di Franco, Fabrizio Conti
989 [GO] 2020―Mai―23 The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: ‘Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India’ by Gupta et al and ‘Antirheumatic agents in covid-19: is IL-6 the right target?’ by Capeechi et al Sara Monti, Carlomaurizio Montecucco
990 [GO] 2020―Mai―22 Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept Pierre-Marie Duret, Eden Sebbag, Auriane Mallick, Simon Gravier, Lionel Spielmann, Laurent Messer
991 [GO] 2020―Mai―22 Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China Cong Ye, Shaozhe Cai, Guifen Shen, Hanxiong Guan, Liling Zhou, Yangyang Hu, et al. (+7)
992 [GO] 2020―Mai―22 Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis Spyridon Megremis, Thomas D J Walker, Xiaotong He, William E R Ollier, Hector Chinoy, Lynne Hampson, et al. (+2)
993 [GO] 2020―Mai―21 Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19 Maximilian F Konig, Alfred HJ Kim, Marc H Scheetz, Elizabeth R Graef, Jean W Liew, Julia Simard, et al. (+5)
994 [GO] 2020―Mai―21 Response to ‘Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?’ by Moiseev et al Francesca Romana Spinelli, Fulvia Ceccarelli, Manuela Di Franco, Fabrizio Conti
995 [GO] 2020―Mai―21 Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: ‘Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)’ by Giollo et al Sara Monti, Carlomaurizio Montecucco
996 [GO] 2020―Mai―21 Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey Alessandro Tomelleri, Silvia Sartorelli, Corrado Campochiaro, Elena Marina Baldissera, Lorenzo Dagna
997 [GO] 2020―Mai―20 Rheumatic diseases in intensive care unit patients with COVID-19 Sergey Moiseev, Sergey Avdeev, Michail Brovko, Andrey Yavorovskiy, Pavel I Novikov, Karina Umbetova, et al. (+3)
998 [GO] 2020―Mai―20 Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? Piero Ruscitti, Onorina Berardicurti, Antonio Barile, Paola Cipriani, Yehuda Shoenfeld, Annamaria Iagnocco, Roberto Giacomelli
999 [GO] 2020―Mai―20 Hydroxychloroquine shortages during the COVID-19 pandemic Arielle Mendel, Sasha Bernatsky, J Carter Thorne, Diane Lacaille, Sindhu R Johnson, Évelyne Vinet
1000 [GO] 2020―Mai―20 Response to: ‘Hydroxychloroquine shortages during the COVID-19 pandemic’ by Mendel et al Iain McInnes
1001 [GO] 2020―Mai―20 Comorbidities and rheumatological diseases at the time of COVID-19. Response to: ‘Rheumatic diseases in intensive care unit patients with COVID-19’ by Moiseev et al Sara Monti, Carlomaurizio Montecucco
1002 [GO] 2020―Mai―18 Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation? Gian Luca Erre, Edoardo Sean Ferraccioli, Matteo Piga, Arduino Mangoni, Giuseppe Passiu, Elisa Gremese, Gianfranco Ferraccioli
1003 [GO] 2020―Mai―18 Response to: ‘Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?’ by Erre et al Elizabeth R Graef, Jean W Liew, Alfred HJ Kim, Jeffrey A Sparks
1004 [GO] 2020―Mai―15 Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: ‘COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs’ by Conticini et al Sara Monti, Carlomaurizio Montecucco
1005 [GO] 2020―Mai―15 COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs Edoardo Conticini, Elena Bargagli, Marco Bardelli, Giuseppe Domenico Rana, Caterina Baldi, Paolo Cameli, et al. (+9)
1006 [GO] 2020―Mai―15 Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: ‘Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia’ by Guilpain et al Sara Monti, Carlomaurizio Montecucco
1007 [GO] 2020―Mai―13 Response to: ‘Patients with lupus are not protected from COVID-19: a comment’ by Sawalha, ‘No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit’ by Romão et al and ‘SLE patients are not immune to COVID-19: importance of sending the right message across’ by Goyal Beuy Joob, Viroj Wiwanitkit
1008 [GO] 2020―Mai―13 No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: response to the comment by Joob and Wiwanitkit Vasco C. Romão, Ana Rita Cruz-Machado, João Eurico Fonseca
1009 [GO] 2020―Mai―06 Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series Achille Aouba, Aurelie Baldolli, Loïk Geffray, Renaud Verdon, Emmanuel Bergot, Nicolas Martin-Silva, Aurélien Justet
1010 [GO] 2020―Apr―28 Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19 Haralampos M Moutsopoulos
1011 [GO] 2020―Apr―24 Patients with lupus are not protected from COVID-19 Amr H Sawalha
1012 [GO] 2020―Apr―23 Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: ‘Does hydroxychloroquine prevent the transmission of COVID-19?’ by Heldwein and Calado and ‘SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment’ by Joob and Wiwanitkit Sara Monti, Carlomaurizio Montecucco
1013 [GO] 2020―Apr―23 SLE patients are not immune to covid-19: importance of sending the right message across Mohit Goyal
1014 [GO] 2020―Apr―23 Myositis as a manifestation of SARS-CoV-2 Maxime Beydon, Kevin Chevalier, Omar Al Tabaa, Sabrina Hamroun, Anne-Sophie Delettre, Marion Thomas, et al. (+3)
1015 [GO] 2020―Apr―22 Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID) Alessandro Giollo, Giovanni Adami, Davide Gatti, Luca Idolazzi, Maurizio Rossini
1016 [GO] 2020―Apr―22 What is the true incidence of COVID-19 in patients with rheumatic diseases? Ennio Giulio Favalli, Francesca Ingegnoli, Rolando Cimaz, Roberto Caporali
1017 [GO] 2020―Apr―22 To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic Konstantinos Parperis
1018 [GO] 2020―Apr―21 Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Sergey Moiseev, Sergey Avdeev, Michail Brovko, Pavel Novikov, Victor Fomin
1019 [GO] 2020―Apr―21 Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality? Wenhui Xie, Yu Wang, Zhuoli Zhang
1020 [GO] 2020―Apr―20 Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques MARIA, et al. (+4)
1021 [GO] 2020―Apr―16 COVID-19 and rheumatology: first steps towards a different future? Iain B McInnes
1022 [GO] 2020―Apr―16 Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India Latika Gupta, Durga Prasanna Misra, Vishwesh Agarwal, Suma Balan, Vikas Agarwal
1023 [GO] 2020―Apr―16 Antirheumatic agents in covid-19: is IL-6 the right target? Pier Leopoldo Capecchi, Pietro Enea Lazzerini, Luca Volterrani, Maria Antonietta Mazzei, Barbara Rossetti, Giacomo Zanelli, et al. (+7)
1024 [GO] 2020―Apr―15 Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19 Chenyang Lu, Shasha Li, Yi Liu
1025 [GO] 2020―Apr―15 Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist Elizabeth R Graef, Jean W Liew, Michael S Putman, Julia F Simard, Emily Sirotich, Francis Berenbaum, et al. (+13)
1026 [GO] 2020―Apr―15 SLE, hydroxychloroquine and no SLE patients with covid-19: a comment Beuy Joob, Viroj Wiwanitkit
1027 [GO] 2020―Apr―15 Does hydroxychloroquine prevent the transmission of covid-19? Flavio L Heldwein, Adriano Calado
1028 [GO] 2020―Apr―03 COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD Carina Mihai, Rucsandra Dobrota, Maria Schröder, Alexandru Garaiman, Suzana Jordan, Mike Oliver Becker, et al. (+2)
1029 [GO] 2020―Apr―03 Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Sara Monti, Silvia Balduzzi, Paolo Delvino, Elisa Bellis, Verdiana Serena Quadrelli, Carlomaurizio Montecucco
1030 [GO] 2020―Apr―03 To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic Francesca Romana Spinelli, Fulvia Ceccarelli, Manuela Di Franco, Fabrizio Conti
1031 [GO] 2020―Mrz―23 Are my patients with rheumatic diseases at higher risk of COVID-19? Gabriel Figueroa-Parra, Gloria Mayela Aguirre-Garcia, Carmen Magdalena Gamboa-Alonso, Adrian Camacho-Ortiz, Dionicio Angel Galarza-Delgado
 [1] 

1031 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.416 sec